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Abstract
The work of this dissertation describes the design and synthesis of 1,2,4-triazine ligands
and other N-containing heterocycles and their use in the copper-catalyzed azide-alkyne
cycloaddition (CuAAC). A variety of ligands were synthesized to probe the steric and
electronic demands required for use in the CuAAC reaction. Substituents on the 1,2,4triazine were systematically altered and the core 1,2,4-triazine modified to determine the
most active ligand. Additional experiments explored the variability in the reaction
conditions, such as solvent choice, use of reducing agents, and optimal stoichiometry.
Under optimum conditions 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine and copper (II)
tetrafluoroborate in the presence of triethylamine was found to be an effective
accelerant producing 97% of the desired 1,2,3-triaozle in 1 hour. A broad substrate
scope was conducted with an assortment of azides and alkynes.
The use of 1,2,4-triazine-accelerated CuAAC was applied to the synthesis of solidsupported catalysts on both polystyrene and silica. Immobilized catalysts provide
advantages over their soluble counterparts in that they can be recycled and can prevent
metal contamination of 1,2,3-triazole products. Results indicated that 1,2,4-triazines
appended to solid supports were more effective when compared to 1,2,3-triazole control
catalysts. In addition, less metal leaching occurred with triazine supports as compared
to triazole controls.
The optimal ligand from the homogeneous screening was then used in the synthesis of
a library of small molecules containing 1,2,3-triazoles and/or 1,2,4-triazoles. Upon
synthesis, compounds were screened for activity against various histone deacetylase
(HDAC) enzymes for both activity and selectivity. Although successfully synthesized,
the molecules did not prove to be active against the selected metalloenzyme.

v

Table of Contents
Chapter 1. Azide-Alkyne Cycloaddition and 1,2,3-Triazoles .................................... 1
1.1. Click Chemistry .................................................................................................. 2
1.2. 1,2,3-Triazoles as Pharmacophores .................................................................. 4
1.3. Azide-Alkyne Cycloadditions .............................................................................. 7
1.4. Copper-Catalyzed Azide-Alkyne Cycloaddition .................................................. 9
1.5. Ligand-Accelerated CuACC (Homogeneous & Heterogeneous Applications) . 11
1.6. Mechanistic Considerations ............................................................................. 16
1.7. 1,2,4-Triazines as Ligands ............................................................................... 18
1.8. Scope of this Work ........................................................................................... 20
Chapter 2. Design & Synthesis of 1,2,4-Triazine Ligands ...................................... 22
2.1. Background & Significance .............................................................................. 23
2.2. Synthetic Strategies for 1,2,4-Triazine Synthesis ............................................. 25
2.3. Ring Closure Reactions ................................................................................... 27
2.3.1. Synthesis of 3-substituted-5,6-diphenyl-1,2,4-triazine ............................... 27
2.3.2. Synthesis of 3-pyridyl-5,6-disubstituted-1,2,4-triazines ............................. 31
2.4. Substituent Modifications ................................................................................. 37
2.5. Ring Transformations ....................................................................................... 39
2.6. Conclusions...................................................................................................... 41
2.7. Experimental .................................................................................................... 42
Chapter 3. Catalytic Activity of 1,2,4-Triazine Ligands ........................................... 67
3.1. Background & Significance .............................................................................. 68
3.2. Optimization of Reaction Conditions for 1,2,4-Triazine Accelerated CuAAC ... 68
3.3. Substrate Scope............................................................................................... 72
3.4. Ligand Scope ................................................................................................... 74
3.5. Mechanistic Considerations ............................................................................. 77
3.6. Other Catalytic Applications ............................................................................. 79
3.7. Solid-Supported 1,2,4-Triazines ....................................................................... 85
3.7.1. Overview of Synthesis of Solid-Supported 1,2,4-Triazines and Control
1,2,3-Triazole Resins .............................................................................................. 85
3.7.1. Catalytic Activity of Solid Supported 1,2,4-Triazines ................................. 88
3.8. Conclusions...................................................................................................... 94
3.9. Experimental .................................................................................................... 96
Chapter 4. Design and Synthesis of Metalloenzyme Inhibitors ........................... 115
4.1. Background and Significance of Histone Deacetylase (HDAC)...................... 116
4.2. Histone Deacetylase Inhibitors (HDACi) ........................................................ 121
4.3. Strategies for Synthesis ................................................................................. 124
4.3.1. Solid Phase Approach ............................................................................. 127
4.3.2. Solution Phase Approach ........................................................................ 129
4.4. Screening of Synthesized Small Molecules for HDAC inhibition .................... 135
4.4.1. General procedure for performing enzyme inhibition assays: .................. 135
4.5. Analysis of Enzyme Inhibition Results ............................................................ 137
4.6. Conclusions.................................................................................................... 141
4.7. Experimental .................................................................................................. 141
vi

Chapter 5. Conclusions and Future Work .............................................................. 156
5.1. Concluding Remarks ...................................................................................... 157
References ................................................................................................................. 158
Vita.............................................................................................................................. 165

vii

List of Tables
Table 1.1 Comparison of activation energy barriers for proposed intermediates in
CuAAC. ....................................................................................................................................18
Table 3.1 Optimization of CuAAC reaction conditions using 1,2,4-triazines.a ....................69
Table 3.2 Evaluation of Base and Substrate Concentration in CuAAC.a .............................71
Table 3.3 Evaluation of Solvent for CuAAC.a ........................................................................71
Table 3.4 Substrate scope for 1,2,4-triazine accelerated CuAAC.a ......................................73
Table 3.5 Evaluation of 1,2,4-triazines and other heterocycles for CuAAC.a ......................75
Table 3.6 Initial studies of 1,2,4-triazines as additives in Sonogashira reaction.a..............81
Table 3.7 Evaluation of one-pot Sonogashira-CuAAC reaction.a.........................................81
Table 3.8 Optimization of deprotection of TMS-phenylacetylene and concurrent
cycloaddition.a ........................................................................................................................83
Table 3.9 Deprotection of TMS-phenylacetylene in the presence of palladium. .................83
Table 3.10 Re-evaluation of triazine ligand in one pot Sonogashira-CuAAC reaction. ......84
Table 3.11 Copper loading and catalytic activity of various polystyrene supports. ..........90
Table 3.12 Recyclability of polystyrene supported catalysts.a ............................................92
Table 3.13 Copper retention by polystyrene supported catalysts.a.....................................92
Table 3.14 Evaluation of solvents with various polystyrene and silica catalysts. ..............94
Table 4.1 Features of the various isoforms of HDAC Class I, II and IV. ............................119

viii

List of Figures
Figure 1.1 Representation of reactions conforming to “click” guidelines. .......................... 3
Figure 1.2 Triazoles as isosteres for amide bonds. ............................................................... 5
Figure 1.3 Selected molecules containing 1,2,3-triazoles and their potential applications. 6
Figure 1.4 Potential pharmaceuticals containing a 1,2,3-triazole.11...................................... 7
Figure 1.5 Synthesis of 1,2,3-triazole regioisomers. ............................................................. 9
Figure 1.6 Heterocyclic ligands used for azide-alkyne cycloaddition. ................................12
Figure 1.7 Additional nitrogen containing ligands used for azide-alkyne cycloadditions. 13
Figure 1.8 Catalysts invovling metal-coordination atoms other than nitrogen. .................14
Figure 1.9 Examples of heterogeneous ligands used to accelerate CuAAC. .....................16
Figure 1.10 Proposed catalytic cycle of CuAAC.67................................................................19
Figure 1.11 Possible byproducts observed during CuAAC. ................................................20
Figure 1.12 Coordination mode of 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine ........................21
Figure 2.1 Natural products containing or synthesized from 1,2,4-triazine. .......................23
Figure 2.2 Selected molecules containing 1,2,4-triazine scaffold. ......................................24
Figure 2.3 Comparison of retrosynthetic pathways for 1,2,4-triazines and 1,2,4-triazoles.
.................................................................................................................................................25
Figure 2.4 General synthetic strategies for the synthesis of 1,2,4-triazines. ......................26
Figure 2.5 Areas of 1,2,4-triazine that could be manipulated. ..............................................27
Figure 2.6 Illustration showing modeling of 1,2,4-triazines in Sybyl. ..................................35
Figure 3.1 UV-Vis spectra of 1,2,4-triazine-accelerated CuAAC ..........................................78
Figure 3.2 Kinetic NMR Data of 1,2,4-Triazine-Accelerated CuAAC Reaction. ...................79
Figure 3.3 Summary of triazine ligands attached to polystyrene resins containing
unreacted azides. ....................................................................................................................89
Figure 3.4 Summary of triazine ligands attached to polystyrene containing free amines. 89
Figure 4.1 Equilibrium between transcriptional repression and transcriptional activation.
...............................................................................................................................................117
Figure 4.2 Representation of binding with A) substrate (proposed) and with B)
hydroxamate inhibitor. .........................................................................................................121
Figure 4.3 The general regions for consideration in design of HDAC inhibitors..............122
Figure 4.4 Selected HDAC inhibitors ...................................................................................122
Figure 4.5 Molecules synthesized for HDAC inhibition involving 1,2,3-triazoles. ............126
Figure 4.6 Electrostatic potential map comparing 1,2,3-triazoles to hydroxamic acids. .126
Figure 4.7 Different solid phase resins for HDAC inhibitor synthesis. .............................127

ix

Figure 4.8 Analysis of 1,2,3-triazoles as zinc binding groups for HDAC inhibition. .........138
Figure 4.9 Comparison of interaction with A) hydroxamic acid and B) proposed inhibitor.
...............................................................................................................................................139
Figure 4.10 Analysis of 1,2,4-triazoles as zinc binding groups for HDAC inhibition. .......140

x

List of Schemes
Scheme 2.1 Synthesis of 3-substituted-5,6-diphenyl-1,2,4-triazines. ..................................28
Scheme 2.2 Synthesis of 1,2,4-triazines from carboxylic acids or esters. ..........................29
Scheme 2.3 Attempted routes to synthesize 3-methylimidazoyl triazine. ...........................30
Scheme 2.4 Successful synthesis of 3-methylimidazoyl triazine. .......................................30
Scheme 2.5 Attempted synthesis of 3-(1,2,4-triazol-3-yl)-triazine. ......................................31
Scheme 2.6 Synthesis of 3-(2-pyridyl),5,6-disubsituted triazines. .......................................32
Scheme 2.7 Synthesis of nitro and amine substituted 1,2,4-triazines.................................33
Scheme 2.8 Synthesis of triazines using cyclic or fused diketones. ..................................35
Scheme 2.9 Synthesis of bis1,2,4-triazine. ............................................................................36
Scheme 2.10 Synthesis of triazole triazine............................................................................36
Scheme 2.11 Synthesis of 3-phenyl-5,6-di(2-pyridyl)-1,2,4-triazine. ....................................37
Scheme 2.12 Synthesis of 1,2,4-triazines by substituent modification. ..............................38
Scheme 2.13 Diels-Alder reactions of tetrazines and triazines. ...........................................40
Scheme 2.14 Non-1,2,4-triazine heterocycles containing sp2 nitrogens. ............................41
Scheme 3.1 Synthesis of solid-supported control 1,2,3-triazoles. ......................................86
Scheme 3.2 Synthesis of alkyne on 3-substituent of 1,2,4-triazine. ....................................87
Scheme 3.3 Synthesis of alkyne on 5-substituent of 1,2,4-triazine. ....................................87
Scheme 4.1 Solid phase synthetic scheme for HDAC inhibitors. ......................................128
Scheme 4.2 One pot procedure for synthesis of HDAC inhibitors. ...................................129
Scheme 4.3 Two-step synthesis for HDAC inhibitors containing 1,2,3-triazoles. ............130
Scheme 4.4 Synthetic scheme for synthesis of 1,2,4-triazole containing HDAC inhibitors.
...............................................................................................................................................132
Scheme 4.5 Synthesis of previously published HDAC Inhibitor. .......................................133
Scheme 4.6 Synthesis of 1,2,4-triazole hydroxamic acid compound. ...............................134
Scheme 4.7 Synthesis of 1,2,3-triazole anilide....................................................................135

xi

Abbreviations and Acronyms
ACN
AcOH
Br2
CHCl3
DCE
DCM
DMF
CuAAC
Cu(BF4)2 • 6H2O
CuCN
CuI
[Cu(MeCN)4]+BF4CuSO4 • 5H2O
Et2O
Et3N
EtOAc
EtOH
GC-MS
H2SO4
HBTU
HCl
HDAC
HDACi
HNO3
HOBt
HPLC
IC50
ICP-OES
IR
KBr
KCN
KMnO4
KOH
LC/MS
MeCN
MeOH
MMP
MW
NaHCO3

Acetonitrile
Acetic Acid
Bromine
Chloroform
Dichloroethane
Dichloromethane
N,N-Dimethylfomamide
Copper-Catalyzed Azide-Alkyne Cycloaddition
Copper tetrafluoroborate hexahydrate
Copper cyanide
Copper iodide
Tetrakis(acetonitrile-N)copper(I) tetrafluoroborate
Copper sulfate pentahydrate
Diethyl ether
Triethylamine
Ethyl acetate
Ethanol
Gas chromatography – mass spectroscopy
Sulfuric acid
O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluorophosphate
Hydrochloric acid
Histone deacetylase
Histone deaceytlase inhibitor
Nitric acid
1-Hydroxybenzotriazole hydrate
High-pressure liquid chromatography
Inhibitory concentration of half-maximum (50%) activity
Inductively coupled plasma – optical emission spectroscopy
Infrared spectroscopy
Potassium bromide
Potassium cyanide
Potassium permanganate
Potassium hydroxide
Liquid chromatography-mass spectroscopy
Acetonitrile
Methanol
Matrix metalloproteinase
Microwave
Sodium bicarbonate

xii

NaN3
NaNO2
NH4OAc
NMP
NMR
Pd(OAc)2
Pd(PPh3)2Cl2
SAHA
SAR
SeO2
TBAB
TBAF
TBAI
TBTA
TFA
TFAA
THF
TLC
TSA
SnCl2 • 2H2O
UV-Vis

Sodium azide
Sodium nitrite
Ammonium acetate
N-Methylpyrolidinone
Nuclear magnetic resonance
Palladium(II) acetate
Bis(triphenylphosphine)palladium(II) chloride
Suberoylanilide hydroxamic acid
Structure Activity Relationship
Selenium dioxide
Tetrabutylammonium bromide
Tetrabutylammonium fluoride
Tetrabutylammonium iodide
Tris(benzyltriazolylmethyl)amine
Trifluoroacetic acid
Trifluoroacetic anhydride
Tetrahydrofuran
Thin-layer chromatography
Trichostatin A
Tin(II) chloride dihydrate
Ultraviolet – visible spectroscopy

xiii

Chapter 1.
Azide-Alkyne Cycloaddition and 1,2,3-Triazoles

1

1.1.

Click Chemistry

In the realm of synthesis, there are two broad schools of thought. One approach is to
construct products using combinations of novel reactions regardless of how difficult the
target might be, as long as a desired activity is present. Natural product synthesis
usually evokes this process to make the difficult molecules or metabolites, naturally
occurring in plants, marine species, or other native environments. Sometimes these
methods are not conducive to scale-up, commercialization, or synthesis of
corresponding analogues. A second approach is to restrict drug discovery targets to
molecules that are easy to make and through methods that can be rapidly modified to
introduce diversity. Researchers estimate that there are on order of between 1062 and
1063 druglike candidates.1 Druglike candidates are defined as having less than 30 nonhydrogen atoms, containing C,H, N, O, P, Cl, Br and stable at ambient temperature, in
the presence of oxygen and water.1 With the amount of probable druglike molecules, it
is reasonable to attempt synthesis of molecules that can easily be made. This is a shift
to focus more on the activity than the structure of the desired molecule. If the synthesis
can be easily modified for diversity elements, one can more rapidly complete a
structure-activity relationship (SAR) study.
From this idea, was born the “click chemistry” philosophy described by K.B Sharpless et
al.2 Reactions that fit into the click chemistry philosophy should be “modular, wide in
scope,

high

yielding,

generate

only

inoffensive

byproducts

removed

by

nonchromatographic methods, and stereospecific.” Reaction conditions should be
insensitive to water and oxygen, use no solvent, a benign solvent, or an easily removed
solvent, and be amenable to simple product isolation. Starting materials should be
readily available to further expedite the process. 2 This process should be as simple as
joining two units together, such as fitting two puzzle pieces together. The reactive
fragments should only react with one another and the reaction conditions should be
tolerable to a wide array of functional groups, without the need for protecting group
chemistry.
The constraints of click chemistry may seem demanding, but several reactions fit into
this category. Figure 1.1 shows examples of click chemistry which include oxidative
2

additions to carbon-carbon multiple bonds such as epoxidation, aziridination, and
dihydroxylation. Michael additions of nucleophiles to unsaturated systems also fit into
this category, along with nucleophilic ring opening of strained rings, such as aziridines
or epoxides. Non-aldol additions to carbonyls such as in formation of ureas, amides, or
oxime ethers are also consistent with the constraints of click chemistry. Non-aldol
carbonyl chemistry to form aromatic systems also falls within the definition of click
reactions. Finally, several cycloaddition reactions, including Diels-Alder transformations
and 1,3-dipolar cycloaddition reactions fit into the framework of click chemistry. With the
exception of Diels-Alder, the majority of these reactions take advantage of carbonheteroatom linkages. These heteroatom linkages can be described as mimics of nature,
as a large number of diverse compounds (nucleic acids, proteins, polysaccharides) are
generated from only a small number of naturally occurring building blocks.

Figure 1.1 Representation of reactions conforming to “click” guidelines. Adapted from
Moses et. al3 & Kolb et. al4
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Among these reactions, one has emerged as the centerpiece of “click chemistry”
sometimes being incorrectly defined as click chemistry, in itself. Since the discovery of
the copper catalyzed variant of the Husigen azide-alkyne cyclocaddition (CuAAC), the
field of click chemistry has expanded to include drug discovery,4 biological applications,5
materials science and polymer chemistry6,7 and has produced a number of reviews in
various areas.3,8,9 Why has this reaction had such a dramatic impact on the way
scientists approach these fields? This reaction is highly regioselective, involves two
relatively unreactive starting materials, and forms a stable product that has implications
in biological systems.

1.2.

1,2,3-Triazoles as Pharmacophores

The field of drug discovery has been greatly influenced by the discovery of a coppercatalyzed azide-alkyne cycloaddition (CuAAC). This has allowed the rapid synthesis of
a number of 1,2,3-triazole containing molecules for a wide variety of applications.
Several reviews have summarized the growing trend of triazoles as important
pharmacophores and their use in biological applications.10-14
One reason for the growing use of triazoles stems from the suggestion as amide bond
replacements.15 Evidence suggests that 1,2,3-triazoles can be both electronically and
spatially similar to amide bonds. Amide bonds, in either the E or Z conformation, can be
related to disubstituted 1,2,3-triazoles, either in a 1,4- or 1,5-substitution pattern (Figure
1.2).12 The 1,4-disubstituted-1,2,3-triazoles mimic the Z-amide bond. Electronically, N(2)
or N(3) of the triazole can serve as a hydrogen bond acceptor similar to the carbonyl
oxygen of an amide. Both the amide and the triazole can also serve as hydrogen bond
donors with the C(5)-H of the triazole mimicking the NH of an amide. Both also have
electrophilic carbons (C-O vs. C-N). Although similar, the triazole has a larger dipole
moment, making its hydrogen bond donor and acceptor abilities greater than those of
the amide. This could also contribute to its increased activity in biological systems.

4

Figure 1.2 Triazoles as isosteres for amide bonds. Modified from Tron et. al.12 Comparison
between A) Z-amide bond and 1,4-disubstituted-1,2,3-triazole and B) E-amides and 1-,5disubstituted-1,2,3-triazole.

The geometry and spatial arrangement of atoms in a triazole ring are similar to that of
the amide bond as well, with the triazole spacing being slightly longer by 1.1 Å.12 In
addition, triazoles have also been demonstrated to retain conformational geometries in
secondary structures when replacing amide bonds in α-helices16 and β-turns.17
There are two significant differences between amide bonds and triazoles, both of which
tip the scales in favor of the triazole: stability and ease of synthesis. Triazoles are stable
under a wide array of conditions, including resistance to hydrolysis, oxidation, and
reduction, conditions by which the amide bond is susceptible. Triazoles are compatible
with either acidic or basic media, and degradation by metabolic pathways does not
interfere with the triazole scaffold. With the discovery of copper-catalyzed azide-alkyne
cycloaddition and the analogous ruthenium-catalyzed azide-alkyne cycloaddition, the
5

synthesis of 1,2,3-triazoles is much less laborious and has abounded in a number of
biologically relevant molecules being synthesized. Because triazole synthesis is
amenable to a variety of functional groups, diverse libraries of compounds can be
quickly and efficiently synthesized to screen for a wide array of biological activities.
The triazole core is present in a variety of drug leads (Figure 1.3) such as antiviral,18
anti-HIV,19

antituberculosis

activity,20,21

antifungal,22

anti-inflammatory,23

and

antiobesity.24 Additional uses of 1,2,3-triazoles are in the design of histone deacetylase
(HDAC) inhibitors,25 or resveratrol mimics,26 and anti-cancer therapeutics.27 Some
triazole containing compounds have undergone clinical trials or are commercially
available (Figure 1.4). The synthesis of additional triazole molecules is now greatly
aided by the copper-catalyzed azide-alkyne cycloaddition.

Figure 1.3 Selected molecules containing 1,2,3-triazoles and their potential applications.

6

Figure 1.4 Potential pharmaceuticals containing a 1,2,3-triazole.11 Generic and trade names
listed for commercial products along with supplier.

1.3.

Azide-Alkyne Cycloadditions

The azide-alkyne cycloaddition has made it possible to synthesize a large number of
1,2,3-triazoles. Even prior to the discovery of the copper catalyzed variant, thousands of
1,4-disubstituted-1,2,3-triazoles had been synthesized. The azide-alkyne cycloaddition
falls into the family of 1,3-dipolar cycloadditions, which was the topic of extensive
research by Rolf Huisgen and colleagues.28 1,3-Dipolar cycloadditions provide a general
method of synthesizing 5-membered heterocycles, starting from a 1,3-dipole, containing
both electrophilic and nucleophilic atoms and a dipolarophile, containing a multiple
bond. The azide-alkyne cycloaddition focuses on the azide as the dipole and alkyne as
the dipolarophile. The first 1,2,3-triazole synthesis was performed by A. Michael in
1893.29 Further work was explored by Huisgen throughout the 1950s-1970s. The
original reaction between azides and alkynes was thermally controlled, leading to
prolonged reaction times, low yields, and low selectivity. Changes to the electronics of
the azide or alkyne contribute to the overall reactivity, making the scope of the reaction
limited. With cycloadditions, there are two possible overlaps between the dipole HOMO
7

and dipolarophile LUMO or dipole LUMO and dipolarophile HOMO. Because the
difference in the molecular orbitals is small, a mixture of regioisomers is formed. 9
Electron deficient alkynes could be used to tune the reaction to achieve better
regioselectivity, but this again limits the overall diversity attached to the triazole scaffold.
Although the triazole formation could be slow and non-regiospecific, there was still a
desire to further investigate the azide-alkyne cycloaddition. Organic azides are unique
dipoles in that they can be made, handled, and stored as stable compounds. Azides
and alkynes are relatively non-polar, and can remain hidden from and unreactive with
most other functionalities, allowing their installation early on in a synthetic scheme. The
reaction would also be

atom-economical, employing accessible dipoles and

dipolarophiles. Finally, the triazole product is a stable aromatic structure (serving as an
amide bond replacement).9 If the azide-alkyne reaction could be catalyzed and be tuned
for regioselectivity, it had potential to find a place in the “click chemistry” world.
In 2001, the groups of Meldal30 and Fokin and Sharpless31 accomplished this feat and
discovered the copper-catalyzed variant of the azide-alkyne cycloaddition, which
exclusively produced the 1,4-disubstituted triazole isomer. The analogous ruthenium
catalyzed reaction to produce the 1,5-disubstituted isomer (or 1,4,5-trisubstituted isomer
if internal alkynes are used) was also discovered by Fokin and Sharpless.32 An
additional method of producing 1,2,3-triazoles was also sought after especially for
biological applications in which copper toxicity limits applications with living cells.
Several researchers have explored the use of strained cyclooctyne systems to perform
selective cycloaddition reactions in living systems.33,34 This copper free process has
allowed the selective modification of biomolecules to study proteins, lipids,
bactereriophages, and small organisms, such as zebrafish. 34 Although this method can
produce two regioisomers, this would not have an adverse effect on the biological
applications. The four methods of producing triazoles from azides and alkynes are
illustrated in Figure 1.5.
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Figure 1.5 Synthesis of 1,2,3-triazole regioisomers. Synthesis can occur through (A) thermal
cycloaddition, yielding a mixture of regioisomers, through (B) copper-catalyzed variant
producing 1,4-disubstituted-1,2,3-triazoles, or through (C) ruthenium-catalyzed variant
producing 1,5-disubstituted or 1,4,5-trisubsituted triazoles or (D) copper-free cycloaddition of
strained alkynes

1.4.

Copper-Catalyzed Azide-Alkyne Cycloaddition

In addition to providing a regioselective path to 1,2,3-triazoles, the copper-catalyzed
variant also accelerates the cycloaddition on the order of 10 6 relative to the uncatalyzed
reaction.9 This allows the reaction to now take place within a reasonable time frame,
minutes or hours as opposed to days, and at room temperature. The catalyzed variant
is also not limited by sterics or electronics of the azide or alkyne component, and most
organic functional groups are not affected, eliminating the need for protecting groups.
Due to the rate acceleration and the high regioselectivity, azide-alkyne cycloaddition
has become a leading method for covalent assembly of molecules, large and small.
The copper-catalyzed reaction is fairly insensitive to reaction conditions, as long as a
source of CuI is present. Both aqueous and organic solvents may be employed and the
9

reaction proceeds with solution-phase or solid-supported reagents. An important note is
that CuI must be present or generated in situ and should be kept at a high level with
regards to the inactive CuII or Cu0 oxidation states. An extensive list of CuI sources has
been compiled and summarized by Meldal.8 The CuI can come from three main
categories, from a CuI salt, from a CuII salt and a reducing agent, or through oxidation of
Cu0 found in copper wire, turnings, or powders. Of these methods, the most commonly
employed is the use of copper (II) sulfate in the presence of a reducing agent,
commonly sodium ascorbate. These reaction conditions allow for less air-susceptibility,
not requiring dry solvents, or inert atmospheres to carry out the reaction. Copper sulfate
in the presence of a reducing agent and alkyne can form the active copper-acetylide
species required for the reaction immediately, but this process is not as facile for copper
halides such as CuI or CuBr. These salts typically require additional amine base or high
temperatures to form copper-acetylides. The copper halides favor anhydrous conditions
and tend to have better solubility in solvents of intermediate polarity such as acetonitrile,
tetrahydrofuran, and dimethylsulfoxide. The final method is the use of elemental copper.
The downside to this method is the increased reaction time, since the active species
must be formed first. The advantage lies in product isolation in which solid copper can
be easily removed.
Recent reports have attempted to explain catalysis of azide-alkyne cycloaddition by
copper (II) salts with the argument that these reactions are catalyzed by copper (II) and
not the more common copper (I) state.35 According to the experts in the field,9 these
reports are not accurate. The most likely explanation for these reports is that reduction
of the starting copper (II) salt is occurring to produce copper (I). Since Cu II serves as a
good oxidizing agent, it is likely that solvent or even starting alkynes are being oxidized,
resulting in the reduced and catalytically active CuI species. Even a small amount of
copper (I) in the reaction mixture is sufficient to catalyze the cycloaddition. 8 Although
there has been much success in the field of copper-catalyzed azide-alkyne
cycloaddition, there was a desire to find better conditions, such that less copper could
be employed and separation from copper salts was not as tedious or cumbersome.
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1.5.

Ligand-Accelerated CuACC (Homogeneous & Heterogeneous

Applications)
Although not a necessity, many researchers have chosen to include a ligand to enhance
either the reaction rate or to protect the active CuI from oxidation. Additional benefits
from utilizing ligands are reduced catalyst loadings and improved product purity with
less copper contamination. Ligands can be especially useful for demanding
applications. The added ligands can either be soluble homogeneous ligands or ligands
attached to an insoluble support. A large number of ligands have been synthesized,
generally including heteroatoms, and reviewed.36 Nitrogen based ligands make up the
majority of those explored for azide-alkyne cycloaddition. The simplest and earliest
additives

employed

were

amines

such

as

2,6-lutidine,

triethylamine

or

diisopropylethylamine (DIEA), or proline.37 Other early ligands involved nitriles,
guanidines, imines, or halides. With the early ligands, two main problems arose. Some
of these ligands (halides and amines) were too labile and did not protect the copper
from oxidation to an inactive state. Other ligands (nitriles) were found to bind the metal
too tightly, resulting in decreased reactivity of the needed copper center. 8
and Fokin

38

Sharpless

realized during kinetic investigations that reaction rates of selected

substrates were extremely high, almost appearing autocatalytic; the triazole product
could be catalyzing its own formation. Since triazoles had earlier been difficult to
synthesize, using triazoles as ligands for product triazole formation had previously been
unexplored. This work began a new approach in designing ligands for CuAAC. TBTA
(Figure 1.6, 1-1) was found to be an effective ligand.38 From this work, stemmed several
additional ligands. Finn and coworkers kept the central amine framework the same and
changed the surrounding heterocycle. The 1,2,3-triazole was exchanged for
benzimidazole, benzothiazole, pyridine,

and related derivatives. A systematic

exploration of various hybrid ligands was undertaken to determine optimal reaction
conditions, mechanistic insights, and dependence on solvent and ligand metal
stochiometries.39 This led to hybrid or mixed ligands similar to TBTA, but with more than
one different heterocycle attached to the core amine. Bim(Py)2 (1-3) was found to be the
best ligand for strict organic conditions.
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Figure 1.6 Heterocyclic ligands used for azide-alkyne cycloaddition.

Inspired by this work and the results observed, other researchers began to investigate
tripodal ligands (Figure 1-7). One downfall of the TBTA system was its poor water
solubility. This leads to difficulty in biological applications as an increased copper
loading is necessary, resulting in toxicity within living systems. As a potential solution,
researchers designed additional analogues of TBTA and examined their water solubility,
azide-alkyne reaction rate, and cytotoxicity.40 Addition of BTTES (1-4) premixed with
copper sulfate (and reduced with sodium ascorbate) was found to be a more effective
accelerant of azide-alkyne cycloaddition compared to TBTA-Cu(I) catalyst. In addition,
cell death was suppressed in BTTES-Cu(I) treated cells compared to Cu(I) treated cells,
showing a decreased toxicity. Additional work looked at catalysts containing long alkyl
amines around a central nitrogen atom. This [Cu(C186tren)]Br catalyst (1-5) had been
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Figure 1.7 Additional nitrogen containing ligands used for azide-alkyne cycloadditions.

previously prepared and used in atom transfer radical polymerization (ATRP)
reactions.41 Because of the increased stability towards aerobic conditions and its ability
to be isolated and handled without air-free techniques, it was screened as a catalyst for
azide-alkyne cycloaddition. This proved to be effective and reusable up to three times
without a loss in activity. Additional benzimidazole ligands were synthesized by Li and
Hor42 with 1-6 showing good activity for both azide-alkyne cycloaddition and N-arylation
reactions.
Other nitrogen containing ligands have been explored including bipyridines (1-7),
phenanthrolines, and imidazoles. Imidazoles, such as 1-8 (Figure 1.7) with a long alkyl
linker were found to give cycloaddition products in good yields when performed neat or
in water.43 Sulfonated bathophenanthroline (1-9) has proven to be superior to TBTA
under some conditions and has proved useful in bioconjugation contexts. 44
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Ligands can also be extended to include other heteroatoms, such as phosphorus,
sulfur, oxygen, or carbon. NHCs (N-heterocyclic carbenes) contain nitrogens but are
actually coordinated through a carbon (or more specifically a carbene). Most of the
studies with NHC-containing ligands focus on methodology, and have not fully been
explored within the context of complex systems, although promising results are present.
The best NHC ligand has resulted from the addition of an aromatic nitrogen based
ligand, such as phenanthroline45 to combine the best of both features in one molecule.
Figure 1-8 illustrates a mixed NHC-phenanthroline copper complex (1-11) that was used
in the synthesis of potential metal chelators. In general, there remains work in this field
to match the abilities of other ligands in azide-alkyne cycloadditions.
Additional ligands involving other heteroatoms are relatively scarce.

Two notable

phosphorus complexes are [CuBr(PPh3)3] and [Cu(phen)(PPh3)]NO3.46,47 The former
adhered to strict “click” conditions, using low catalyst loadings, benign solvents, short
reaction times, and no additional purifications. Oxygen ligands have also been used,
most notable are carboxylic acids. Copper (I) acetate has been shown to outperform
other CuI salts in the absence of other additives. The theory behind this activity was the
ability of the acetate to effectively coordinate the copper. Other carboxylic acids such as
benzoic acids (1-12)48 have been shown to act as ligands. Finally, sulfur ligands have
displayed good activity even if there is not much interest in this area. This ligand (1-13)
was successfully used to decorate dendrimers with a derivatized sugar azide.49

Figure 1.8 Catalysts invovling metal-coordination atoms other than nitrogen.
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Attempts have been made to compare the various ligand-accelerated reactions, but
because of the wide variety of reaction conditions employed it has been difficult to carry
out a direct comparison. Despite the ability of several ligands to accelerate the
cycloaddition of simple azide alkyne systems, there remains a need to identify and
investigate ligands for increasingly demanding applications.
An additional growing area of research is the use of heterogeneous materials to
catalyze the azide-alkyne cycloaddition. Heterogeneous ligands and catalysts can have
distinct advantages over their homogeneous counterparts. The main advantages with
using solid supports are the ease in product isolation, decreased metal contamination of
products, and potential recyclability of the catalyst. In addition, a wide range of insoluble
supports are commercially available. Some heterogeneous materials can be directly
used in the presence of metal to catalyze the desired cycloaddition reaction. Other
materials can be easily modified to covalently attach a metal binding ligand, and then
used for catalytic applications. Surfaces that have been used to catalyze the
cycloaddition include copper clusters50, copper-aluminum hydrotalcite,51 copper
zeolites,52 copper nanoparticles on alumina53 and copper in charcoal.54 Although these
surfaces can coordinate copper, there was an effort to design more steric and
electronically demanding ligands to match those of homogeneous ligands. Fokin and
Chan55 developed a solid supported version of TBTA (1-14) to lead the way. The
structures of a selection of solid supported catalysts are illustrated in Figure 1.9. These
include other ligands attached to polystyrene resins56 and silica.57,58

These

heterogeneous catalysts have proven to be useful from a synthetic standpoint. There
still remain some disadvantages in terms of cost of support-bound catalysts, increased
reaction times, and increased temperatures. There is still a need to develop better
heterogeneous catalysts for CuAAC.
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Figure 1.9 Examples of heterogeneous ligands used to accelerate CuAAC.

1.6.

Mechanistic Considerations

From a mechanistic perspective, it is important to realize that the reaction is fairly
insensitive to reaction conditions, performing in the presence of Cu I, with aqueous or
organic solvents, and working in either solution- or solid-phase environments. Many
reports exist in an effort to explain the mechanism of the azide-alkyne cycloaddition.
Experimental evidence has been collected with regards to copper-catalyzed
cycloadditions in both the presence and the absence of additional ligands.
Using pseudo-first order kinetics or through DFT calculations, several mechanistic
theories have been presented to explain experimental observations. A point of dispute
between researchers is the nature of the copper intermediate. Copper acetylides and
copper π-complexes have both been proposed as intermediates. Cantillo and
16

coworkers recently performed a computational analysis using DFT to compare the
various proposed mechanisms and to compare catalyzed and uncatalyzed pathways. 59
As can be expected, in the uncatalyzed version, no significant energy difference exists
between the two possible activation energy barriers leading to 1,4- or 1,5-disubstituted1,2,3-triazoles. This explains the lack of regioselectivity in the uncatalyzed version, and
the high activation energy of 36 kcal/mol for both pathways explains the sluggish
reaction. From their research, activation energy barriers were calculated for the
following proposed intermediates: mononuclear copper acetylides, dinuclear copper
acetylides, mononuclear and dinuclear pi copper complexes, and tetranuclear copper
acetylides. These values are summarized in Table 1.1.
The lowest activation energy barrier points to the copper acetylides with two metal
centers as being a plausible intermediate, which was previously proposed by Fokin et.
al through kinetic studies.60 Figure 1.11 highlights the catalytic cycle for the coppercatalyzed azide-alkyne cycloaddition. The initial step begins with coordination of the
copper with the alkyne to form the π-alkyne copper complex. The coordination of the
copper lowers the pKa of the alkyne proton by approximately 10 units, making it much
more acidic. The alkyne is deprotonated and the copper acetylide forms. It is proposed
that a second copper interacts with the copper acetylide through a second π-complex.
The azide then becomes activated by coordination to the copper atom. An unusual sixmembered metallocycle is formed. The ring contraction step is highly favored and
occurs rapidly to form the copper-triazolyl species. Proteolysis is the final step in which
the copper is regenerated and the triazole product formed.
Depending on the conditions employed, byproducts can result during the azide-alkyne
cycloaddition. Common byproducts are shown in Figure 1.12. These byproducts are a
result of oxidative couplings which are also catalyzed by copper (I) species. Fortunately,
methods exist to minimize the amount of byproducts formed by addition of reducing
agents or metal-binding ligands.
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Table 1.1 Comparison of activation energy barriers for proposed intermediates in
CuAAC.

Activation Energy Barrier

Activation Energy Barrier

(1,4-disubstituted-1,2,3-

(1,5-disubstituted-1,2,3-

triazole) kcal/mol

triazole) kcal/mol

36.1

35.6

27.1

40.1

mononuclear π complex

29.1

34.0

dinuclear π complex

21.7

27.6

28.5

38.7

16.0

20.4

uncatalyzed
mononuclear copper
acetylide

tetranuclear copper
acetylide
dinuclear copper acetylides

1.7.

1,2,4-Triazines as Ligands

Previous challenges in our group had included synthesis of 1,2,3-triazoles, even in the
presence of a supporting ligand. We embarked on a project to pursue ligands to
improve the efficiency of the copper-catalyzed azide-alkyne cycloaddition. Our
inspiration for using 1,2,4-triazines was their known ability to coordinate various
transition metals and several complexes, especially with copper, had been synthesized
and studied.61-64 Through these studies 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine was
shown to coordinate a copper atom through coordination of N2 of the triazine and the
nitrogen of the pyridine substituent (Figure 1.12). It could be hypothesized that
coordination could occur through the N4 position of the 1,2,4-triazine, but the
substituent at position 5 creates steric bulk disfavoring that conformation. In addition, to
the binding of copper, it is proposed that triazines can stabilize copper (I) oxidation state
by disfavoring disproportionation.65,66 Based on the literature precedents, 1,2,4-triazines
were ligands worthy of exploring.
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Figure 1.10 Proposed catalytic cycle of CuAAC.67
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Figure 1.11 Possible byproducts observed during CuAAC.

1.8.

Scope of this Work

This dissertation describes the research towards using 1,2,4-triazines as ligands for the
copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC). Chapter 2 details the
design and synthesis of 1,2,4-triazines and similar nitrogen containing heterocycles.
Chapter 3 discusses the catalytic activity of both homogeneous 1,2,4-triazines and
heterogeneous 1,2,4-triazines, with regards to CuAAC. An extension of the catalytic
activity was then applied to a small study on one-pot Sonogashira-CuAAC reactions.
Chapter 4 details the synthesis of small molecules as potential metalloenzyme inhibitors
using 1,2,4-triazines as ligands. The activity of these synthesized inhibitors in
fluorescence assays against various histone deacetylase (HDAC) isoforms will also be
discussed.
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Figure 1.12 Coordination mode of 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine
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Chapter 2.
Design & Synthesis of 1,2,4-Triazine Ligands

22

2.1.

Background & Significance

1,2,4-Triazines are well established compounds with a number of publications
describing the preparation, physical or theoretical properties, and applications, including
a thorough review by Lindsley et al.68 The 1,2,4-triazine core is scarce in natural
products with compounds 2-169 and 2-270 (Figure 2.1) highlighting two rare naturally
occurring examples. Despite the lack of natural occurring sources, the triazine core has
found utility as an intermediate in the synthesis of natural products. It is especially
useful in the synthesis of pyridine ring systems by undergoing Diels-Alder reactions with
numerous dienophiles, as can be seen by the synthesis of the pyridine alkaloids of the
Louisianin family (2-3)71 and phomazarin (2-4).72 The potential uses of triazines are
encompassing of many areas including molecular probes (2-5),73 potential therapeutics
for Parkinson’s disease (2-6),74 or cancer treatments (2-7).75 Additional applications of
1,2,4-triazines include use as metal chelators (2-8),76 dyes, as backbone of polymers (29),68 or as agrochemicals such as the herbicide (2-10).77 A selection of molecules with
a 1,2,4-triazine scaffold are included in Figure 2.2.
Of the potential uses of triazines, the metal chelation abilities sparked our interest in the
triazine scaffold. Several metal complexes have been synthesized, their crystal
structures analyzed and properties investigated, including complexes of copper, 63 iron,78
and even lanthanide metals.79 Of particular interest were copper complexes of 1,2,4triazines.61

Copper complexes of 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazines showed a

high CuII-CuI redox potential, which is synonymous with destabilization of Cu II. Prior to

Figure 2.1 Natural products containing or synthesized from 1,2,4-triazine.
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Figure 2.2 Selected molecules containing 1,2,4-triazine scaffold.

this research project, an underlying interest was the synthesis of 1,2,3-triazoles for
bioorganic research, but that project had struggled due to a lack of an efficient way to
synthesize the molecules of interest. Our goal became to investigate the abilities of
1,2,4-triazines to accelerate copper-catalyzed azide-alkyne cycloaddition, and use that
to synthesize medicinally relevant compounds. Literature is abundant on the uses of
triazines as metal chelators and the use of various nitrogen ligands as ligands for
CuAAC, but prior to this work these two had not been merged. Further support for this
project was gained since the precursors needed for synthesis of triazines were readily
available and overlapped with precursors needed for other ongoing projects within the
group (Figure 2.3).
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Figure 2.3 Comparison of retrosynthetic pathways for 1,2,4-triazines and 1,2,4-triazoles.

2.2.

Synthetic Strategies for 1,2,4-Triazine Synthesis

The general synthesis of 1,2,4-triazines can be classified into 5 broad categories
(Figure 2.4).68 The most common of these methods is the ring closure in which one,
two, or three N-C bonds are made. Several modifications and variations exist for ringclosure reactions, making 1,2,4-triazines accessible from a number of starting materials.
A second method, ring transformation, begins with a nitrogen containing heterocycle
that is either rearranged or reacted to form 1,2,4-triazines. Substituted pyrazoles,
imidazoles and tetrazines are common starting materials for ring transformations. A
third method of substituent modifications alters a substituent on the preformed 1,2,4triazine. Depending on the starting nature of the triazine, nucleophilic or electrophilic
substitution can occur. The starting materials and reagents can be tuned for selective
substitution. Annulation of a second heterocycle onto an existing 1,2,4-triazine nucleus
is a common method employed for 1,2,4-triazines fused to other heterocycles, such as
imidazoles, pyrazoles, or triazoles. Finally, a method commonly employed with di- or
tetrahydrotriazines or triazine-ones is to aromatize through elaborate oxidative methods
or elimination to afford aromatic 1,2,4-triazines.
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Figure 2.4 General synthetic strategies for the synthesis of 1,2,4-triazines.

From our perspective, there were three major areas that could be manipulated when
synthesizing 1,2,4-triazines: the substituent at the 3 position, substituents at the 5,6
positions, and the core triazine (Figure 2.5). The ring closure method would provide us
with the most versatility to modify these three areas. Ring transformations and
substituent modifications would allow us to diversify triazines synthesized through ring
closure reactions. Our goal was to construct a library of triazines consisting of various
stereoelectronic features and analyze each for catalytic activity in CuAAC reaction.
From this, we hoped to gain the structural and electronic requirements necessary for
activity.
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Figure 2.5 Areas of 1,2,4-triazine that could be manipulated.

2.3.

Ring Closure Reactions

The most common method to form 1,2,4-triazines is through ring closure reactions by
forming three nitrogen-carbon bonds or forming two nitrogen-carbon bonds depending
on the starting materials employed. Substituents at the 3, 5, and 6 position can be
varied and a combinatorial library quickly assembled by altering the two starting
materials.

2.3.1. Synthesis of 3-substituted-5,6-diphenyl-1,2,4-triazine
Our initial synthetic goal was to vary the 3-position of the 1,2,4-triazine while keeping
the 5,6-positions constant. The formation of two N-C bonds involved a two-step
procedure (Scheme 2.1), in which nitriles are first converted to amidrazones using
hydrazine hydrate at room temperature. After isolation, the amidrazone is reacted with a
diketone, benzil, to afford the desired 1,2,4-triazine in approximately 75% yield. This
method provided rapid access to 1,2,4-triazines in good yield (70% over two steps) and
purity. Both the amidrazone intermediate and triazine product were isolated by filtration
resulting in an easy workup. Various heterocyclic nitriles were available and subjected
to reaction with hydrazine and condensation with benzil to form a series of 1,2,4triazines with varying substituents at the 3-position.
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Scheme 2.1 Synthesis of 3-substituted-5,6-diphenyl-1,2,4-triazines.

In some instances, the nitrile was not available, but instead the corresponding
carboxylic acids or esters were available. For those cases, a second method was
utilized to react a hydrazide with a diketone in the presence of ammonium acetate. This
reaction can be performed thermally, but this leads to slow and sometimes incomplete
conversion. Initially, this reaction was performed in a conventional microwave using
phenyl hydrazide and benzil, with low yields (51%) still being the drawback. Literature
suggested that these reactions could be performed in a microwave reactor to achieve
higher yields (> 79%) and less side product formation (>75% purity).80
Upon

acquiring

a

Microwave

Synthesizer,

we

attempted

this

protocol

with

heteroaromatic compounds to construct triazines containing substituents, such as
indole, benzofuran, benzothiophene, and benzothiazole. The carboxylic acid or ester
was converted to the hydrazide using hydrazine hydrate under reflux or microwave
conditions. The hydrazide was then reacted with a diketone in the microwave in the
presence of ammonium acetate to afford the desired triazine (Scheme 2.2). The
reaction to synthesize indole triazine resulted in a higher yield (63%) compared to the
other heterocyclic triazines, including benzothiophene substituted triazine (28%),
benzofuran triazine (42%), and benzothiazole triazine (34%). This was due to byproduct formation. While these byproducts were not isolated and characterized,
additional UV-active spots were observed via TLC. In an attempt to decrease the side
product formation, the hydrazine was reacted with the diketone at 60°C to form the
imine. Once the hydrazide was consumed, the reaction was completed in the
microwave. Unfortunately, this didn’t increase the yields significantly. Decreasing the
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substrate concentration in the reaction mixture or shorter reaction times could help limit
the side product formation.

Scheme 2.2 Synthesis of 1,2,4-triazines from carboxylic acids or esters.

These two methods afforded several heterocycles appended to the 3 position of the
1,2,4-triazine. Based on initial screening results (discussed in the following chapter), the
3-position was the most influential portion of the molecule. There was a desire to
substitute other nitrogen based heterocycles, such as an imidazole or a 1,2,4-triazole,
both known to coordinate metals. To synthesize the imidazole derivative, the initial
approach was to make the 2-cyano-methylimidazole derivative starting from methyl
imidazole.

Method A81 (Scheme 2.3) used a mixture of cyanogen bromide and

dimethylaminopyridine which resulted in desired product but in a low yield. Conditions
were slightly altered but sufficient yields were not achieved. Method B82 used copper
cyanide and sodium cyanide as the nitrile source and relied on the addition of
phenanthroline. This resulted in only recovered starting material. This was likely due to
low solubility in the recommended solvent of dioxanes and m-xylene. Since installation
of the nitrile functional group was problematic, other alternatives were sought after.
Literature methods show that 1,2,4-triazines are electrophilic at the 3-position when a
good leaving group such as methanesulfonyl was present, and considering that the
other two positions (5,6) are occupied by phenyl rings. 83 Imidazole could be used as a
nucleophile to replace the SO2Me group. Although this would lead to the formation of an
N-C bond with the triazine, it was worth the attempt, but this method also proved futile.
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.
Scheme 2.3 Attempted routes to synthesize 3-methylimidazoyl triazine.

The final attempt was to synthesize the hydrazide substituted imidazole since this could
be used in place of the amidrazone to produce the triazine (Scheme 2.4). Methyl
imidazole was first converted to the trichloroacetyl methyl imidazole.84 This intermediate
could then be reacted with hydrazine hydrate to afford the desired hydrazide. The
hydrazide was then condensed with benzil in the presence of acetic acid and
ammonium acetate to form the desired imidazole substituted triazine (2-38) in 52%
yield. The last heterocycle attempted was to position a 1,2,4-triazole in the 3-position
(Scheme

2.5),

beginning

from

commercially

available

methyl-1,2,4-triazole-3-

carboxylate. Although a single product was isolated after silica gel column
chromatography, the low solubility of the product made it difficult to fully characterize by
NMR. For this reason it was not screened for catalytic activity.

Scheme 2.4 Successful synthesis of 3-methylimidazoyl triazine.
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Scheme 2.5 Attempted synthesis of 3-(1,2,4-triazol-3-yl)-triazine.

2.3.2. Synthesis of 3-pyridyl-5,6-disubstituted-1,2,4-triazines
Up to this point only the substituent at the 3-position had been altered. It was desirable
to attempt to tune the activity by altering the substituents at the 5,6 positions. Other
commercial dicarbonyls available were glyoxal, and 2,3-butanedione. These were
condensed with 2-pyridyl amidrazone (2-14) to yield triazines 2-42 and 2-43 in 83% and
90% yield (Scheme 2.6A). This allowed exploration of the effect of non-aryl substituents
and the influence of steric bulk at these positions. Using pyridil as the diketone allowed
us to construct the tripyridine triazine 2-44 in 95% yield.
It was also advantageous to explore the effect of substituents at the 5 and 6 positions
independently. Thus far, we had only used symmetric diketones, so the 5 and 6
positions were identical. By employing ketoaldehydes, we had hoped to synthesize the
triazine with substitution at position 5 in one isomer and substitution at the 6 position in
the other isomer (Scheme 2.6B). The ketoaldehydes were synthesized from substituted
acetophenones using selenium dioxide. Condensation with the amidrazone (2-14) under
neutral conditions resulted in a single isomer (2-49) in 82% yield.85 The most
nucleophilic nitrogen is the terminal nitrogen of the hydrazono group and this will react
with the more electrophilic carbon of the aldehyde, leading to the substituent at the 5
position. Attempts to synthesize the other isomer were not successful, although
literature methods reported that this should be the predominant isomer under acidic
conditions.86
In addition to sterics, electronic properties of the triazine substituents were investigated
by installation of electron withdrawing and electron donating substituents. These
diketones were not on hand, so the diketones were first synthesized through a Benzoin
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Scheme 2.6 Synthesis of 3-(2-pyridyl),5,6-disubsituted triazines. From A) commercial
dicarbonyls, B) from substituted acetophenones, and C) from substituted benzaldehyde
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Condensation (Scheme 2.6C). The substituted aldehyde was exposed to KCN in
refluxing EtOH and H2O, followed by refluxing nitric acid. Although this worked for the
methyl substituent, the Benzoin Condensation failed with strongly withdrawing nitro
groups. An alternate synthesis involved formation of an oxazole and subsequent
nitration, and oxidative opening of the oxazole to lead to the formation of the desired
diketone (Scheme 2.7). Reaction with amidrazone (2-14) yielded the nitro substituted
1,2,4-triazine derivative (2-59). Although the reaction between amidrazone and diketone
produced 93% product, the yield over four steps from starting benzoin was a minuscule
15%. Reduction of the nitro groups resulted in the amine derivative, but difficulties in
isolation resulted in only 80% purity of 2-60.

Scheme 2.7 Synthesis of nitro and amine substituted 1,2,4-triazines.
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Now that we had changed the size of the functional groups and the electronics of the
groups attached to the 1,2,4-triazine, we next explored syntheses to impact the shape
of the molecule. At first glance, one might think the molecules synthesized previously
are planar or flat. The 3-substituent lies within the same plane as the 1,2,4-triazine, but
the 5 and 6 positions are slightly twisted out of this plane with a dihedral angle of 63°
between the two phenyl substituents.87 To illustrate this, we examined the lowest energy
conformation of 2 selected 1,2,4-triaines (Figure 2.6). Sybyl modeling software was
used to obtain a rough estimation of the geometry of 1,2,4-triazines in the lowest energy
conformation. In 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine (2-17) the lowest energy
conformation showed twisted phenyl rings as was expected. If the 5,6 substituents were
connected (2-62) the lowest energy conformation was entirely planar. To see if this
would alter the catalytic activity, we chose to use diketones that would “lock” these
substituents into the same plane. Three diketones, phenanthrene-9,10-dione (2-61),
1,10-phenanthroline-5,6-dione (2-64), and isatin (2-66) were reacted with amidrazone 214 to afford the corresponding triazines in 74%, 75% and 59% yield (Scheme 2.8).
Encouraged by some of the results from catalytic screening, our next goal was to
incorporate two 1,2,4-triazines within one molecule, bridged by a pyridine ring. The most
straight forward route was to construct a bis-amidrazone and react it with two
equivalents of benzil. (Scheme 2.9) 2,6-Dicyanopryridine was synthesized starting from
pyridine dicarboxylic acid. The acid was converted into the bisamide followed by
dehydrating conditions to give the desired 2,6-dicyanopyridine. Reaction with hydrazine
hydrate resulted in the bis-amidrazone which was reacted with benzil to form the
desired bis-triazine (2-72) in 92% yield. The overall yield through 5 steps was only 16%,
but each intermediate was isolated through either filtration or aqueous extraction,
eliminating the need for column chromatography and allowing the synthesis to be
completed rather quickly.
Having synthesized the bistriazine, we were curious if another nitrogen heterocycle
could be appended in close proximity to the triazine core. One idea was to synthesize a
1,2,3-triazole triazine. Conversion of an aromatic amine to an azide occurs easily under
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Figure 2.6 Illustration showing modeling of 1,2,4-triazines in Sybyl. Two phenyl
substituents are twisted in 5,6-diphenyl-1,2,4-triazine (2-17), but are planar in “fused” triazine (262).

Scheme 2.8 Synthesis of triazines using cyclic or fused diketones.
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Scheme 2.9 Synthesis of bis1,2,4-triazine.

diazotization conditions, using sodium nitrite and sodium azide in acidic media (Scheme
2.10).88 For this reason, we began with the amino methyl benzoate and converted it into
the corresponding hydrazide followed by condensation with benzil and ammonium
acetate under microwave conditions. The amine was left unprotected as the hydrazide
amine should be much more reactive than the aromatic amine. After converting the
amine to the azide, a CuAAC reaction with propargyl alcohol installed the 1,2,3-triazole,
to provide an additional metal binding functional group with an overall yield of 19% over
4 steps.

Scheme 2.10 Synthesis of triazole triazine.
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One final ring closure reaction was conducted between phenyl hydrazide (2-20) and
pyridil (Scheme 2.11) to give a triazine with pyridyl substituents in the 5- and 6positions, and a phenyl in the 3-position. The triazine synthesis was carried out in the
microwave to yield the product (2-78) in 40% yield after column chromatography. This
does not fit into either of the categories discussed earlier, since all three substituents
are being modified. The series of triazines including 2-17, 2-44, and 2-78 has the
pattern of increasing the pyridine substituents from 1 to 2 to 3. The addition of this
compound could help us to better understand the dependence on the location of the
pyridine substituent.

Scheme 2.11 Synthesis of 3-phenyl-5,6-di(2-pyridyl)-1,2,4-triazine.

2.4.

Substituent Modifications

Substituent modifications were at first an appealing route to install additional
heterocycles onto synthesized triazines. Depending on the existing substitution pattern,
the reactivity pattern for 1,2,4-triazines is C5 > C3 > C6.83 A good leaving group can be
installed during the initial 1,2,4-triazine formation and displaced at a later point. From
the observed activities of triazines, we were interested in substituting additional
heterocycles at the 3-position. This was in response to work by Finn and colleagues in
their synthesis of tailored tripodal ligands.39 Although we had successfully synthesized a
1,2,3-triazole and a second 1,2,4-triazine in close proximity to the 1,2,4-triazine core, we
wanted to install a 1,2,3-triazole, 1,2,4-triazole or 1,2,4-triazine directly attached to the
triazine core.
Initially, we synthesized the 3-thiomethyl-1,2,4-triazine through a ring closure reaction
between benzil and S-methylisothiosemicarbazide hydroiodide salt 2-79 in 89% yield
(Scheme 2.12). The methylthiol group was easily displaced by hydrazine hydrate, which
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was reacted with an aldehyde to form the imine containing triazine (2-82) in 80% yield.
We then displaced the thiomethyl group using sodium azide as the nucleophile, but all
attempts at a cycloaddition with propargyl alcohol resulted in recovery of starting
material. The azide is in equilibrium with the tetrazole formed by reaction with the
triazine core, with the tetrazole being the dominant form, preventing the cycloaddition
reaction.89

Scheme 2.12 Synthesis of 1,2,4-triazines by substituent modification.

With the attempt to install a 1,2,3-triazole halted, we moved on to the next heterocycle.
The substitution by cyanide was not successful from thiomethyl triazine (2-80). This
required us to oxidize the thiomethyl substituent to the mesyl group, which would serve
as a better leaving group (2-83). The substitution proceeded in decent yield, but
unfortunately the reactivity observed was not as expected. Instead of the nucleophile
reacting at the nitrile carbon, the triazine carbon proved to be more susceptible to
nucleophilic attack. This led to the displacement of the nitrile functional group by
nucleophiles such as hydrazine, 2-pyridyl hydrazide, and n-butanol.90 Attempts to
include a 1,2,3-triazole, 1,2,4-triazole, or a 1,2,4-triazine directly connected to the 3position of the existing 1,2,4-triazine were all unsuccessful.
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2.5.

Ring Transformations

Despite unsuccessful attempts in the synthesis of the heterocycles above, there were
still other triazines and related heterocycles that could be synthesized. Ring
transformations are a less common way to make 1,2,4-triazines. This method was not
fully explored to make 1,2,4-triazines, but rather as a way to make other nitrogen
containing heterocycles. In an attempt to synthesize one of the molecules above, we
heated 2-cyanopyridine in the presence of hydrazine hydrate. This resulted in an orange
solid, but did not match the expected spectral data. It was confirmed that we had
synthesized the dihydrotetrazine (2-85), rather than the expected triazine (Scheme
2.13). To our advantage, this material could be oxidized to the aromatic tetrazine (2-86)
and then reacted with an alkyne in an inverse electron-demand Diels-Alder to form the
pyridazine (2-87) in 77% yield. Changing the dienophile from an alkyne to a nitrile would
result in a 1,2,4-triazine (2-88), but this reaction wasn’t fully explored. With this route,
we were also interested in observing if the presence of all three nitrogens of the core
triazine were necessary for activity. The bipyridine derivative (2-89) was synthesized
utilizing aza-Diels-Alder to expel nitrogen (N2) and form the bipyridine in 66% yield.91
Finally, we included a few additional heterocycles that contained aromatic nitrogens but
were not classified as triazines (Scheme 2.14). Reaction of amidrazone 2-14 with an
aldehyde resulted in non-cyclic triazine derivatives (2-92, 2-93) in excess of 80% yield.
This would allow us to probe the catalytic activity and observe if a closed aromatic ring
was necessary for activity. Quinoxalines (2-94) are also interesting scaffolds and could
be made from diketones and 1,2-phenylenediamines. The position of the nitrogen atoms
appeared able to bind metal. Finally, pyridil was reacted with an aromatic amine to form
the imine (2-95) in 53% yield after column chromatography. Due to steric bulk, the
amine only added to one carbonyl of the diketone, even with excess amine and applied
heat. The proximity of the pyridine from the diketone and the imine from the aromatic
amine appear to be comparable to the proximity of the pyridine and 1,2,4-triazine core
in 2-17.
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Scheme 2.13 Diels-Alder reactions of tetrazines and triazines.
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Scheme 2.14 Non-1,2,4-triazine heterocycles containing sp2 nitrogens.

2.6.

Conclusions

A series of 1,2,4-triazines was synthesized using ring closure and substituent
modifications. Ring closure reactions between amidrazones and dicarbonyls were the
most effective method of synthesizing 1,2,4-triazines, resulting in yields between 70 –
90%, most of which could be isolated by filtration. Ring closure reactions between
hydrazides and diketones in the presence of ammonium acetate in the microwave was
used to synthesize additional 1,2,4-triazines. Yields were much lower, in the range of 28
– 68%, and triazines required chromatographic purification. Substituent modification
reactions of preformed triazines led to imine substituted triazines, but failed to provide
1,2,3-triazoles or 1,2,4-triazines substituted in the 3-position.
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Additional sp2 nitrogen containing ligands, such as pyridines, pyridazines, imines, and
quinoxalines were also synthesized using ring closure and ring transformations
methods. Overall modifications of 1,2,4-triazines were made to the 3-position, 5 and 6
positions, and to the core 1,2,4-triazine. The activity of the synthesized triazine ligands
will be explored in Chapter 3.

2.7.

Experimental

Materials and General Methods. Reagents and solvents were purchased from various
commercial sources and used without further purification unless otherwise stated.
Anhydrous solvents were purified using a Grubbs solvent system. Analytical thin-layer
chromatography (TLC) was performed using aluminum backed silica gel TLC plates
with UV indicator from Sorbent Technologies.

Flash column chromatography was

performed using 40-63 μm (230 x 400 mesh) silica gel from Sorbent Technologies.
and

1

H

13

C NMR were recorded at 600 MHz and 151 MHz, respectfully, on a Varian Inova

spectrometer or at 500 MHz and 125 MHz, on a Varian spectrometer. All chemical
shifts were reported in δ units relative to tetramethylsilane using the corresponding
deuterated solvent as a reference point.

High resolution mass spectra (ESI) were

obtained on a JEOL AccuTOF DART spectrometer. Infrared spectra were recorded on
a Varian 4100 FT-IR using KBr pellets or KBr salt plates. Absorption spectra were
collected on a Thermo Scientific Evolution 600. High pressure liquid chromatography
(HPLC) was performed using a Beckman Coulter System equipped with a UV-Vis
detector, autosampler, Varian C18 column, and a mobile phase composed of
acetonitrile and trifluoroacetic acid. Microwave reactions were performed in sealed vials
using a Biotage Initiator Microwave Synthesizer.

picolinohydrazonamide (2-14). 2-7 (5g, 48 mmol) was dissolved in EtOH
(6mL) and hydrazine hydrate (3.26 mL, 67 mmol) and stirred at room
temperature overnight. The pale white precipitate was filtered and washed
with Et2O in 94% yield. 1H NMR (CDCl3, 600 MHz) δ 8.52 (m, 1H), 8.01 (d, 1H, J = 7.8
Hz), 7.69 (t, 1H, J = 7.8 Hz), 7.26 (m, 1H), 5.27 (br, 2H), 4.59 (b, 2H).
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13

C NMR (CDCl3,

151 MHz) δ 150.8, 148.7, 147.9, 136.4, 123.8, 119.7. HRMS (ESI) m/z calculated
137.08272 (C6H9N4, [M+H]+), m/z observed 137.08324 (C6H9N4, [M+H]+).

pyrimidine-2-carbohydrazonamide (2-15). 2-8 (250 mg, 2.38 mmol) was
dissolved in EtOH (0.3 mL) and hydrazine hydrate (0.163 mL, 3.33 mmol)
and stirred overnight at room temperature. Reaction was monitored by TLC.
The reaction was concentrated in vacuo to yield a yellow oil in quantitative yield.

1

H

NMR (CDCl3, 600 MHz) δ 8.77 (d, 2H, J = 4.8 Hz), 7.26 (t, 1H, J = 4.8 Hz), 5.17 (b, 2H),
4.83 (b, 2H).

13

C NMR (CDCl3, 151 MHz) δ 158.8, 157.2, 146.6, 120.6. HRMS (ESI)

m/z calculated 138.07797 (C5H8N5, [M+H]+), m/z observed 138.07782 (C5H8N5, [M+H]+).

pyrazine-2-carbohydrazonamide (2-16). 2-9 (250 mg, 2.38 mmol) was
dissolved in EtOH (0.3 mL) and hydrazine hydrate (0.163 mL, 3.33 mmol)
and stirred overnight at room temperature. Reaction was monitored by TLC.
The pale white precipitate was filtered and washed with EtOH resulting in a 60% yield.
1

H NMR (CDCl3, 600 MHz) δ 9.27 (s, 1H), 8.51 (m, 1H), 8.44 (m, 1H), 5.12 (b, 2H), 4.72

(b, 2H).

13

C NMR (CDCl3, 151 MHz) δ 146.6, 146.4, 144.1, 142.8, 142.3. HRMS (ESI)

m/z calculated 138.07797 (C5H8N5, [M+H]+), m/z observed 138.07783 (C5H8N5, [M+H]+).

5,6-diphenyl-3-(pyridin-2-yl)-1,2,4-triazine (2-17).

2-10 (500 mg,

3.67 mmol) and benzil (772 mg, 3.67 mmol) were added to 10 mL of
EtOH. The slurry was heated at 80°C for 6 h with complete dissolution.
Progress of the reaction was monitored by TLC. The reaction mixture was cooled to
room temperature and the resulting precipitate was filtered and washed with EtOH and
Et2O resulting in a 76% yield.

1

H NMR (CDCl3, 600 MHz) δ 8.91 (d, 1H, J = 4.2 Hz),

8.70 (d, 1H, J = 7.8 Hz), 7.91 (t, 1H, J = 7.8 Hz), 7.68 (d, 2H, J = 7.8 Hz), 7.64 (d, 2H, J
= 7.8 Hz), 7.46 (t, 1H, J = 6.6 Hz), 7.43-7.31 (m, 6H).

13

C NMR (CDCl3, 151 MHz) δ

160.7, 156.5, 156.3, 152.9, 150.5, 137.0, 135.6, 135.3, 130.7, 129.9, 129.7, 129.6,
128.6. 128.5, 125.4, 124.1. UV-Vis (MeCN) λmax nm (ε M-1 cm-1): 387 (454.7). HRMS
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(ESI) m/z calculated 311.12967 (C20H15N4, [M+H]+), m/z observed 311.12831
(C20H15N4, [M+H]+).

5,6-diphenyl-3-(pyrimidin-2-yl)-1,2,4-triazine (2-18). 2-11 (100 mg,
0.730 mmol) and benzil (153 mg, 0.730 mmol) were added to 2 mL of
EtOH. The slurry was heated for 6 h at 80°C. Progress of the reaction
was monitored by TLC. The reaction mixture was cooled to room temperature and the
resulting yellow precipitate was filtered and washed with EtOH resulting in a 75% yield.
1

H NMR (CDCl3, 600 MHz) δ 9.10 (d, 2H, J = 4.8 Hz), 7.68-7.64 (m, 4H), 7.51 (t, 1H, J =

4.8 Hz), 7.46-7.43 (m, 2H), 7.41-7.39 (m, 2H), 7.38-7.35 (m, 2H).

13

C NMR (CDCl3, 151

MHz) δ 161.8, 160.2, 158.3, 157.4, 156.7, 135.5, 135.2, 131.0, 130.1, 129.9, 128.8,
121.9. UV-Vis (MeCN) λmax nm (ε M-1 cm-1): 386 (460.4). HRMS (ESI) m/z calculated
312.12492 (C19H14N5, [M+H]+), m/z observed 312.12414 (C19H14N5, [M+H]+).

5,6-diphenyl-3-(pyrazin-2-yl)-1,2,4-triazine (2-19).

2-12 (100 mg,

0.730 mmol) and benzil (153 mg, 0.730 mmol) were added to 2 mL of
EtOH.

The slurry was heated overnight at 80°C.

Progress of the

reaction was monitored by TLC. The reaction mixture was cooled to room temperature
and concentrated in vacuo to quantitatively yield the product as a yellow solid.

1

H NMR

(CDCl3, 600 MHz) δ 9.91 (s, 1H), 8.87 (s, 1H), 8.78 (s, 1H), 7.69 (d, 2H, J = 7.2 Hz),
7.65 (d, 2H, J = 7.8 Hz), 7.48-7.45 (m, 2H), 7.42-7.37 (m, 4H).

13

C NMR (CDCl3, 151

MHz) δ 159.6, 157.2, 156.7, 148.6, 146.3, 145.7, 145.0, 135.4, 135.1, 131.2, 130.2,
130.1, 129.8, 128.9, 128.8. UV-Vis (MeCN) λmax nm (ε M-1 cm-1): 386 (523.6). HRMS
(ESI) m/z calculated 312.12492 (C19H14N5, [M+H]+), m/z observed 312.12346
(C19H14N5, [M+H]+).

General Hydrazide Method A:

Methyl (or Ethyl) Ester (1 eq) was dissolved in

hydrazine hydrate (2.5 eq) and MeOH (or EtOH) (3.5 M) and refluxed overnight. MeOH
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(or EtOH) and excess hydrazine hydrate were removed in vacuo. The precipitated
product was dried under vacuum.

General Hydrazide Method B: Carboxylic acid (1 eq) was dissolved in xylenes (0.6 M)
and hydrazine hydrate (10 eq) was added to the mixture. This was microwaved at
180°C for 6 hours. The resulting mixture was extracted with DCM and concentrated in
vacuo.

benzohydrazide (2-25). Prepared using general hydrazide method A and
isolated as a white solid. 1H NMR (CD3CN, 600 MHz) δ 8.23 (br), 7.76 (d,
2H, J = 7.2 Hz), 7.52 (m, 1H), 7.45 (t, 2H, J = 7.2 Hz)

13

C NMR (CD3CN, 151 MHz) δ

168.3, 134.3, 132.3, 129.4, 127.8. HRMS (ESI) m/z calculated 137.07149 (C 7H9N2O,
[M+H]+), m/z observed 137.07190 (C7H9N2O, [M+H]+).

benzo[b]thiophene-2-carbohydrazide (2-26). Prepared using general
hydrazide method B and isolated as a brown solid in 54% yield.
1

H NMR (d6-DMSO, 600 MHz) δ 10.03 (bs, 1H), 8.00 – 8.02 (m, 2H), 7.91 (d, 1H, J =

7.2 Hz), 7.41 – 7.46 (m, 2H).

13

C NMR (d6-DMSO, 151 MHz) δ 161.3, 139.9, 139.2,

138.4, 126.0, 125.0, 124.9, 124.1, 122.7.

HRMS (ESI) m/z calculated 193.04356

(C9H9N2OS, [M+H]+), m/z observed 193.04230. (C9H9N2OS, [M+H]+).

benzofuran-2-carbohydrazide

(2-27).

Prepared

using

general

hydrazide method B and isolated as a white solid in 63% yield.
1

H NMR (d6-DMSO, 600 MHz) δ 10.02 (bs, 1H), 7.75 (d, 1H, J = 7.8 Hz), 7.63 (d, 1H, J

= 8.4 Hz), 7.51 (s, 1H), 7.44 (t, 1H, J = 7.8 Hz), 7.32 (t, 1H, J = 7.8 Hz), 4.85 (b, NH2).
13

C NMR (d6-DMSO, 151 MHz) δ 157.8, 154.1, 148.4, 127.0, 126.6, 123.6, 122.6,

111.7, 108.7.

HRMS (ESI) m/z calculated 177.06640 (C9H9N2O2, [M+H]+), m/z

observed 177.06594. (C9H9N2O2, [M+H]+).
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1H-indole-2-carbohydrazide (2-28). Prepared using general hydrazide
method B and isolated as a pale yellow solid in 64% yield. Used crude
for next step. HRMS (ESI) m/z calculated 176.08239 (C9H10N3O,
+

[M+H] ), m/z observed 176.08134. (C9H10N3O, [M+H]+).

ethyl benzo[d]thiazole-2-carboxylate (2-24). 2-aminothiophenol (1eq)
was dissolved in diethyloxalate (2 eq) and heated at 120°C overnight.
Reaction progress was followed by TLC. Upon consumption of starting material,
reaction mixture was poured into a mixture of HCl, H2O, and EtOH. Two layers formed.
Stir biphasic solution. Once solid formation begins, place in chilled water bath. Filter and
wash solid with small amounts of cold water. Isolated in 72% yield as a pale green solid.
1

H NMR (CDCl3, 600 MHz) δ 8.25 (d, 1H, J = 8.4 Hz), 7.98 (d, 1H, J = 7.8 Hz), 7.58 (t,

1H, J = 7.8 Hz), 7.54 (t, 1H, J = 7.8 Hz), 4.56 (q, 2H, J = 7.2 Hz), 1.49 (t, 3H, J = 7.2
Hz).

13

C NMR (CDCl3, 151 MHz) δ 160.8, 158.7, 153.4, 136.9, 127.7, 127.2, 125.7,

122.2, 63.3, 14.4. HRMS (ESI) m/z calculated 208.04322 (C10H10NO2S, [M+H]+), m/z
observed 208.04252. (C10H10NO2S, [M+H]+).

benzo[d]thiazole-2-carbohydrazide (2-29). Ester 2-24 (1 eq) was
dissolved in EtOH (0.4 M) and to this mixture was added hydrazine
hydrate (1.5 eq). This solution was heated overnight at 80°C with complete dissolution.
Reaction progress was followed by TLC. Upon removal of solution from heat, yellow
precipitate formed. Filter and wash with small portions of EtOH. Resultant solid dried
under vacuum. Collected yellow solid in 81% yield.

1

H NMR (CDCl3, 600 MHz) δ 10.46

(s, 1H) 8.22 (d, 1H, J = 7.8 Hz), 8.11 (d, 1H, J = 7.8 Hz), 7.62 (t, 1H, J = 7.8 Hz), 7.57 (t,
1H, J = 7.8 Hz), 4.72 (bs, 2H, NH2).

13

C NMR (CDCl3, 151 MHz) δ 163.7, 158.1, 152.8,

135.7, 127.0, 126.7, 123.9, 122.9. HRMS (ESI) m/z calculated 194.03881 (C8H8N3OS,
[M+H]+), m/z observed 194.03803. (C8H8N3OS, [M+H]+)
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General Triazine Method B: Heterocyclic hydrazide (1.1 eq) was dissolved in AcOH
(0.25 M). To this mixture was added benzil (1 eq) and NH4OAC (10 eq). This solution
was heated in a sealed vial using a microwave synthesizer at 180°C.

3,5,6-triphenyl-1,2,4-triazine (2-30). 2-16 (142 mg, 1.05 mmol), benzil
(200 mg, 0.95 mmol), and ammonium acetate (732 mg, 9.50 mmol)
were suspended in AcOH (2 mL). The suspension was heated in a
conventional microwave at 750W and monitored by TLC until benzil no longer
remained. The reaction mixture was concentrated in vacuo and precipitated out of
EtOH. The product was isolated as a pale yellow solid in 51% yield.

1

H NMR (CDCl3,

600 MHz) δ 8.67 (s, 1H), 7.67 (d, 2H, J = 7.2 Hz), 7.62 (d, 2H, J = 7.2 Hz), 7.55-7.54
(m, 3H), 7.44-7.34 (m, 6H).

13

C NMR (CDCl3, 151 MHz) δ 161.3, 155.48, 155.46,

135.9, 135.5, 134.8, 131.5, 130.7, 129.8, 129.5, 129.4, 128.8, 128.6, 128.5, 128.3. UVVis (MeCN) λmax nm (ε M-1 cm-1): 385 (480.9). HRMS (ESI) m/z calculated 310.13442
(C21H16,N3, [M+H]+), m/z observed 310.13349 (C21H16N3, [M+H]+).

3-(benzo[b]thiophen-2-yl)-5,6-diphenyl-1,2,4-triazine

(2-31).

Prepared using general triazine method B. The solid formed upon
heating was centrifuged, washed with AcOH, and purified over silica
gel, eluting with a gradient of hexanes and ethyl acetate to afford a
yellow solid in 28% yield.

1

H NMR (CDCl3, 500 MHz) δ 8.53 (s, 1H), 7.91 – 7.94 (m,

2H) 7.66 – 7.70 (m, 2H), 7.60 – 7.62 (m, 2H), 7.37 – 7.50 (m, 8H).

13

C NMR (CDCl3,

125 MHz) δ 159.3, 155.9, 155.6, 142.4, 140.1, 139.8, 135.63, 135.56, 131.0, 130.0,
129.8, 129.6, 128.8, 128.7, 127.3, 126.4, 125.2, 125.0, 122.9.

HRMS (ESI) m/z

+

calculated 366.10649 (C23H16N3S, [M+H] ), m/z observed 366.10475. (C23H16N3S,
[M+H]+).

3-(benzofuran-2-yl)-5,6-diphenyl-1,2,4-triazine (2-32). Prepared
using general triazine method B. The fine solid formed upon heating
was centrifuged, washed with AcOH, and purified over silica gel,
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eluting with a gradient of hexanes and ethyl acetate to afford a pale yellow solid in 42%
yield. 1H NMR (CDCl3, 600 MHz) δ 7.97 (s, 1H), 7.75 (d, 1H, J = 7.8 Hz) 7.71 (d, 1H, J
= 8.4 Hz), 7.67 (d, 2H, J = 7.2 Hz), 7.62 (d, 2H, J = 7.2 Hz), 7.42 – 7.49 (m, 3H), 7.37 –
7.41 (m, 4H), 7.33 (t, 1H, J = 7.2 Hz).

13

C NMR (CDCl3, 151 MHz) δ 156.5, 156.13,

156.07, 155.8, 151.4, 135.6, 135.4, 131.0, 130.0, 129.9, 129.7, 128.8, 128.3, 126.9,
123.8, 122.5, 112.5, 111.3.

HRMS (ESI) m/z calculated 350.12934 (C23H16N3O,

[M+H]+), m/z observed 350.12765. (C23H16N3O, [M+H]+).

2-(5,6-diphenyl-1,2,4-triazin-3-yl)-1H-indole

(2-33).

Prepared

using general triazine method B. The fine solid formed upon
heating was centrifuged, washed with AcOH, and purified over
silica gel, eluting with a gradient of hexanes and ethyl acetate to
afford a bright yellow solid in 63% yield. 1H NMR (CDCl3, 600 MHz) δ 9.57 (s, 1H), 7.76
(d, 1H, J = 8.4 Hz) 7.68 (s, 1H), 7.66 (d, 2H, J = 7.2 Hz), 7.59 (d, 2H, J = 7.2 Hz), 7.32
(t, 1H, J = 7.2 Hz), 7.17 (t, 1H, J = 7.2 Hz), 7.46 – 7.51 (m, 2H), 7.41 – 7.45 (m, 1H),
7.37 – 7.41 (m, 4H).

13

C NMR (CDCl3, 151 MHz) δ 157.0, 156.2, 155.4, 137.7, 135.8,

135.6, 133.0, 131.0, 130.0, 129.7, 129.6, 128.9, 128.7, 124.9, 122.3, 120.9, 111.9,
107.1.

HRMS (ESI) m/z calculated 349.14532 (C23H17N4, [M+H]+), m/z observed

349.14435. (C23H17N4, [M+H]+).

2-(5,6-diphenyl-1,2,4-triazin-3-yl)benzo[d]thiazole

(2-34).

Prepared using general triazine method B. The solution was diluted
with water and extracted with DCM (3x). The organic layer was
concentrated in vacuo and the resultant material was purified over
silica gel, eluting with a gradient of hexanes and ethyl acetate to afford a yellow solid in
34% yield.

1

H NMR (CDCl3, 600 MHz) δ 8.32 (d, 1H, J = 8.4 Hz), 8.03 (d, 1H, J = 7.8

Hz), 7.71 (d, 2H, J = 7.8 Hz), 7.65 (d, 2H, J = 8.4 Hz), 7.58 (t, 1H, J = 7.2 Hz, 8.4 Hz),
7.52 (t, 1H, J = 7.2 Hz, 8.4 Hz), 7.45 – 7.49 (m, 2H), 7.38-7.42 (m, 4H).

13

C NMR

(CDCl3, 151 MHz) δ 164.1, 157.9, 157.5, 156.8, 154.6, 136.8, 135.09, 135.07, 131.3,
130.3, 130.2, 129.8, 128.9, 128.8, 127.0, 126.9, 125.3, 122.1.
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HRMS (ESI) m/z

calculated 367.10174 (C22H15N4S, [M+H]+), m/z observed 367.09878 (7.98 ppm).
(C22H15N4S, [M+H]+).

2,2,2-trichloro-1-(1-methyl-1H-imidazol-2-yl)ethanone

(2-36).

Methyl

imidazole (1 mmol) was dissolved in DCM (1.3 mL). In a separate flask,
combine DCM (1.3 mL) and trichloroacetylchloride (1.1 mmol). To a stirred solution of
methyl imidazole in DCM, and the trichloroacetylchloride in DCM dropwise. Solution
turned cloudy upon first drops, but quickly turned transparent yellow. Upon stirring
solution became cloudy yellow. Stir at room temperature overnight. Cool reaction
mixture in ice bath and dropwise add triethylamine (1.1 mmol). Solution turned from
thick bright yellow to dark brown upon addition. Concentrate in vacuo and resulting
residue purified via silica gel chromatography using gradient elution of hexanes and
DCM. Isolated as a white solid in 72% yield.

1-methyl-1H-imidazole-2-carbohydrazide (2-37). Dissolve 2-36 (1 mmol)
in dioxanes (5 mL). Cool solution in ice bath, and add hydrazine hydrate (2
mmol) to cooled solution. Remove ice bath and stir solution at room temperature
overnight. Reaction progress followed by TLC. Upon completion, reaction mixture was
concentrated in vacuo to yield an off-white solid in 90% yield.

3-(1-methyl-1H-imidazol-2-yl)-5,6-diphenyl-1,2,4-triazine

(2-38).

Benzil (1 mmol) and hydrazide 2-37 (1.05 mmol) were combined in
AcOH (4 mL) in a microwave vessel. Reaction mixture was stirred at
60°C overnight. TLC shows consumption of starting material. Add NH4OAC (10 mmol)
and microwave at 180°C for 10 min. Starting materials consumed by TLC. Add H2O and
extract with DCM. Combine organics and wash with H2O. Concentrate in vacuo and
purify over silica gel eluting with hexanes, ethyl acetate, and MeOH. Isolated a yellow
solid in 52% yield.

1

H NMR (CDCl3, 600 MHz) δ 7.67 – 7.69 (m, 2H), 7.61 – 7.62 (m,

2H), 7.42 – 7.45 (m, 2H), 7.38 – 7.40 (m, 2H), 7.32 – 7.36 (m, 3H), 7.15 (s, 1H), 4.28 (s,
3H).

13

C NMR (CDCl3, 151 MHz) δ 156.6, 156.0, 155.6, 141.9, 135.5, 135.4, 131.0,
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130.6, 130.2, 129.9, 129.6, 128.8, 128.6, 126.2, 37.4.

HRMS (ESI) m/z calculated

314.14057 (C19H16N5, [M+H]+), m/z observed 314.14014. (C19H16N5, [M+H]+).

3-(pyridin-2-yl)-1,2,4-triazine (2-42). 2-14 (500 mg, 3.67 mmol) and 2-39
(40% by wt in water, 533 mg, 3.67 mmol) were added to 10 mL of EtOH.
The slurry was heated overnight at 60°C with complete dissolution.
Progress of the reaction was monitored by TLC. The reaction mixture was cooled to
room temperature and filtered.
orange-brown solid in 83% yield.

The filtrate was concentrated in vacuo to yield an
1

H NMR (CDCl3, 600 MHz) δ 9.29 (s, 1H), 8.89 (d,

1H, J = 4.2 Hz), 8.82 (s, 1H), 8.68 (d, 1H, J = 7.8 Hz), 7.93 (m, 1H), 7.49 (t, 1H, J = 6.6
Hz)

13

C NMR (CDCl3, 151 MHz) δ 163.6, 152.5, 150.7, 149.5, 148.8, 137.4, 126.0,

124.2. UV-Vis (MeCN) λmax nm (ε M-1 cm-1): 388 (376.0). HRMS (ESI) m/z calculated
159.06707 (C8H7N4, [M+H]+), m/z observed 159.06661 (C8H7N4, [M+H]+).

5,6-dimethyl-3-(pyridin-2-yl)-1,2,4-triazine (2-43). 2-14 (600 mg, 4.17
mmol) and 2-40 (377 mg, 4.38 mmol) were added to 10 mL of EtOH.
The slurry was heated at 80°C overnight with complete dissolution.
Progress of the reaction was monitored by TLC. After concentration in vacuo, the crude
product was purified by silica gel chromatography with gradient elution using EtOAc and
hexanes to yield a pale brown solid in 90.0% yield.

1

H NMR (CDCl3, 600 MHz) δ 8.88

(m, 1H), 8.65 (d, 1H, J = 8.4 Hz), 7.90 (t, 1H, J = 7.8 Hz), 7.46-7.44 (m, 1H), 2.78 (s,
3H), 2.70 (s, 3H).

13

C NMR (CDCl3, 151 MHz) δ 161.5, 159.6, 157.0, 153.0, 150.3,

137.1, 125.2, 123.8, 22.1, 19.7. UV-Vis (MeCN) λmax nm (ε M-1 cm-1): 372 (378.1).
HRMS (ESI) m/z calculated 187.09782 (C10H11N4, [M+H]+), m/z observed 187.09857
(C10H11N4, [M+H]+).

3,5,6-tri(pyridin-2-yl)-1,2,4-triazine (2-44).

2-14 (100 mg, 0.730

mmol) and 2-44 (150 mg, 0.730 mmol) were added to 2 mL of EtOH.
The slurry was heated overnight at 80°C with complete dissolution.
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Progress of the reaction was monitored by TLC. The reaction mixture was cooled to
room temperature and the resulting precipitate was filtered and washed with EtOH
resulting in a 95% yield. 1H NMR (CDCl3, 600 MHz) δ 8.94 (d, 1H, J = 3.6 Hz), 8.75 (d,
1H, J = 7.8 Hz), 8.36-8.35 (m, 2H), 8.27-8.25 (m, 2H), 7.96 (dt, 1H, J = 7.8, 1.8 Hz),
7.93-7.87 (m, 2H), 7.52-7.49 (m, 1H), 7.32-7.29 (m, 2H).

13

C NMR (CDCl3, 151 MHz) δ

161.5, 156.37, 156.35, 154.9, 154.8, 152.8, 150.8, 148.93, 148.92, 137.4, 137.21,
137.19, 125.9, 125.1, 124.70, 124.66, 124.5, 124.0. UV-Vis (MeCN) λmax nm (ε M-1 cm1

): 382 (495.9).

HRMS (ESI) m/z calculated 313.12017 (C18H13N6, [M+H]+), m/z

observed 313.11959 (C18H13N6, [M+H]+).

2-oxo-2-phenylacetaldehyde (2-47). Selenium dioxide (924 mg, 8.32 mmol)
was suspended in dioxane (4.2 mL) and water (0.20 mL) and heated at 55°C
until mostly dissolved. 2-45 (1 g, 8.32 mmol) was then added and the reaction was
refluxed for 4 h. After cooling to room temperature, the reaction was filtered and the
filtrate was concentrated in vacuo.

Purification via silica gel chromatography with

gradient elution using EtOAc and hexanes was used to further purify the reaction
mixture. The crude product was used in further reactions. MS (ESI) m/z calculated
135.04460 (C8H7O2, [M+H]+), m/z observed 135.042 (C8H7O2, [M+H]+).

2-(4-hydroxyphenyl)-2-oxoacetaldehyde (2-48). Selenium dioxide (814
mg, 7.34 mmol) was suspended in dioxane (3.7 mL) and water (0.18 mL)
and heated at 55°C until mostly dissolved. 2-46 (3 g, 15.0 mmol) was then added and
the reaction was refluxed for 4 h. After cooling to room temperature, the reaction was
filtered and the filtrate was concentrated in vacuo.

Purification via silica gel

chromatography with gradient elution using EtOAc and hexanes was used to further
purify the reaction mixture. The crude product was used in further reactions. MS (ESI)
m/z calculated 151.03952 (C8H7O3, [M+H]+), m/z observed 151.038 (C8H7O3, [M+H]+).
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5-phenyl-3-(pyridin-2-yl)-1,2,4-triazine (2-49).

2-47 (246 mg, 1.84

mmol) and 2-14 (250 mg, 1.84 mmol) were added to 5 mL of EtOH.
The slurry was heated for 4 h at 80°C with complete dissolution.
Progress of the reaction was monitored by TLC. The reaction mixture was cooled to
room temperature and purified by silica gel chromatography with gradient elution using
EtOAc and hexanes to yield a white solid in 82% yield.

1

H NMR (CDCl3, 600 MHz) δ

9.72 (s, 1H), 8.94 (d, 1H, J = 4.2 Hz), 8.68 (d, 1H, J = 7.8 Hz), 8.31 (d, 2H, J = 8.4 Hz),
7.95 (t, 1H, J = 7.8 Hz), 7.63-7.59 (m, 3H), 7.50 (m, 1H).

13

C NMR (CDCl3, 151 MHz) δ

162.9, 156.0, 153.2, 150.7, 145.5, 137.3, 133.6, 132.8, 129.6, 128.0, 125.7, 124.3. UVVis (MeCN) λmax nm (ε M-1 cm-1): 382 (486.2). HRMS (ESI) m/z calculated 235.09837
(C14H11N4, [M+H]+), m/z observed 235.09829 (C14H11N4, [M+H]+).

4-(3-(pyridin-2-yl)-1,2,4-triazin-5-yl)phenol (2-50). 2-48 (150 mg,
1.0 mmol) and 2-14 (136 mg, 1.0 mmol) were added to 3 mL of
EtOH.

The slurry was heated overnight at 80°C with complete

dissolution. Progress of the reaction was monitored by TLC. The reaction mixture was
cooled to room temperature and concentrated in vacuo yielding an orange solid in 90%
yield. 1H NMR (CDCl3, 600 MHz) δ 9.56 (s, 1H), 8.89 (d, 1H, J = 4.2 Hz), 8.72 (d, 1H, J
= 7.8 Hz), 8.10 (d, 2H, J = 8.4 Hz), 8.00 (t, 1H, J = 8.4 Hz), 7.56 (m, 1H), 6.96 (d, 2H, J
= 4.8 Hz), 3.49 (s, 1H).

13

C NMR (CDCl3, 151 MHz) δ 162.5, 161.6, 156.1, 153.1,

149.9, 145.1, 130.2, 126.0, 124.8, 124.7, 116.9. UV-Vis (MeCN) λmax nm (ε M-1 cm-1):
385 (1054.7).

HRMS (ESI) m/z calculated 251.09329 (C14H11N4O, [M+H]+), m/z

observed 251.09254 (C14H11N4O, [M+H]+).

1,2-di-p-tolylethane-1,2-dione (2-53).

2-52 (5 g, 41.6 mmol)

and KCN (1.35 g, 20.8 mmol) was dissolved in EtOH (8 mL) and
water (4 mL). The mixture was heated under reflux for 0.5 h.
After cooling to room temperature, the reaction mixture was poured into an ice bath and
the crude benzoin intermediate was precipitated. The solid was then filtered and further
washed with water. The crude benzoin intermediate was then refluxed in nitric acid (8
52

mL) for 2 h. The reaction mixture was poured into an ice bath and the crude benzil
derivative was precipitated and filtered. Recrystallization from EtOH yielded a yellow
solid in 39% yield. 1H NMR (CDCl3, 600 MHz) δ 7.86 (d, 4H, J = 7.8 Hz), 7.30 (d, 4H, J
= 7.8 Hz), 2.42 (s, 6H).

13

C NMR (CDCl3, 151 MHz) δ 194.6, 146.2, 130.9, 130.2,

129.8, 22.1. HRMS (ESI) m/z calculated 239.10720 (C16H15O2, [M+H]+), m/z observed
152.08191 239.10710 (C16H15O2, [M+H]+).

3-(pyridin-2-yl)-5,6-di-p-tolyl-1,2,4-triazine (2-54). 2-14 (284 mg,
2.10 mmol) and 2-52 (500 mg, 2.10 mmol) were added to EtOH (12
mL).

The slurry was heated at 80°C for 6 h with complete

dissolution. Progress of the reaction was monitored by TLC. After
concentration in vacuo, the crude product was purified by silica gel chromatography with
gradient elution using EtOAc and hexanes to yield a pale yellow solid in 41.1% yield. 1H
NMR (CDCl3, 600 MHz) δ 8.92 (d, 1H, J = 4.8 Hz), 8.70 (d, 1H, J = 7.8 Hz), 7.93 (t, 1H,
J = 7.8 Hz), 7.62 (d, 2H, J = 8.4 Hz), 7.54 (d, 2H, J = 8.4 Hz), (m, 1H), 7.21 (d, 2H, J =
13

7.8 Hz), 7.19 (d, 2H, J = 7.8 Hz), 2.40 (s, 3H), 2.38 (s, 3H).

C NMR (CDCl3, 151 MHz)

δ 160.6, 156.5, 156.3, 153.2, 150.6, 141.3, 140.0, 137.2, 133.1, 132.8, 130.1, 129.6,
129.5, 129.4, 125.4, 124.2, 21.7, 21.6.
(445.5).

UV-Vis (MeCN) λmax nm (ε M-1 cm-1): 400

HRMS (ESI) m/z calculated 339.16097 (C22H19N4, [M+H]+), m/z observed

339.15939 (C22H19N4, [M+H]+).

2-oxo-1,2-diphenylethyl acetate (2-56). 2-55 (4 g, 18.84 mmol) and
acetic anhydride (4.33g, 42.40 mmol) were dissolved in AcOH (4 mL).
Concentrated HCl (0.4 mL) was added dropwise at room temperature. The reaction
was then heated at 100°C for 30 min. After cooling to room temperature, 50 mL of
water was added and the reaction continued to stir at room temperature for an
additional 2 h. The precipitate was filtered and purified by silica gel chromatography
with gradient elution using EtOAc and hexanes to yield a white solid in 63% yield.

1

H

NMR (CDCl3, 600 MHz) δ 7.93 (d, 2H, J = 7.8 Hz), 7.51 (t, 1H, J = 7.8 Hz), 7.47 (d, 2H,
J = 7.8 Hz), 7.41-7.34 (m, 5H), 6.87 (s, 1H), 2.21 (s, 3H).
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13

C NMR (CDCl3, 151 MHz) δ

193.8, 170.6, 134.7, 133.7, 133.6, 129.5, 129.3, 128.9, 128.83, 128.76, 77.8, 20.9.
HRMS (ESI) m/z calculated 255.10212 (C16H15O3, [M+H]+), m/z observed 255.10306
(C16H15O3, [M+H]+).

2-methyl-4,5-bis(4-nitrophenyl)oxazole (2-57).

2-56 (1 g, 3.93

mmol) and ammonium acetate (454 mg, 5.90 mol) were dissolved in
AcOH (1.3 mL) and refluxed for 2 h.

After warming to room

temperature, the crude reaction was poured over ice and extracted
with Et2O. The organic layer was washed with water and brine, then dried with sodium
sulfate. Concentration in vacuo produced the intermediate oxazole as a brown oil. This
oil was dissolved in sulfuric acid (3 mL) and nitric acid (3 mL) was added dropwise at
room temperature. The reaction was then heated at 55 °C for 15 min. Progress of the
reaction was monitored by TLC. After warming to room temperature, ice was added to
precipitate the product.
yield.

1

Recrystalization from AcOH producted yellow solid in 59%

H NMR (CDCl3, 600 MHz) δ 8.26 (t, 4H, J = 8.4 Hz), 7.82 (d, 2H, J = 8.4 Hz),

7.74 (d, 2H, J = 8.4 Hz), 2.62 (s, 3H). 13C NMR (CDCl3, 151 MHz) δ 162.4, 147.9, 147.7,
145.0, 138.3, 136.3, 134.3, 128.9, 127.2, 124.5, 124.3, 14.2.

HRMS (ESI) m/z

+

calculated 326.07770 (C16H12N3O5, [M+H] ), m/z observed 326.07637 (C16H12N3O5,
[M+H]+).

1,2-bis(4-nitrophenyl)ethane-1,2-dione (2-58). 2-57 (600 mg,
1.85 mmol) and sodium acetate (1.2 g, 14.8 mmol) were
dissolved in a combination of AcOH (6.6 mL) and water (0.67
mL). Bromine (591 mg, 7.4 mmol) was then added and the reaction was refluxed for 2
h. Progress of the reaction was monitored by TLC. After cooling to room temperature,
the reaction was poured over ice and filtered. Recrystalization from AcOH produced a
yellow solid in 42% yield. 1H NMR (CDCl3, 600 MHz) δ 8.39 (d, 4H, J = 8.4 Hz), 8.21 (d,
4H, J = 8.4 Hz). 13C NMR (CDCl3, 151 MHz) δ 190.4, 151.7, 136.9, 131.4, 124.4. HRMS
(ESI) m/z calculated 301.04606 (C14H9N2O6, [M+H]+), m/z observed 301.04552
(C14H9N2O6, [M+H]+).
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5,6-bis(4-nitrophenyl)-3-(pyridin-2-yl)-1,2,4-triazine (2-59). 2-14
(136 mg, 1.0 mmol) and 2-58 (300 mg, 1.0 mmol) were added to 6
mL of EtOH.

The slurry was heated overnight at 80°C with

complete dissolution. Progress of the reaction was monitored by
TLC.

The reaction mixture was cooled to room temperature and the resulting

precipitate was filtered and washed with EtOH resulting in a 93% yield.

1

H NMR

(CDCl3, 600 MHz) δ 8.96 (d, 1H, J = 4.2 Hz), 8.75 (d, 1H, J = 7.8 Hz), 8.30-8.27 (m,
4H), 7.99 (dt, 1H, J = 7.8, 1.2 Hz), 7.86 (d, 2H, J = 7.2 Hz), 7.82 (d, 2H, J = 6.6 Hz),
7.56-7.54 (m, 1H).

13

C NMR (CDCl3, 151 MHz) δ 161.6, 154.7, 154.6, 152.0, 151.0,

149.5, 149.1, 141.1, 140.7, 137.5, 131.2, 130.8, 126.3, 124.8, 124.33, 124.28. UV-Vis
(MeCN) λmax nm (ε M-1 cm-1): 404 (546.5). HRMS (ESI) m/z calculated 401.09983
(C20H13N6O4, [M+H]+), m/z observed 401.09918 (C20H13N6O4, [M+H]+).

4,4’-(3-(pyridin-2-yl)-1,2,4-triazine-5,6-diyl)dianiline (2-60). 2-59
(200 mg, 0.5 mmol), and 5% palladium/carbon (2 mg), and
hydrazine hydrate (1 mL) were added to 2.5 mL of EtOH. The
reaction was refluxed for 6 h and progress was monitored by TLC.
Upon completion, reaction was filtered through celite and eluted with MeOH.
Concentration in vacuo yielded the crude product as an orange solid in 85% yield.
HPLC purity: 80%.

UV-Vis (9:1 MeCN:DMSO) λmax nm (ε M-1 cm-1): 475 (483.0).

HRMS (ESI) m/z calculated 341.15147 (C20H17N6, [M+H]+), m/z observed 341.15043
(C20H17N6, [M+H]+).

3-(pyridin-2-yl)phenanthro[9,10-e][1,2,4]triazine (2-62).

2-14 (500

mg, 3.67 mmol) and 2-61 (764 mg, 3.67 mmol) were added to 10 mL of
ACN.

The slurry was heated at 80°C overnight with complete

dissolution. Progress of the reaction was monitored by TLC. The reaction mixture was
cooled to room temperature and the resulting precipitate was filtered and washed with
ACN and Et2O resulting in a 75% yield.

1

H NMR (CDCl3, 600 MHz) δ 9.55 (d, 1H, J =
55

7.8 Hz), 9.49 (d, 1H, J = 7.8 Hz), 9.01 (d, 1H, J = 4.8 Hz), 8.90 (d, 1H, J = 7.8 Hz), 8.61
(d, 2H, J = 7.8 Hz), 8.01 (t, 1H, J = 7.8 Hz), 7.91 (t, 1H, J = 7.8 Hz), 7.86 (t, 1H, J = 7.8
Hz), 7.82 (t, 1H, J = 7.2 Hz), 7.78 (t, 1H, J = 7.2 Hz), 7.53 (m, 1H).

13

C NMR (CDCl3,

151 MHz) δ 160.67, 153.7, 150.6, 145.6, 143.3, 137.2, 133.9, 132.6, 131.4, 131.1,
128.7, 128.1, 127.9, 127.5, 127.2, 125.31, 125.28, 124.3, 123.1, 123.0. UV-Vis (DCE)
λmax nm (ε M-1 cm-1): 424 (381.7). HRMS (ESI) m/z calculated 309.11402 (C20H13N4,
[M+H]+), m/z observed 309.11249 (C20H13N4, [M+H]+).

1,10-phenanthroline-5,6-dione (2-64). 2-63 (500 mg, 2.78 mmol) and KBr
(700 mg, 5.88 mmol) was added to a mixture of concentrated sulfuric acid (5
mL) and nitric acid (2.5 mL) at -5°C.

The mixture was stirred at that

temperature for 15 min and then brought to reflux and heated for 4 h. The yellow
solution was allowed to cool and poured over 50 g of ice and carefully brought to pH 9
by addition of 5 M sodium hydroxide. The suspension was extracted with CHCl3, dried
over anhydrous sodium sulfate, and concentrated in vacuo to yield fine yellow needles
in 84% yield. 1H NMR (CDCl3, 600 MHz) δ 9.14 (d, 2H, J = 4.8 Hz), 8.52 (d, 2H, J = 7.8
Hz), 7.60 (dd, 2H, J = 7.8, 4.8 Hz).

13

C NMR (CDCl3, 151 MHz) δ 178.7, 156.4, 152.9,

137.3, 128.1, 125.6. HRMS (ESI) m/z calculated 211.05075 (C 12H7N2O2, [M+H]+), m/z
observed 211.05055 (C12H7N2O2, [M+H]+).

3-(pyridin-2-yl)-[1,2,4]triazino[5,6-f][1,10]phenanthroline (2-65). 214 (64 mg, 0.476 mmol) and 2-64 (100 mg, 0.476 mmol) were added
to 4 mL of DMF.

The slurry was heated at 80°C overnight with

complete dissolution. Progress of the reaction was monitored by TLC. The reaction
mixture was cooled to room temperature and the resulting precipitate was filtered and
washed with DMF and Et2O resulting in a 74% yield.

1

H NMR (d6-DMSO, 600 MHz) δ

9.71 (d, 1H, J = 7.8 Hz), 9.66 (d, 1H, J = 7.2 Hz), 9.35 (s, 1H), 9.31 (s, 1H), 8.96 (s, 1H),
8.84 (d, 1H, J = 7.8 Hz), 8.17 (t, 1H, J = 7.2 Hz), 8.05 (s, 2H), 7.72 (s, 1H).

13

C NMR

(d6-DMSO, 151 MHz) δ 160.9, 154.4, 153.2, 152.8, 150.4, 149.3, 147.1, 144.5, 142.6,
137.6, 133.9, 132.1, 126.0, 125.4, 125.1, 124.84, 124.78, 124.5.
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UV-Vis (9:1

DCE:MeOH) λmax nm (ε M-1 cm-1): 423 (376.6). HRMS (ESI) m/z calculated 311.10452
(C18H11N6, [M+H]+), m/z observed 311.10452 (C18H11N6, [M+H]+).

3-(pyridin-2-yl)-5H-[1,2,4]triazino[5,6-b]indole (2-67). 2-14 (500 mg,
3.67 mmol) and 2-66 (540 mg, 3.67 mmol) were added to 10 mL of
EtOH.

The slurry was heated at 80°C overnight with complete

dissolution. Progress of the reaction was monitored by TLC. The reaction mixture was
cooled to room temperature and the resulting orange precipitate was filtered and
washed with EtOH and Et2O resulting in a 59% yield. 1H NMR (CDCl3, 600 MHz) δ 8.67
(d, 1H, J = 4.2 Hz), 8.50-8.47 (m, 2H), 8.02 (bs, 1H), 7.90 (dt, 1H, J = 9, 1.8 Hz), 7.50
(m, 1H), 7.32 (t, 1H, J = 7.8 Hz), 7.11 (t, 1H, J = 7.8 Hz), 6.90 (d, 1H, J = 7.8 Hz).

13

C

NMR (CDCl3, 151 MHz) δ 166.9, 160.6, 149.6, 148.9, 146.3, 142.4, 137.0, 131.8, 128.9,
126.1, 123.0, 122.7, 118.5, 110.3

MS (ESI) m/z calculated 248.09362 (C 14H10N5,

[M+H]+), m/z observed 248.09721 (C14H10N5, [M+H]+).

diethyl pyridine-2,6-dicarboxylate.

2-68 (2 g, 11.97 mmol) was

suspended in EtOH (5 mL) and HCl (0.5 mL). The suspension was
heated in a conventional microwave oven at 750W and monitored by TLC until starting
material no longer remained. The reaction mixture was concentrated in vacuo and
redissolved in water. After adjusting the pH to 8 with 10 M sodium hydroxide, the
reaction was extracted with EtOAc (x3) and rinsed with brine. The solution was dried
with sodium sulfate and concentrated in vacuo to yield a white solid in 56% yield.

1

H

NMR (CDCl3, 600 MHz) δ 8.28 (d, 2H, J = 6.6 Hz), 8.00 (t, 1H, J = 6.6 Hz), 4.48 (d, 4H,
J = 6.0 Hz), 1.45 (s, 6 H).

13

C NMR (CDCl3, 151 MHz) δ 164.8, 148.8, 138.3, 128.0,

62.5, 14.4. HRMS (ESI) m/z calculated 224.09228 (C11H14NO4, [M+H]+), m/z observed
224.09179 (C11H14NO4, [M+H]+).

pyridine,2-6-dicarboxamide (2-69). Ammonium hydroxide (2.5 mL)
was added to 2-24 (1.5 g, 6.72 mmol) and warmed at 35°C for 1 h with
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vigorous stirring. After cooling to 0°C, the precipitate was filtered and washed with
water. The resulting white solid was dried under vacuum in an 80% yield. 1H NMR (d6DMSO, 600 MHz) δ 8.87 (s, 2H), 8.19-8.14 (m, 3H), 7.70 (s, 2H).
151 MHz) δ 165.4, 149.1, 139.1, 124.1.

13

C NMR (d6-DMSO,

HRMS (ESI) m/z calculated 166.06165

(C7H8N3O2, [M+H]+), m/z observed 166.06152 (C7H8N3O2, [M+H]+).

pyridine-2,6-dicarbonitrile

(2-70).

Anhydrous

THF

(5

mL)

and

triethylamine (1.58 mL, 11.31 mmol) were added to 2-69 (850 mg, 5.14
mmol) under nitrogen atmosphere.

The suspension was cooled to 0°C and

trifluoroacetic anhydride (1.57 mL, 11.31 mmol) was added dropwise. After 10 min, the
solution was allowed to stir at room temperature for 3 h.

The reaction was then

quenched with 5 mL of saturated sodium bicarbonate. The resulting precipitate was
filtered and washed with water. The resulting white solid was dried under vacuum in a
52% yield.
Hz)

1

H NMR (CDCl3, 600 MHz) δ 8.06 (t, 1H, J = 7.8 Hz), 7.92 (d, 2H, J = 7.8

13

C NMR (CDCl3, 151 MHz) δ 138.7, 135.4, 131.0, 115.4.

HRMS (ESI) m/z

calculated 130.04052 (C7H4N3, [M+H]+), m/z observed 130.03995 (C7H4N3, [M+H]+).

pyridine-2,6-bis(carbohydrazonamide) (2-71). 2-26 (288 mg, 2.23
mmol) was dissolved in EtOH (0.5 mL) and hydrazine hydrate (0.5 mL,
8.93 mmol) and stirred overnight at room temperature.

EtOH and

excess hydrazine hydrate were removed in vacuo. The white solid was dried under
vacuum and then stored at 0°C in a 73% yield.

1

H NMR (d6-DMSO, 600 MHz) δ 7.93

(d, 2H, J = 7.8 Hz), 7.66 (t, 1H, J = 7.8 Hz), 6.18 (br), 3.29 (br).
151 MHz) δ 149.6, 146.0, 136.0, 119.1.

13

C NMR (d6-DMSO,

HRMS (ESI) m/z calculated 194.11542

(C7H12N7, [M+H]+), m/z observed 194.11599 (C7H12N7, [M+H]+).

2,6-bis(5,6-diphenyl-1,2,4-triazin-3-yl)pyridine (2-72).

2-

71 (288 mg, 1.49 mmol) and benzil (642 mg, 3.05 mmol)
were added to 4 mL of EtOH.
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The slurry was heated

overnight at 80°C with complete dissolution. Progress of the reaction was monitored by
TLC.

The reaction mixture was cooled to room temperature and the resulting

precipitate was filtered and washed with EtOH and Et 2O resulting in a 92% yield.

1

H

NMR (CD2Cl2, 600 MHz) δ 8.86 (d, 2H, J = 7.8 Hz), 8.23 (t, 1H, J = 7.8 Hz), 7.73 (d, 4H,
J = 7.2 Hz), 7.66 (d, 4H, J = 7.2 Hz), 7.51-7.48 (m, 4 H), 7.47-7.40 (m, 8H).

13

C NMR

(CD2Cl2, 151 MHz) δ 160.9, 156.9, 156.5, 153.8, 138.5, 135.9, 135.7, 131.0, 130.1,
130.0, 129.8, 128.84, 128.75, 125.9. UV-Vis (9:1 DCE:MeOH) λmax nm (ε M-1 cm-1): 394
(1039.0). HRMS (ESI) m/z calculated 542.20932 (C35H24N7, [M+H]+), m/z observed
542.21167 (C35H24N7, [M+H]+).

2-aminobenzohydrazide (2-74).

Prepared using general hydrazide

method A and isolated as a pale brown solid. 1H NMR (CD3CN, 600 MHz)
δ 8.04 (br) 7.34 (d, 2H, J = 7.8 Hz), 7.18 (t, 1H, J = 7.2 Hz). 6.71 (d, 1H, J = 7.2 Hz),
6.59 (t, 1H, J = 7.2 Hz), 4.79 (br).

13

C NMR (D2O, 151 MHz) δ 170.8, 146.5, 132.8,

128.3, 118.5, 117.9, 117.3. HRMS (ESI) m/z calculated 152.08239 (C7H10N3O, [M+H]+),
m/z observed 152.08191 (C7H10N3O, [M+H]+).

2-(5,6-diphenyl-1,2,4-triazin-3-yl)aniline (2-75). 2-74 (230 mg, 1.52
mmol), benzil (306 mg, 1.46 mmol), and ammonium acetate (1.02 g,
13.2 mmol) were suspended in AcOH (3 mL). The suspension was
heated in a conventional microwave at 750W and monitored by TLC until benzil no
longer remained. The reaction mixture was concentrated in vacuo and precipitated out
of EtOH. The product was isolated as an orange solid in 42% yield.

1

H NMR (CDCl3,

600 MHz) δ 8.61 (d, 1H, J = 7.8 Hz), 7.66 (d, 2H, J = 7.8 Hz), 7.60 (d, 2H, J = 7.2 Hz),
7.46-7.35 (m, 6H), 7.29 (t, 1H, J = 7.2 Hz), 6.84-6.79 (m, 2H), 6.39 (s, 2H).

13

C NMR

(CDCl3, 151 MHz) δ 163.3, 155.3, 154.0, 149.3, 136.2, 135.8, 132.3, 131.0, 130.9,
130.0, 129.7, 129.6, 128.8, 128.7, 117.5, 117.2, 115.8. UV-Vis (MeCN) λmax nm (ε M-1
cm-1): 373 (5762.7). HRMS (ESI) m/z calculated 325.14532 (C21H17N4, [M+H]+), m/z
observed 325.14438 (C21H17N4, [M+H]+).
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(1-2-(5,6-diphenyl-1,2,4-triazin-3-yl)phenyl)-1H-1,2,3-triazol-4yl)methanol (2-77). 2-75 (50 mg, 0.154 mmol) was dissolved in 2
mL EtOAc. 1 mL of 1.5 M HCl was added and the solution was
cooled to 0°C in an ice bath. Sodium nitrite (21 mg, 0.308 mmol)
was dissolved in 0.5 mL water and added dropwise to the reaction solution while stirring
at 0°C. After 15 min, sodium azide (40 mg, 0.616 mmol) was dissolved in 0.5 mL water
and added dropwise to the reaction solution while stirring at 0°C. After slowly warming
to room temperature, the reaction was monitored by TLC.

Upon completion, the

reaction was extracted with EtOAc (x3), washed with 1 M HCl, water, and brine, and
dried with sodium sulfate.

After concentration in vacuo, the crude material was

dissolved in 0.4 mL ACN. Propargyl alcohol (4.3 mg, 0.077 mmol) and triethylamine
(10.7 μL, 0.077 mmol) were added to the reaction solution. 5,6-diphenyl-3-(pyridin-2yl)-1,2,4-triazine

(0.2

mg,

0.77

μmol)

and

tetrakis(acetonitrile-N)copper(I)

tetrafluoroborate (0.2 mg, 0.77 μmol) were then added to the reaction solution. The
reaction was stirred at room temperature overnight. After concentration in vacuo, the
crude product was purified by silica gel chromatography with gradient elution using
EtOAc and hexanes to yield a pale yellow solid in 57% yield.

1

H NMR (CDCl3, 600

MHz) δ 8.47 (d, 1H, J = 7.2), 7.83 (s, 1H), 7.77-7.72 (m, 2H), 7.59-7.56 (m, 3H), 7.417.29 (m, 9H), 4.73 (s, 2H).

13

C NMR (CDCl3, 151 MHz) δ 161.1, 155.4, 155.3, 136.1,

135.1, 135.0, 132.2, 131.9, 131.5, 130.9, 130.4, 129.8, 129.7, 129.5, 128.6, 128.4,
127.0, 56.5. HRMS (ESI) m/z calculated 407.16203 (C24H19N6O, [M+H]+), m/z observed
407.16117 (C24H19N6O, [M+H]+).

3-phenyl-5,6-di(pyridin-2-yl)-1,2,4-triazine

(2-78).

Phenyl

hydrazide, 2-20 (1 mmol), was dissolved in AcOH (4 mL) in a
microwave vial. To this was added 2-2’-pyridil (1 mmol) and
ammonium acetate (10 mmol). The reaction mixture was sealed and microwaved for 4
hours at 180°C. Consumption of starting materials was confirmed by TLC. H 2O and
DCM were added to the reaction mixture and transferred to a separatory funnel. The
aqueous layer was neutralized with NaOH, and extracted with DCM (3x). Combined
organics were dried over sodium sulfate, filtered, and concentrated in vacuo. The
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resultant solid was purified over silica eluting with hexanes and ethyl acetate to yield a
yellow solid in 40% yield. 1H NMR (CDCl3, 600 MHz) δ 8.68 – 8.70 (m, 2H), 8.35 (t, 2H,
J = 4.2 Hz), 8.26 (dd, 2H, J = 7.8 Hz, J = 4.2 Hz), 7.91 (tq, 2H, J = 7.8 Hz, J = 1.8 Hz),
7.56 – 7.60 (m, 3H), 7.32 (ddd, 1H, J = 7.2 Hz, J = 4.8 Hz, J = 1.2 Hz), 7.30 (ddd, 1H, J
= 7.2 Hz, J = 4.8 Hz, J = 1.2 Hz).

13

C NMR (CDCl3, 151 MHz) δ 161.9, 155.5, 155.4,

155.2, 155.0, 148.83, 148.76, 137.10, 137.07, 134.7, 132.0, 129.0, 128.7, 124.64,
124.61, 124.1, 123.7. HRMS (ESI) m/z calculated 312.12492 (C19H14N5, [M+H]+), m/z
observed 312.12461. (C19H14N5, [M+H]+).

methyl

hydrazinecarbimiodthioate

hydroiodide

(2-79).

Thiosemicarbazide (500 mg, 5.49 mmol) was dissolved in 10 mL EtOH
and heated at 60°C for 30 min. Iodomethane (0.38 mL, 6.06 mmol) was added portion
wise and continue stirring at 60°C for an additional 30 min.

After cooling to room

temperature, the mixture was concentrated in vacuo resulting in a pale brown solid in
quantitative yield. The recovered solid was used in further reactions without additional
purification.

3-(methylthio)-5,6-diphenyl-1,2,4-triazine

(2-80).

2-79 (500 mg,

2.15 mmol) and benzil (451 mg, 2.15 mmol) were dissolved in 10 mL of
EtOH and stirred overnight at room temperature.

Progress of the

reaction was monitored by TLC. The reaction was quenched by addition of saturated
sodium bicarbonate and solid sodium sulfate and stirring 30 min. The mixture was
filtered and DCM was added to the resulting precipitate. The DCM solution was filtered
and the corresponding filtrate concentrated in vacuo. The product was isolated as a
yellow solid in 89% yield. 1H NMR (CDCl3, 600 MHz) δ 7.55 (d, 2H, J = 8.4 Hz), 7.52 (d,
2H, J = 7.8 Hz), 7.44-7.39 (m, 2H), 7.37-7.32 (m, 4H), 2.76 (s, 3H).

13

C NMR (CDCl3,

151 MHz) δ 171.3, 155.6, 153.9, 135.54, 135.52, 131.0, 130.0, 129.57, 129.56, 128.8,
128.7, 14.2. HRMS (ESI) m/z calculated 280.09084 (C16H14N3S, [M+H]+), m/z observed
280.08966 (C16H14N3S, [M+H]+).
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3-hydrazinyl-5,6-diphenyl-1,2,4-triazine (2-81). 2-80 (200 mg, 0.717
mmol) and hydrazine hydrate (336 mg, 4.30 mmol) were dissolved in 2
mL of EtOH and heated at 80°C overnight. Progress of the reaction
was monitored by TLC.

The reaction mixture was concentrated in

vacuo and dried under vacuum yielding a green-yellow solid in 84% yield.

1

H NMR

(CDCl3, 600 MHz) δ 7.49-7.48 (m, 2H), 7.43-7.41 (m, 3H), 7.36-7.32 (m, 5H), 6.60 (br,
1H), 4.17 (br, 2H).

13

C NMR (CDCl3, 151 MHz) δ 162.42, 157.3, 151.4, 136.2, 136.1,

130.7, 129.8, 129.5, 128.8, 128.6. UV-Vis (MeCN) λmax nm (ε M-1 cm-1): 353 (2894).
HRMS (ESI) m/z calculated 264.12492 (C15H14N5, [M+H]+), m/z observed 264.12513
(C15H14N5, [M+H]+).

5,6-diphenyl-3-(2-(pyridin-2-ylmethylene)hydrazinyl)-1,2,4triazine

(2-82).

2-81 (75 mg, 0.285 mmol) and

2-

pyridinecarbaldehye (31 mg, 0.285 mmol) were dissolved in 3 mL
of EtOH and refluxed for 4 h.

After cooling to room temperature, the resulting

precipitate was filtered and rinsed with EtOH yielding a yellow solid in 80% yield.

1

H

NMR (d6-DMSO, 600 MHz) δ 8.60 (d, 1H, J = 4.8 Hz), 8.34 (s, 1H), 8.00 (d, 1H, J = 8.4
Hz), 7.87 (t, 1H, J = 7.8 Hz), 7.05-7.36 (m, 12H).

13

C NMR (d6-DMSO, 151 MHz) δ

158.4, 156.6, 153.6, 151.4, 149.4, 144.3, 136.8, 136.0, 135.8, 130.3, 129.5, 129.1,
128.5, 128.30, 128.29, 123.8, 119.5. UV-Vis (9:1 DCE/MeOH) λmax nm (ε M-1 cm-1): 376
(13290).

HRMS (ESI) m/z calculated 353.15147 (C21H17N6, [M+H]+), m/z observed

353.14993 (C21H17N6, [M+H]+).

3-(methylsulfonyl)-5,6-diphenyl-1,2,4-triazine (2-83). Dissolved 2-80
(2.5 g, 8.9 mmol) and tetrabutylammonium bromide (287 mg, 0.89
mmol) in 60 mL of benzene and 18 mL of AcOH. Added potassium
permanganate (2.8 g, 17.9 mmol) as a solution in 90 mL of water to the reaction and
stirred at room temperature overnight. Added saturated sodium bisulfite (approx 5 mL)
until color disappeared. Neutralized solution with solid potassium carbonate. Dried
organic layer with anhydrous sodium sulfate and concentrated in vacuo yielding a
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yellow solid in 77% yield. Compound was used immediately or carefully stored away
from light and in the freezer to prevent decomposition.

1

H NMR (CDCl3, 600 MHz) δ

7.68 (d, 2H, J = 7.2 Hz), 7.62 (d, 2H, J = 7.2 Hz), 7.52-7.49 (m, 2H), 7.43 (t, 2H, J = 7.8
Hz), 7.37 (t, 2H, J = 7.8 Hz).

13

C NMR (CDCl3, 151 MHz) δ 164.5, 159.7, 158.1, 134.2,

133.8, 132.33, 131.0, 130.4, 129.7, 129.4, 129.0, 128.5. HRMS (ESI) m/z calculated
312.08067 (C16H14N3O2S, [M+H]+), m/z observed 312.08136 (C16H14N3O2S, [M+H]+).

5,6-diphenyl-1,2,4-triazine-3-carbonitrile (2-84). Dissolved 2-83 (500
mg, 1.61 mmol) and finely crushed KCN (210 mg, 3.22 mmol) in 16 mL of
DMF and stirred at room temperature.

Progress of the reaction was

closely monitored by TLC and not allowed to stir overnight. When reaction reached
completion, added a small amount of water and extracted with DCM. Purification by
alumina chromatography with gradient elution using EtOAc and hexanes yielded a
yellow solid in 75% yield. 1H NMR (CDCl3, 600 MHz) δ 7.63 (d, 4H, J = 7.8 Hz), 7.51 (t,
2H, J = 7.8 Hz), 7.43 (t, 2H, J = 7.8 Hz), 7.39 (t, 2H, J = 7.8 Hz).

13

C NMR (CDCl3, 151

MHz) δ 158.3, 156.5, 144.8, 134.1, 133.6, 132.3, 131.2, 130.1, 129.8, 129.2, 129.1. MS
(ESI) m/z calculated 259.09837 (C16H11N4, [M+H]+), m/z observed 259.09377
(C16H11N4, [M+H]+).

3,6-di(pyridin-2-yl)-1,2-dihydro-1,2,4,5-tetrazine

(2-85).

2-

cyanopyridine (1.0 g, 10.5 mmol) and hydrazine hydrate (2 mL, 42
mmol) was dissolved in 8 mL of EtOH and refluxed overnight. Progress
of the reaction was monitored by TLC.

The reaction mixture was cooled to room

temperature and the resulting orange precipitate was filtered and washed with Et 2O
resulting in a 42% yield. 1H NMR (CDCl3, 600 MHz) δ 8.58-8.57 (m, 4H), 8.05 (d, 2H, J
= 7.8 Hz), 7.75 (dt, 2H, J = 7.2, 1.8 Hz), 7.40-7.34 (m, 2H).

13

C NMR (CDCl3, 151 MHz)

δ 148.5, 147.7, 146.7, 136.9, 125.0, 121.4. UV-Vis (MeCN) λmax nm (ε M-1 cm-1): 382
(350.3).

HRMS (ESI) m/z calculated 239.10452 (C12H11N6, [M+H]+), m/z observed

239.10400 (C12H11N6, [M+H]+).
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3,6-di(pyridin-2-yl)-1,2,4,5-tetrazine (2-86). To a stirring suspension
of 2-85 (500 mg, 2.1 mmol) in 2.5 mL of AcOH at 0°C was added
dropwise 0.4 mL of concentrated nitric acid. The slurry was allowed to
warm to room temperature overnight. The mixture was poured over cold water and
made alkaline by addition of sodium carbonate solution. The resulting purple precipitate
was filtered, washed with water, and dried under vacuum in 66% yield. 1H NMR (CDCl3,
600 MHz) δ 9.00 (d, 2H, J = 3.6 Hz), 8.76 (d, 2H, J = 8.4 Hz), 8.02 (dt, 2H, J = 8.4, 1.8
Hz), 7.60-7.58 (m, 2H).

13

C NMR (CDCl3, 151 MHz) δ 164.0, 151.2, 150.3, 137.6,

126.7, 124.7. UV-Vis (MeCN) λmax nm (ε M-1 cm-1): 539 (351.9). HRMS (ESI) m/z
calculated 237.08887 (C12H9N6, [M+H]+), m/z observed 237.08985 (C12H9N6, [M+H]+).

4-phenyl-3,6-di(pyridin-2-yl)pyridazine (2-87).

2-86 (260 mg, 0.85

mmol) and phenylacetylene (173 mg, 1.69 mmol) was dissolved in 5 mL
of toluene.

The reaction was refluxed for 8 h with progress of the

reaction monitored by TLC. Upon disappearance of the starting materials, the reaction
was concentrated in vacuo and purified by silica gel chromatography with gradient
elution using EtOAc and hexanes to yield a pale brown solid in 77% yield.

1

H NMR

(CDCl3, 600 MHz) δ 8.81 (d, 1H, J = 8.4 Hz), 8.74 (d, 1H, J = 4.8 Hz), 8.67 (s, 1H), 8.48
(d, 1H, J = 4.8 Hz), 7.94-7.89 (m, 2H), 7.80 (dt, 1H, J = 9.0, 1.8 Hz), 7.43-7.41 (m, 1H),
7.34-7.30 (m, 3H), 7.29-7.26 (m, 3H).

13

C NMR (CDCl3, 151 MHz) δ 158.5, 157.9,

156.0, 153.6, 149.6, 149.2, 140.7, 137.4, 137.1, 136.7, 129.1, 128.57, 128.55, 125.8,
125.04, 124.95, 123.5, 122.1. UV-Vis (MeCN) λmax nm (ε M-1 cm-1): 350 (344.8). HRMS
(ESI) m/z calculated 311.12967 (C20H15N4, [M+H]+), m/z observed 311.12827
(C20H15N4, [M+H]+).

5,6-diphenyl-2,2’-bipyridine (2-89). 2-17 (250 mg, 0.81 mmol) and
2,5-norbornadiene (746 mg, 8.1 mmol) were added to 5.4 mL EtOH and
refluxed overnight. Progress of the reaction was monitored by TLC.
After concentration in vacuo, the crude product was purified by silica gel
chromatography with gradient elution using EtOAc and hexanes to yield a white solid in
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66% yield.

1

H NMR (CDCl3, 600 MHz) δ 8.71 (d, 1H, J = 4.8 Hz), 8.60 (d, 1H, J = 7.8

Hz), 8.45 (d, 1H, J = 7.8 Hz), 7.87 (d, 1H, J = 8.4 Hz), 7.82 (dt, 1H, J = 7.8, 1.2 Hz),
7.49-7.48 (m, 2H), 7.33-7.27 (m, 7H), 7.25-7.23 (m, 2H).

13

C NMR (CDCl3, 151 MHz) δ

156.4, 156.2, 154.7, 149.2, 140.5, 140.1, 139.7, 137.0, 136.2, 130.3, 129.7, 128.5,
127.97, 127.96, 127.4, 123.9, 121.6, 119.3. UV-Vis (DCE) λmax nm (ε M-1 cm-1): 350
(240.5).

HRMS (ESI) m/z calculated 309.13917 (C22H17N2, [M+H]+), m/z observed

309.13781 (C22H17N2, [M+H]+).

benzylidenepicolinohydrazonamide (2-92).

2-14 (250 mg, 1.84

mmol) and 2-89 (390 mg, 3.67 mmol) were added to 5 mL of EtOH.
The reaction was heated overnight at 80°C with progress of the
reaction monitored by TLC. The reaction mixture was cooled to room temperature and
concentrated in vacuo. Purification by silica gel chromatography with gradient elution
using EtOAc and hexanes yielded a yellow solid in 87% yield.

1

H NMR (CDCl3, 600

MHz) δ 8.61 (d, 1H, J = 4.8 Hz), 8.57 (s, 1H), 8.35 (d, 1H, J = 8.4 Hz), 7.84-7.82 (m,
2H), 7.80-7.78 (m, 1H), 7.44-7.40 (m, 3H), 7.40-7.37 (m, 1H), 6.57 (br, 2H).

13

C NMR

(CDCl3, 151 MHz) δ 157.2, 156.1, 150.4, 148.5, 136.7, 135.4, 130.3, 128.8, 128.1,
125.3, 121.5. UV-Vis (MeCN) λmax nm (ε M-1 cm-1): 332 (26568). HRMS (ESI) m/z
calculated 225.11402 (C13H13N4, [M+H]+), m/z observed 225.11336 (C13H13N4, [M+H]+).

(pyridin-2-ylmethylene)picolinohydrazonamide (2-93).

2-14 (250

mg, 1.84 mmol) and 2-90 (394 mg, 3.67 mmol) were added to 5 mL of
EtOH. The reaction was heated overnight at 80°C with progress of the
reaction monitored by TLC. The reaction mixture was cooled to room temperature and
concentrated in vacuo. Purification by silica gel chromatography with gradient elution
using EtOAc and hexanes yielded a yellow solid in 84% yield.

1

H NMR (CDCl3, 600

MHz) δ 8.67 (d, 1H, J = 4.2 Hz), 8.63 (s, 1H), 8.60 (d, 1H, J = 4.2 Hz), 8.38 (d, 1H, J =
8.4 Hz), 8.08 (d, 1H, J = 8.4 Hz), 7.80 (dt, 1H, J = 7.2, 1.2 Hz), 7.31 (dt, 1H, J = 7.2, 1.8
Hz), 7.40-7.38 (m, 1H), 7.29-7.27 (m, 1H), 7. 6.63 (br, 2H).

13

C NMR (CDCl3, 151 MHz)

δ 157.9, 156.3, 154.4, 150.2, 149.8, 148.5, 136.8, 136.4, 125.5, 124.7, 121.8, 121.7.
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UV-Vis (MeCN) λmax nm (ε M-1 cm-1): 332 (32452).

HRMS (ESI) m/z calculated

226.10927 (C12H12N5, [M+H]+), m/z observed 226.11020 (C12H12N5, [M+H]+).

2,3-di(pyridin-2-yl)quinoxaline (2-94). 1,2-phenylenediamine (50 mg,
0.472 mmol) and pyridil (2-41) (100 mg, 0.472 mmol) were dissolved in
2.4 mL of EtOH and refluxed for 6 h. After cooling to room temperature,
the reaction mixture was concentrated in vacuo yielding a pale brown solid in
quantitative yield. 1H NMR (CDCl3, 600 MHz) δ 8.38 (d, 2H, J = 4.8 Hz), 8.23 (dd, 2H, J
= 3.6, 2.4 Hz), 7.96 (d, 2H, J = 7.8 Hz), 7.84-7.80 (m, 4H), 7.24 (m, 2H).

13

C NMR

(CDCl3, 151 MHz) δ 157.6, 152.6, 148.8, 141.3, 136.8, 130.6, 129.6, 124.4, 123.1. UVVis (MeCN) λmax nm (ε M-1 cm-1): 332 (8345). HRMS (ESI) m/z calculated 285.11402
(C18H13N4, [M+H]+), m/z observed 285.11511 (C18H13N4, [M+H]+).

1,2-di(pyridin-2-yl)-2-(p-tolylimino)ethanone (2-95). 2,2’-pyridil (1
mmol) was dissolved in EtOH (4 mL). To this was added p-toluidine (2
mmol). The reaction mixture was stirred at room temperature overnight. Consumption of
2,2’-pyridil was confirmed by TLC. Reaction mixture was concentrated in vacuo to
remove EtOH. Residue was purified over silica eluting with hexanes and ethyl acetate to
yield a yellow solid in 53% yield. 1H NMR (CDCl3, 500 MHz) δ 8.57 (dq, 1H, J = 4.5 Hz,
J = 1.0 Hz), 8.46 (dq, 1H, J = 5.0, 1.0 Hz), 8.36 (dt, 1H, J = 8.0 Hz, J = 1.0 Hz), 7.97 (dt,
1H, J = 8.0 Hz, J = 1.0 Hz), 7.83 (td, 1H, J = 7.5 Hz, J = 1.5 Hz), 7.78 (td, 1H, J = 7.5
Hz, J = 1.5 Hz), 7.37 (qd, 1H, J = 5.0 Hz, J = 1.0 Hz), 7.30 (qd, 1H, J = 5.0 Hz, J = 1.0
Hz), 6.94 (d, 1H, J = 7.5 Hz), 6.85 (d, 1H, J = 8.5 Hz), 2.21 (s, 3H).

13

C NMR (CDCl3,

125 MHz) δ 198.8, 167.0, 155.4, 152.9, 149.7, 148.9, 137.0, 136.9, 129.3, 127.4, 125.1,
122.0, 121.6, 120.3HRMS (ESI) m/z calculated 302.1293 (C19H16N3O, [M+H]+), m/z
observed 302.13002 (C19H16N3O, [M+H]+).

66

Chapter 3.
Catalytic Activity of 1,2,4-Triazine Ligands
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3.1.

Background & Significance

Despite the ability of copper to catalyze the azide-alkyne cycloaddition, more
demanding applications have arisen, which have led to the synthesis of ligands to
further accelerate the cycloaddition reaction. Ligands can be designed to tailor to the
conditions required. With this in mind, we synthesized a series of 1,2,4-triazine ligands
to study their ability to catalyze the CuAAC reaction. Depending on the substitution
pattern of the 1,2,4-triazine, the ligands could be potent accelerants using CuI or CuII
salts in the presence of a reducing agent. Optimal conditions were determined using a
model reaction between benzyl azide and phenylacetylene, including amount of base,
catalyst loading, and stoichiometry between ligand and copper. Additional azide and
alkyne substrates were then examined. Finally, a study of the catalytic activity of various
1,2,4-triazines outlined the structural and electronic characteristics necessary to
catalyze the reaction.
As an application, the 1,2,4-triazine ligand was used to attach an alkyne bearing triazine
to different solid supports, polystyrene and silica. These heterogeneous ligands were
also screened for CuAAC activity, and were found to be effective accelerants. The
recyclability and the copper retention were also explored, showing some catalysts were
reusable up to 3 times without loss of activity or significant copper leaching.

3.2.

Optimization of Reaction Conditions for 1,2,4-Triazine Accelerated CuAAC

Our initial screening for catalytic activity involved the use of several heterocycles. We
initially screened 1,2,4-triazoles (substituted at both the 1 and 4 positions), 1,2,3triazoles, and 1,2,4-triazines. Of these, only 1,2,4-triazines produced an efficient yield of
the desired 1,2,3-triazole product under ambient conditions. 1,2,4-Triazoles were
somewhat effective, but required heat in order to form the active copper complex.
With this knowledge in hand we moved on to further optimize and explore the conditions
under which 1,2,4-triazines could effectively accelerate CuAAc. We began by evaluating
the model reaction between benzyl azide and phenylacetylene in acetonitrile. We
initially tested the catalyst loading and the use of Cu I or CuII salts. Reactions were
conducted at room temperature for 1 hour, diluted, and analyzed by LC-MS for yield of
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triazole product. With addition of ligand, 2-17, a significant enhancement in product
formation was seen over the control reaction which had copper but no ligand (Table 3.1
Entry 3 vs. Entry 6). The best results were observed with 1 mole percent of ligand and
copper using either CuI or CuII salts (Entries 3, 7, 8). In order to prevent oxidation to
CuII, a nitrogen base was also added. This served as a reducing agent to convert the
starting CuII to CuI. CuII salts generally have better solubility than the analogous CuI salt.
Although [Cu(MeCN)4]+BF4- was initially chosen due to its solubility, the compound was
hydroscopic and unless stored tightly or free from air and water, it became less soluble
when dissolved for subsequent catalytic trials. Because of this decreased solubility, we
began to use Cu(BF4)·6H2O in its place. It had a much better solubility. Additional CuII
salts could also be used without significant loss of catalytic activity (Entry 7). After the
initial LC-MS analysis, work was continued to optimize the reaction conditions. Product
1,2,3-triazoles were isolated after 1 hour and percent yields reported based on the
isolated products rather than LC-MS yields.

Table 3.1 Optimization of CuAAC reaction conditions using 1,2,4-triazines.a
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Simultaneously we examined the effect of substrate concentration and the amount of
nitrogen base (or reducing agent) required (Table 3.2). Since the pyridine functional
group is capable of binding copper, we wanted to compare the activity of pyridine to that
of the synthesized triazine containing a pyridine functional group. We were surprised to
observe that the addition of pyridine did not result in product formation. Pyridine may
have been binding to the copper, but possibly it remained in the inactive CuII state.
Alkyl amines such as triethylamine (Et3N) are employed to reduce CuII to the active CuI
species.92 The addition of Et3N was deemed necessary for this reaction (entry 4), but
Et3N without triazine 2-17 (Table 3.1, Entry 6) resulted in very minimal product
formation. From the studies on substrate concentration, very little change occurred
when the concentration was decreased to 0.1 M. The reaction was still viable at 0.05 M,
but longer reaction times (3 hrs) were necessary with a decreased overall yield of 64%
(Table 3.2 Entries 4-6). We also examined if stoichiometric or catalytic amounts of base
were required. Typical azide-alkyne cycloadditions use excess reducing agent when
compared to loading of copper catalyst. If the triethylamine is acting as a reducing agent
alone, the cycloaddition should still work with decreased amounts of amine. At 0.5 eq of
triethylamine, high yields (97%) were observed within an hour (Table 3.2, Entry 7). With
0.06 equivalents, the reaction still progressed but at a much slower rate. After 1 hour,
very little product had formed. Upon stirring for an additional 5 hours, 91% of the triazole
product was isolated (Table 3.2, Entry 8).
We also evaluated the solvent scope (Table 3.3). Nonpolar, aprotic solvents appeared
to be optimal solvents giving the highest isolated yields of 1,2,3-triazole (Entries 1-4, 67) Reactions carried out in polar protic and polar aprotic solvents were met with some
difficulty. Solvents such as dimethylformamide (DMF) and isopropanol had significantly
lower yields. The major reason for this was the result of side product formation of bistriazole (3-4).93 This reduced the triazole product yield and also made isolation of the
pure triazole product difficult. One surprising note from this data set was when
tetrahydrofuran was employed as the solvent. Initially, the reaction did not progress and
the solution remained green in color. The reaction was left stirring overnight and
eventually the solution turned dark and product formation was evident by TLC. Possible
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Table 3.2 Evaluation of Base and Substrate Concentration in CuAAC.a

Table 3.3 Evaluation of Solvent for CuAAC.a
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competition between the THF and triazine ligand for access to the copper or solvation of
the copper by THF may have caused the delay in the reaction.

3.3.

Substrate Scope

Having optimized the general conditions, we moved on to test the substrate
compatibility by examining various azides and alkyne substrates with various
stereoelectronic properties (Table 3.4). Electron rich and electron poor aromatic azides,
primary and secondary alkyl azides, and benzylic azides all showed good product yields
(> 80%). Sterically hindered aromatic azides also produced the corresponding triazoles
in high yield. Alkyl azides containing an acid functional group surprisingly did not
undergo the cycloaddition in good yield (Entry 11, 47%). Even with an additional
equivalent of base, this reaction did not proceed well. Since other alkyl azides had
produced triazole in efficient yield, the acid functional group was most likely the cause of
the poor yield in this case. The only azide found to be unreactive was the tertiary
adamantyl azide which produced very little product even after prolonged reaction times
(Entry 10).
While azides were not particularly sensitive to the reaction conditions, alkynes proved to
be more problematic. Aromatic alkynes containing ether or ester functional groups
resulted in a second UV active spot observable via TLC. This was determined by NMR
to be the bis-triazole byproduct, not easily separated from the product triazole, resulting
in reduced yields or purity. Luckily, this byproduct could be circumvented by use of a
different solvent, particularly DCM. DCM or DCE were substituted for MeCN to prevent
side product formation. The yields for triazoles synthesized by varying the
stereoelectronics of alkynes were more varied as compared to the azide counterpart,
ranging from 68 – 95%. The only alkyne that did not perform particularly well was the
alkyl decyne. This resulted in only 23% yield after 1 hour. Possible options to increase
the yield would be to heat the reaction or increase the reaction time. Despite the lower
yields with some substrates, reasonable yields were observed with a variety of azide
and alkyne substrates.
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Table 3.4 Substrate scope for 1,2,4-triazine accelerated CuAAC.a
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3.4.

Ligand Scope

As we were optimizing the conditions for triazine-accelerated CuAAC, we were also
synthesizing additional 1,2,4-triazines in hopes of finding more active ligands. The
optimization conditions were all conducted with 5,6-diphenyl-3-(2-pyridyl)-1-2-4-triazine
which gave 97% isolated yield of product triazole after 1 hour under the best conditions.
The results from screening of various ligands are compiled in Table 3.5. Since the
pyridyl substituent was active, we also screened the pyrimidine and pyrazine substituted
triazines. These turned out to be completely inactive (Entries 2-3), showing that more
nitrogens isn’t always better. We also wanted to investigate if the pyridine was
necessary for activity. If pyridine was better than pyrimidine and pyrazine, would a
phenyl substituent be better than pyridine? When the pyridine was replaced by phenyl,
the activity significantly decreased to 2% isolated yield (Entry 4). This seemed
reasonable as coordination of the copper occurs through the pyridine nitrogen. The 2pyridyl substituent at the 3 position seemed to be necessary for activity, so we decided
to investigate other N, O, or S containing heterocycles that could potentially replace the
pyridine ring. Of the five heterocycles synthesized, benzothiophene, benzofuran, indole,
and benzothiazole were all inactive, producing only trace amounts of triazole product.
The only substituent at the 3-position that showed intermediate activity was the
replacement of the pyridine with methyl imidazole to yield 50% of triazole product in 1
hour (Entries 5-9).
The pyridine substituent at the 3 position appeared to be irreplaceable, so we decided
to move onto the 5,6 position to see if the activity could be tuned with respect to those
substituents. Other commercial dicarbonyls allowed us to investigate the steric bulk.
The replacement of the phenyl rings with H decreased the yield, only slightly, from 97%
to 91%. The methyl substituents at 5 and 6 positions did not fare as well. This product
was not an easily handled powder like the other triazines, but instead formed a semisolid oily residue, making it slightly less soluble, and more difficult to measure out.
Replacement of the phenyl rings with pyridine to make 3,5,6-tripyridyl-1,2,4-triazine also
did not increase the activity, rather decreasing it, much to our disappointment (Entry
12).
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Table 3.5 Evaluation of 1,2,4-triazines and other heterocycles for CuAAC.a
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Through our screening it was identified that both phenyl rings were not required as a 6phenyl-1,2,4-triazine displayed similar activity to the initial ligand 2-17 (Entry 13). The
triazine containing an alcohol functional group (2-50) was not active. This compound
wasn’t very soluble in DCM or DCE, which could have led to the decreased catalytic
activity. Use of a different solvent for this triazine ligand could improve the activity. The
addition of the nitro and amine substituents did not have a positive impact on the
catalytic activitiy (Entries 16-17). The activity decreased for both triazines. Neither of
these triazines were particularly soluble, so the decreased solubility could have led to
their decreased activity.
Locking the conformation of the 5,6 substituents gave similar results (96%) to the
original triazine 2-17 (Entries 18-19). Surprisingly, the addition of nitrogens in 2-65 did
not have an adverse effect on the catalytic activity. Since these nitrogens are pointed
away from the metal binding region of the molecule, it could be proposed that these
additional nitrogens wouldn’t interfere with copper coordination and access by the azide
or alkyne components. Contrary to this, the nitrogen in 2-67 is closer to the metal
binding center and is also more basic than the pyridine nitrogen. This triazine resulted in
only a trace amount of product formed (Entry 20).
Somewhat of a disappointment were the results from the bis-triazine and the 1,2,3triazolyl-1,2,4-triazine. (Entries 21, 23) Neither of these proved to be active for the
azide-alkyne cycloaddition. The metal binding site is more crowded now, so this might
either lead to no binding of the copper by the triazine, or the alkyne cannot access the
copper once bound. Either of these would prevent the cycloaddition.
Of the remaining ligands, pyridazine (2-87) showed some modest activity with 63%
isolated yield over 1 hour (Entry 29). The imine (2-95) resulted in 95% yield but the
reaction progressed for an additional 4 hours. After 1 hour, the reaction was not
complete, so longer reaction times were necessary. It would be of interest to explore
this scaffold further.
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3.5.

Mechanistic Considerations

A limited amount of data was collected in order to explore the copper dependence on
1,2,4-triazine accelerated CuAAC. The first method was to examine the UV-Vis
absorption spectra of 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine (2-17) with copper (I) and
copper (II) salts, in the presence or absence of triethylamine (Figure 3.1). For ligand and
copper (II) containing spectra, an absorbance was present around 700 nm. This is
characteristic of the d-d transitions in copper (II) complexes. This absorbance band was
diminished with the addition of base, and a new absorbance peak around 480 nm was
present. The spectra obtained from a solution containing ligand, copper, and base are
superimposable when comparing copper (I) to copper (II) salts. The absorbance
spectrum of copper (I) and ligand alone is similar to the spectrum of the same solution
with base added. The intensity of the peaks may differ, but the general features are
similar. From this data we could confidently state that the CuII was being reduced to
generate the active CuI species.
Although from our optimization studies (Table 3.2), it was shown that a catalytic amount
of base was sufficient to convert CuII into CuI and yield the desired triazole product, the
UV-Vis scan did not show the CuI species. The experiment with catalytic base required
longer reaction times (> 5 hr) to yield product triazoles in moderate yield. For the UV-Vis
experiment, scans were conducted immediately after mixing the ligand, copper, and
base. For a better comparison, the UV-Vis spectrum should be taken at various time
points. The conversion of CuII to CuI is not instantaneous with catalytic amount of base,
especially since the reaction mixtures were not being stirred within the UV-Vis.
The addition of substrates did not affect the features of the absorption spectra as can be
seen when comparing Figure 3.1B to Figure 3.1A. The intensity of the spectral features
may have increased slightly, but there was no shift in the wavelength at which the
absorption took place.
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Figure 3.1 UV-Vis spectra of 1,2,4-triazine-accelerated CuAAC. 5,6-diphenyl-3-(pyridin-2yl)-1,2,4-triazine (0.01 eq) (2-17) in acetonitrile with either tetrakis(acetonitrile-N)copper(I)
tetrafluoroborate (0.01 eq) or copper(II) tetrafluoroborate hexahydrate (0.01 eq). The addition of
triethylamine (0.01 eq or 1.0 eq) was studied without (A) and with (B) benzyl azide (1.0 eq) and
phenylacetylene (1.0 eq).

A preliminary kinetics investigation was undertaken using 1H NMR to monitor the
reaction between phenylacetylene and benzyl azide. (Figure 3.2) The initial
observations revealed a reaction order of zero with respect to the azide substrate.
When concentration of azide was doubled the reaction rate was unaffected. When the
copper and ligand concentrations were doubled, the reaction rate also doubled.
Changing the concentration of alkyne was more difficult, as doubling the concentration
led to the formation of precipitate. Changes to the solvent could potentially eliminate this
issue. A more thorough investigation and mathematical processing of the data is
required to provide more concrete evidence about the nature of the mechanism.
Preliminary electrochemical experiments were also conducted.66 Unfortunately, the
addition of ligand, copper, and base resulted in a very dark brown solution, which left
residual components in the frit of the electrode. After a series of experiments, the
contamination of the frit began to influence the spectral features. A consistent baseline
and reproducible spectra were no longer possible to collect. To prevent the
contamination of the frit, more dilute solutions were attempted, but these were too dilute
to measure electrochemical potentials.
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Figure 3.2 Kinetic NMR Data of 1,2,4-Triazine-Accelerated CuAAC Reaction. (A) Standard
conditions: benzyl azide (0.2 M), phenylacetylene (0.2 M), triethylamine (0.4 M), Cu(MeCN)4BF4
(0.002 M), and 5,6-diphenyl-3-(pyridin-2-yl)-1,2,4-triazine (2-17) (0.002 M) in deuterated
acetonitrile. Concentrations for additional reactions were altered as indicated above. Ratio is
percent yield of the indicated reaction divided by that of the standard reaction. (B) Kinetic array
for 1,2,4-triazine-accelerated CuAAC reaction under standard conditions. Disappearance of
alkyne (3.4 ppm) and benzylic azide protons (4.4 ppm) as benzylic triazole protons (5.6 ppm)
appear over time.

Of the limited amount of data collected, the most useful data was the UV-Vis spectra.
This confirmed that the initial CuII salts were being converted to the active CuI species
upon addition of base. For a more complete mechanistic evaluation, additional data is
required.

3.6.

Other Catalytic Applications

Since 3-(2-pyridyl)-1,2,4-triazines are known to bind various metals, we decided to
explore other metal catalyzed reactions to see if triazine presence could accelerate
these reactions. One reaction that we were interested in would be to perform a one-pot
Sonogashira-CuAAC reaction. The reaction would begin with an aryl iodide, which
would be converted into a terminal alkyne. The terminal alkyne would then be reacted
with an azide under 1,2,4-triazine-accelerated CuAAC conditions previously developed.
Many reports exist on the in situ preparation of azides from bromides for a one-pot
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CuAAC reaction,94,95 or the in situ preparation of alkynes from iodides for a one pot
Sonogashira-CuAAC reaction.96 From our experience, synthesis of aryl alkynes is
usually a lengthier process than for the complimentary azides needed for CuAAC
reactions. Alkynes usually are purified by silica gel chromatography to remove excess
palladium and copper salts after the reaction. Our goal was to conduct the Sonogashira
and azide-alkyne cycloaddition in one pot, in the hopes of speeding up the process and
isolation of the final product.
We began the investigation by examining the model reaction between iodobenzene and
phenylacetylene (Table 3.6). Entry 1 represents the standard conditions employed for
Sonogashira conditions. This reaction proceeds at room temperature, but did produce
some oxidative Glaser coupling byproduct. Addition of 1,2,4-triazine (2-17) to
bis(triphenylphosphine)palladium(II) chloride resulted in decreased yield of the desired
internal alkyne (3-5) and no change in the selectivity of 3-5 over 3-6. Other available
palladium sources known to bind 1,2,4-triazines were palladium (II) acetate. On its own
this palladium source did not catalyze the Sonogashira reaction (Entry 3). Addition of
1,2,4-triazine (2-17) increases the yield, but not to that of an appreciable amount. We
next evaluated if the yield could be improved with addition of heat or a change in
solvent. From optimization experiments with CuAAC, THF was observed to delay the
reaction. Changing the solvent and increasing the temperature proved to be very
beneficial. Both acetonitrile and toluene (Entries 10 and 12) displayed modest yields
with acetonitrile showing the best selectivity thus far, with a ratio of nearly 13 : 1 desired
product to Glaser byproduct. Since the palladium exists as a trimer, the stoichiometry of
the added ligand was adjusted to find the optimal ratio between palladium and triazine
(Entry 10, 13).
From these initial results, it appeared that this method could be viable. We then tried to
extend this method to a one-pot reaction in which both the Sonogashira and azide
alkyne cycloaddition would take place in one pot. Unfortunately, our attempts at a onepot Sonogashira-CuAAC only resulted in approximately a 12% isolated yield (Table
3.7). This product was darker in color than the normal product triazole, indicating likely
palladium contamination. Unreacted starting material was a culprit in the low yields.
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Table 3.6 Initial studies of 1,2,4-triazines as additives in Sonogashira reaction.a

Table 3.7 Evaluation of one-pot Sonogashira-CuAAC reaction.a
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From here, we decided to examine the deprotection and cycloaddition steps. In the
examples above, the aryl iodide was reacted with a TMS-protected alkyne. This alkyne
must be deprotected before the azide-alkyne cycloaddition can take place. Since the
Sonogashira reaction was resulting in product, we wanted to isolate the other portions
of the reaction, to determine where the reaction was stalling. For this, TMS-protected
phenylacetylene was synthesized and used to screen various deprotection conditions.
After addition of benzyl azide, triazole product formation was monitored (Table 3.8). We
also decided to take advantage of the Microwave Synthesizer and performed the
reactions in Table 3.8 at 120°C in the microwave. We explored various copper sources
for the cycloaddition and observed that the reaction required larger equivalents of
copper compared to the standard reaction between phenylacetylene and benzyl azide.
Increasing the amount of ligand and copper increased the yield, but in the microwave
the difference between triazine-accelerated and control reaction wasn’t significant (98%
to 86%, Entries 11, 12).
Having observed good yields for triazole formation, we decided to move forward and
once again try a one-pot approach. Using the optimal deprotection conditions,
iodobenzene was converted into TMS-phenylacetylene. Again a problem arose in the
deprotection and no triazole product was formed. Protected phenylacetylene was the
main component in the reaction mixture. This made us begin to question if palladium
was possibly interfering with the deprotection step. First, we examined the presence of
bis(triphenylphosphine)palladium (II) chloride during the deprotection of TMSphenylacetylene with tetrabutylammonium fluoride. There was a dependence on the
solvent used for the deprotection as shown in Table 3.9.
A few more parameters were altered, and now we were able to remove the protecting
group from the alkyne, but we still were not observing triazole product formation (Table
3.10). Instead of recovering protected alkyne, we had a free terminal alkyne, but no
cycloaddition was taking place. The problem appeared to be the addition of palladium
acetate. We then examined the CuAAC reaction in the presence of palladium to
determine if the cycloaddition reaction was being hindered by the presence of
palladium. Using benzyl azide and phenylacetylene as the model system, we added
palladium (Pd3(OAc)6) and tetrabutylammonium fluoride to the reaction mixture. After an
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Table 3.8 Optimization of deprotection of TMS-phenylacetylene and concurrent
cycloaddition.a

Table 3.9 Deprotection of TMS-phenylacetylene in the presence of palladium.
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Table 3.10 Re-evaluation of triazine ligand in one pot Sonogashira-CuAAC reaction.

hour at room temperature, this reaction showed very little progress. After a prolonged
time, product formation began to occur, but additional byproducts were observed by
TLC. This combination was causing a sluggish cycloaddition reaction. Future options
would be to try a different palladium source. The triazine may be binding too tightly to
the palladium and not available to bind to copper to catalyze the cycloaddition reaction.
The last reaction attempted was to use the standard sonogashira conditions
(bis(triphenylphosphine)palladium(II) chloride and copper iodide. The deprotection was
performed using tetrabutylammonium fluoride and the cycloaddition reagents were
copper (II) sulfate and sodium ascorbate. These conditions led to product formation in a
58% yield. This reaction was conducted in order to check for the azide reduction to
amine. No free amine was detected, so it was not believed that azide decomposition
was leading to any prior unreactivities. At this point, it was deemed necessary to place
this work aside and focus on applications of 1,2,4-triazines in heterogeneous systems
and in synthesis of metalloenzyme inhibitors.
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3.7.

Solid-Supported 1,2,4-Triazines

After observing promising activity with the homogeneous triazines, it was decided to
make heterogeneous versions of the triazine catalyst by covalently linking the 1,2,4triazines to both silica and polystyrene supports. This work was discussed in detail by
Prince.97 I will highlight the key schemes used to continue this work, and present the
catalytic activity, recyclability, and copper retention for these heterogeneous supports.

3.7.1. Overview of Synthesis of Solid-Supported 1,2,4-Triazines and Control
1,2,3-Triazole Resins
Commercial Merrifield resin was chosen as a polystyrene support due to its ability to
swell in a number of solvents, low cost, and easy availability. For the synthesis, we used
a high loading resin (1.4 mmol/g) and a low loading resin (0.5 mmol/g). Since a triazine
alkyne was synthesized to attach to the solid support, the polystyrene resin was first
converted from a chloride to an azide using sodium azide. At this time, we synthesized
a series of controls (Scheme 3.1). Azide functional groups are known to bind copper, so
we first coordinated copper (I) and copper (II) to azide derivatized polystyrene.
Additionally, since triazoles are known to catalyze azide-alkyne cycloaddition, we
wanted to ensure that the activity being observed was due to the triazine ligand, and not
due to the presence of the 1,2,3-triazole linker. Therefore, we synthesized two 1,2,3triazoles by reacting the azide resin with phenylacetylene and 2-ethynyl pyridine. The
pyridine derivative would install an additional nitrogen that could be used to bind metal.
Since we had both high loading and low loading resin each reaction was carried out with
each support. Each product was then coordinated with a copper (I) or copper (II) salt to
afford 12 control compounds (Scheme 3.1).
A similar process was carried out using triazine alkynes and the azido resin to form the
1,2,4-triazine supported catalysts. The alkyne of the 1,2,4-triazine was located either on
an aromatic ring at the 3-position or at the 5-position. To synthesize the alkyne
precursor at the 3-position, commercially available 5-bromo-2-cyano-pyridine was
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Scheme 3.1 Synthesis of solid-supported control 1,2,3-triazoles.

converted into the amidrazone (3-26). This was condensed with benzil to afford the
1,2,4-triazine (3-27). The bromide was then converted to the alkyne using the
Sonogashira coupling reaction (Scheme 3.2). The alkyne was produced in 45% yield
over 3 steps. For synthesis of the 5-substituted alkyne triazine, 4-bromoacetophenone
was converted to the ketoaldehyde (3-30) through oxidation with selenium dioxide. This
was condensed with the pyridine amidrazone to yield the 1,2,4-triazine (3-31) with a
bromide on the aryl ring at the 5-position. This bromide was then converted to the
alkyne through the Sonogashira coupling reaction (Scheme 3.3). The overall yield for
this alkyne triazine was 20% over 3 steps.
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Scheme 3.2 Synthesis of alkyne on 3-substituent of 1,2,4-triazine.

Scheme 3.3 Synthesis of alkyne on 5-substituent of 1,2,4-triazine.

The alkyne containing triazines were then subjected to a cycloaddition reaction with the
azide containing solid supports. Triazine 3-28 was attached to both HL and LL
polystyrene supports. Triazine 3-32 was attached only to the HL polystyrene support.
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The alkyne triazine precursor synthesis was lower yielding (and with regards to catalytic
activity was not superior to triazine 3-28). After carrying out the cycloaddition reaction, it
was observed that the reaction did not go to completion, leaving some unreacted azides
on the solid support. This resin was reacted with tin chloride to reduce the unreacted
azides to free amines. Both the azide and amine containing resins were then complexed
with copper (I) and copper (II). This resulted in 12 triazine containing heterogeneous
ligands. A summary of the triazine ligands to be discussed in the results is presented in
Figure 3.3 and Figure 3.4.

3.7.1. Catalytic Activity of Solid Supported 1,2,4-Triazines
With the synthesis of triazine catalysts and appropriate controls completed, we began to
evaluate their catalytic activity. To determine the copper loading, each heterogeneous
support was heated in a solution of either copper (I) or copper (II) for two hours. The
heterogeneous support was filtered and washed thoroughly. The filtrate was
concentrated and rediluted in 2% nitric acid. The filtrate was then analyzed for copper
content using ICP-OES. By difference the copper loading was calculated. The loading
for copper (I) and copper (II) is illustrated in Table 3.11. The triazine ligands (Entries 15) were all efficient at binding copper to a much better extent than the azide derivative
(Entry 6) or the simple 1,2,3-triazole with a phenyl substituent (Entries 7-8). The copper
binding ability of the pyridine substituted 1,2,3-triazole was surprisingly greater than the
binding ability of the 1,2,4-triazines when the high loading polystyrene resin was used
(Entry 9). When low loading resin was used a decrease in copper loading was observed
with both triazines and triazoles. In general copper (II) catalysts had a slightly higher
copper content than their copper (I) counterparts. Supports with residual amine showed
slightly more copper loading when compared to the analogous residual azide supports.
Once the copper loading was determined, the various functionalized supports were
screened for activity using the model system of benzyl azide and phenylacetylene. DCE
was added to 5 mg of the appropriate resin followed by the addition of azide, alkyne,
and triethylamine. Reactions were allowed to proceed for 4 hours at 60°C and the 1,2,3triazole product was separated from the resin by filtration. Concentration in vacuo
afforded the analytically pure triazole. The trend in percent yields was similar to that
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Figure 3.3 Summary of triazine ligands attached to polystyrene resins containing
unreacted azides.

Figure 3.4 Summary of triazine ligands attached to polystyrene containing free amines.
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Table 3.11 Copper loading and catalytic activity of various polystyrene supports.

observed for the copper loading. Copper (II) catalysts outperformed the copper (I)
derivatives in all cases with about a 10% difference in the isolated yields. The activity
between triazines substituted through the 3-position was very similar to the activity of
triazines attached through the 5-position with a slight favoring of the 3-substituted
triazine linker.
One surprising note was the activity of the 1,2,3-triazole with a phenyl substituent (Entry
7) on a high loading resin. This was only slightly less active than the 1,2,4-triazine
supports. When the 1,2,3-triazole supported on a low loading resin was screened, there
was no appreciable activity (Entry 8). It was hypothesized that the higher density of
triazoles on the high loading resin was catalyzing the azide-alkyne cycloaddition.38,55
This was supported by the absence of activity for the low loading triazole resin.
Additionally, the pyridine substituted 1,2,3-triazole also displayed a high activity,
recovering 99% product from the high loading resin and 99% using a low loading resin
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with copper (II) (Entries 9-10). The increased activity at using the low-loading resin was
surprising, but can be explained since the pyridine adjacent to the triazole is able to
chelate the copper to assist in the azide-alkyne cycloaddition.
Since the initial results were promising, we next investigated if the solid supports could
be reused for multiple catalytic cycles. We were interested to see if the simple phenyl or
pyridyl substituted 1,2,3-triazoles were active for multiple cycles. After each
cycloaddition reaction, catalyst resin was filtered, rinsed, and reused without any
additional treatment. Catalysts were reused for up to 4 consecutive reactions. The
isolated product yields were reported (Table 3.12). For these studies only the triazine
appended to the solid support through the 3-position was examined. Since there was
not an appreciable difference in the activity between the two triazines, we elected to
continue studies using the support which was easier to synthesize (the triazine with an
alkyne at the 3-position). For the two triazine ligands (Entries 1-2) moderate yields were
displayed for two cycles with the copper (I) catalyst, while moderate yields were
illustrated for three cycles for the copper (II) catalysts. The 1,2,3-triazole substituted with
a phenyl ring had showed modest activity after one cycle with 73% isolated triazole
product, but trying to reuse the catalyst resulted in very minimal product formation
(Entry 3). The 1,2,3-triazole substituted with a pyridyl ring was active for two
consecutive cycles when the high loading resin was used, but failed to give any
substantial product in cycle 3 (Entries 4-5). The low loading resin with a pyridyl 1,2,3triazole (Entries 6- 7) was only active for one cycle.
Directly related to the recyclability of the resin, is the copper retained by the
heterogeneous catalyst. Since one advantage of heterogeneous catalysts is to prevent
copper contamination in the products, we examined the percentage of copper leached
after consecutive reactions. The isolated triazole product was diluted in 2% nitric acid
and the amount remaining on the solid support was determined by difference from the
ICP-OES results. The copper retention studies (Table 3.13) follow the same pattern
seen in the recyclability studies. As the yield decreased, it can be seen that the
percentage of copper remaining on the polystyrene support was also decreasing. For
the 1,2,3-triazoles without triazines appended, the copper retention decreased to a
range of 11-50% after one cycle. Triazines, by comparison, retained between 80 and
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Table 3.12 Recyclability of polystyrene supported catalysts.a

Table 3.13 Copper retention by polystyrene supported catalysts.a
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90% of the original loaded copper. This data makes sense in that as copper is leached
the catalyst support will not be as effective in a catalytic reaction, since the level of
copper has decreased dramatically. These results were encouraging in that the triazines
could be reused, while the non-triazine controls were more limited.
Additional results not presented here showed that 1,2,4-triazines attached to silica
supports displayed higher isolated yields of 1,2,3-triazole product, and could be used for
up to four cycles while maintaining greater than 90% yields, without significant copper
leaching. Some catalysts were even effective without the addition of triethylamine.
As an extension to this work, an evaluation of solvent was conducted with selected
polystyrene and silica catalysts. Organic solvents such as MeCN, DCE, t-BuOH, and
toluene had been previously evaluated.97 Silica catalysts performed much better over a
wider array of solvents. The polystyrene catalysts were not as effective in solvents such
as tert-butanol or toluene. An additional experiment was conducted to see the activity of
the solid supports in water. Surprisingly, both the polystyrene and silica catalysts
performed well in the presence of water with isolated yields of 98-99% (Table 3.14 Entry
5). We had not explored the use of water as a solvent with homogeneous ligands, since
the substrates did not dissolve in aqueous medium. In this case, the reaction was stirred
to ensure reaction of the nonpolar substrates with the triazine catalyst. The isolation of
the product was also rather simple, as the reaction was filtered, and the resin rinsed
with DCM to dissolve the product triazole. Using water would be more advantageous
especially from a “click” perspective. Additional experiments should be carried out with
the solid supports in water, specifically a study to look at recyclability of catalysts and
the copper retention when water is used for the reaction media. The dependence of
base when reactions are carried out in water would also be a worthwhile experiment.
Finally, since the homogenous ligands were not used with water, it would be
advantageous to test those ligands in aqueous conditions to see if similar results are
obtained.
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Table 3.14 Evaluation of solvents with various polystyrene and silica catalysts.

3.8.

Conclusions

In summary, several parameters were evaluated with respect to the use of
homogeneous triazines as ligands for CuAAC. Optimization studies, evaluation of
substrate scope, and ligand scope were all conducted to explore the feasibility of 1,2,4triazines as ligands for CuAAC. Optimization studies revealed that homogeneous 3-(2pyridyl)-1,2,4-triazines with either copper (I) or copper (II) salts could be used effectively
in the presence of a reducing agent, triethylamine, giving isolated 1,2,3-triazole product
in 97% yield. Best results were observed with an excess of reducing agent (0.5 to 1.0
equivalents) although 0.06 equivalents of triethylamine produced reasonable yields
(91%), but required longer reaction times (5 hours). The substrate concentration could
be reduced to 0.1 M without adverse effects to the catalytic activity, but further
decreasing to 0.05 M decreased the catalytic activity greatly.
The scope of the reaction seems to encompass a wide array of substrate azide and
alkynes. Aryl and alkl azides in general underwent cycloadditions with phenylacetylene
in good yields (>80%). Alkyl acids only gave modest triazole products, and tertiary
azides, such as adamantly azide resulted in minimal product formation. Variations in
azides were more tolerable compared to their alkyne counterparts. Alkyne substituents
were more apt to formation of bistriazole products, requiring modifications to the solvent
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choice, using DCM in place of MeCN. Yields with alkynes, in general, were slightly
lower ranging from 68 – 95%. The exception was the long alkyl alkyne, decyne which
showed poor results. With regards to solvent, the choices were somewhat limited,
working best in nonpolar non-coordinating solvents. Solvents that could coordinate
metals such as DMSO, DMF, or THF led to decreased yields, increased by-product
formation, or longer reaction times.
A ligand scope was also conducted in search of more active nitrogen containing ligands.
The 3-(2-pyridyl)-substituent was deemed necessary for activity. Triazines lacking this
group were inactive with isolated yields less than 10%, with the exception of the
imidazoyl substitutent that produced 50% of triazole product in 1 hour. Modifications to
the 5,6-substitutents proved to be less detrimental to the activity, but did not surpass the
activity of the triazine used for optimization studies (2-17). Replacing the 1,2,4-triazine
core with other heterocycles such as tetrazines, pyridines, or imines did not yield
triazole product in a catalytic fashion. The two exceptions were pyridizine (2-87) which
resulted in 63% yield and imine (2-95) which resulted in 95% yield of the triazole
product. The imine ligand did require longer reaction times compared to 3-(2-pyridyl)1,2,4-triazines.
Two applications utilizing the homogenous triazine ligand were evaluation in other metal
catalyzed reactions, such as the Sonogashira reaction and use in synthesis of solid
supported catalysts. The application of triazines to a one-pot Sonogashira-azide-alkyne
cycloaddition reaction was not fully optimized. Further work is still needed to make this
route viable. Options include changing the palladium source and possibly the copper
salt.
The second application, the synthesis and catalytic activity of the solid-supported
triazines proved to be much more valuable. Good to excellent yields were observed with
polystyrene and silica catalysts containing 1,2,4-triazines. Although heat was needed for
the reaction to proceed, the high yields, easy product isolation, and copper retention by
the support, made this an efficient and viable synthetic route. 1,2,4-triazines were more
effective at binding copper and were able to be recycled compared to 1,2,3-triazoles
which were synthesized as controls. In addition, both polystyrene and silica supported
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1,2,4-triazines worked efficiently in water, affording >98% yield of 1,2,3-triazole product.
Further exploration of this method to the application of more challenging substrates
would be a worthwhile expedition.

3.9.

Experimental

Materials and General Methods. Reagents and solvents were purchased from various
commercial sources and used without further purification unless otherwise stated.
Anhydrous solvents were purified using a Grubbs solvent system. Analytical thin-layer
chromatography (TLC) was performed using aluminum backed silica gel TLC plates
with UV indicator from Sorbent Technologies.

Flash column chromatography was

performed using 40-63 μm (230 x 400 mesh) silica gel from Sorbent Technologies.
and

1

H

13

C NMR were recorded at 600 MHz and 151 MHz, respectfully, on a Varian Inova

spectrometer or at 500 MHz and 125 MHz on a Varian spectrometer. All chemical shifts
were reported in δ units relative to tetramethylsilane or the corresponding deuterated
solvent. High resolution mass spectra (ESI) were obtained on a JEOL AccuTOF DART
spectrometer. Liquid chromatography mass spectra were obtained on a QSTAR XL
Hybrid LC/MS/MS equipped with a Vydac C18 column and a mobile phase composed of
acetonitrile and formic acid. Infrared spectra were recorded on a Varian 4100 FT-IR
using KBr pellets or KBr salt plates. Absorption spectra were collected on a Thermo
Scientific Evolution 600. High pressure liquid chromatography (HPLC) was performed
using a Beckman Coulter System equipped with a UV-Vis detector, autosampler, Varian
C18 column, and a mobile phase composed of acetonitrile and trifluoroacetic acid.
Copper was quantified by inductivel coupled plasma – optical emission spectroscopy
(ICP-OES) using a Perkin Elmer Optima 2100 DV.

WARNING: Low molecular weight azides are potentially explosive. Appropriate
safety measures should always be taken when handling these compounds.
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LC/MS Methodology. All reactants and reagents were added as stock solutions unless
otherwise noted. The concentrations of these stock solutions were determined by UVVis spectroscopy. Reactants and reagents were added in the following order: excess
solvent, azide, alkyne, base, ligand and copper source. After 1 h the reactions were
diluted in acetonitrile to a final concentration range of 15 – 25 μM and analyzed by LCMS using a Vydac C18 column. The isocratic mobile phase was composed of 45%
acetonitrile and 0.5% formic acid. Percent yields were determined based on product
formation using an external calibration curve.

All reactions containing a standard

deviation were run in triplicate unless otherwise noted.

General Azide Method A: Aromatic Azides. The aniline derivative (approx 2 g, 16.24
mmol) was dissolved in 80 mL of EtOAc. 40 mL of 1.5 M HCl was added and the
solution cooled to 0°C in an ice bath. Sodium nitrite (1.68 g, 24.36 mmol) was dissolved
in 20 mL water and added dropwise to the reaction solution while stirring at 0°C. After
15 min, sodium azide (3.17 g, 48.72 mmol) was dissolved in 20 mL water and added
dropwise to the reaction solution while stirring at 0 °C. After slowly warming to room
temperature, the reaction was monitored by TLC. Upon completion, the reaction was
extracted with EtOAc (x3) and washed with 1 M HCl, water, and brine. The solution
was then dried with sodium sulfate and concentrated in vacuo to yield the
corresponding aromatic azide. Yields: 80 – 94%.

General Azide Method B:

Aliphatic/Benzylic Azides.

The bromine derivative

(approx 2 g, 11.17 mmol) was dissolved in 25 mL of dimethylformamide. Sodium azide
(799 mg, 12.28 mmol) was added and the reaction was stirred overnight at room
temperature.

Progress of the reaction was monitored by TLC and GC-MS.

Upon

completion, the reaction was quenched with 50 mL of water (exothermic) and stirred
until reaching room temperature. The solution was then extracted with diethyl ether (x3)
and washed with water (x2), copper sulfate (x1), and brine. The solution was then dried
with sodium sulfate and concentrated in vacuo to yield the corresponding aliphatic
azide. Yields: 79 – 98%.
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(azidomethyl)benzene (3-1a). Prepared using general azide method B
and isolated as a colorless oil. 1H NMR (CDCl3, 600 MHz) δ 7.40-7.37 (m,
13

C NMR (CDCl3, 151 MHz) δ 135.5, 129.0,

2H), 7.35-7.31 (m, 3H), 4.33 (s, 2H).
128.44, 128.35, 54.9.

IR (film) νmax 2099 cm-1.

MS (ESI) m/z calculated 106.066

(C7H8N, [M-N2+H]+), m/z observed 106.064 (C7H8N, [M-N2+H]+).

azidobenzene (3-1b). Prepared using general azide method A and isolated as a
brown oil.

1

H NMR (CDCl3, 600 MHz) δ 7.35 (t, 2H, J = 7.8 Hz), 7.14 (t, 1H, J =

7.8 Hz), 7.03 (d, 2H, J = 7.8 Hz).

13

C NMR (CDCl3, 151 MHz) δ 140.0, 129.8,

124.9, 119.1. IR (film) νmax 2129 cm-1. MS (ESI) m/z calculated 92.050 (C6H6N, [MN2+H]+), m/z observed 92.048 (C6H6N, [M-N2+H]+).

1-azido-4-methoxybenzene (3-1c). Prepared using general azide method A
1

H NMR (CDCl3, 600 MHz) δ 6.95 (d, 2H, J = 9

and isolated as a brown solid.
Hz), 6.89 (d, 2H, J = 9 Hz).
115.1, 55.6.

13

C NMR (CDCl3, 151 MHz) δ 157.0, 132.3, 120.0,

IR (film) νmax 2110 cm-1.

MS (ESI) m/z calculated 122.061

+

(C7H8NO, [M-N2+H] ), m/z observed 122.060 (C7H8NO, [M-N2+H]+).

methyl 4-azidobenzoate (3-1d).

Prepared using general azide

method A and isolated as an orange-brown solid.

1

H NMR (CDCl3,

600 MHz) δ 8.05 (d, 2H, J = 7.4 Hz), 7.07 (d, 2H, J = 7.4 Hz), 3.91
(s, 3H).

13

C NMR (CDCl3, 151 MHz) δ 166.4, 144.9, 131.6, 126.8, 119.0, 52.3. IR (film)

νmax 2125 cm-1. MS (ESI) m/z calculated 150.056 (C8H8NO2, [M-N2+H]+), m/z observed
150.056 (C7H7NO, [M-N2+H]+).

1-azido-2,4-dimethylbenzene (3-1e). Prepared using general azide method
A and isolated as a brown oil. 1H NMR (CDCl3, 600 MHz) δ 7.03-6.97 (m, 3H),
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2.29 (s, 3H), 2.17 (s, 3H).

13

C NMR (CDCl3, 151 MHz) δ 135.6, 134.2, 131.9, 129.3,

127.6, 117.8, 20.8, 17.2. IR (film) νmax 2122 cm-1. MS (ESI) m/z calculated 120.081
(C8H10N, [M-N2+H]+), m/z observed 120.081 (C8H10N, [M-N2+H]+).

2-azido-1,3-dimethylbenzene (3-1f).
method A and isolated as a brown oil.
7.00 (m, 3H), 2.36 (s, 6H).

Prepared using general azide
1

H NMR (CDCl3, 600 MHz) δ 7.02-

13

C NMR (CDCl3, 151 MHz) δ 137.0, 132.1,

128.9, 125.7, 18.2. IR (film) νmax 2129 cm-1. MS (ESI) m/z calculated 120.081 (C8H10N,
[M-N2+H]+), m/z observed 120.081 (C8H10N, [M-N2+H]+).

1-azidoheptane (3-1g). Prepared using general azide method B
and isolated as a clear oil.

1

H NMR (CDCl3, 600 MHz) δ 3.26 (t, 2H, J = 6.6 Hz), 1.62-

1.58 (m, 2H), 1.38-1.27 (m, 8H), 0.89 (t, 3H, J = 6.6 Hz).

13

C NMR (CDCl3, 151 MHz) δ

IR (film) νmax 2099 cm-1.

51.5, 31.7, 28.8, 26.7, 22.6, 14.1, 14.0.

MS (ESI) m/z

+

calculated 114.128 (C7H16N, [M-N2+H] ), m/z observed 114.128 (C7H16N, [M-N2+H]+).

2-azidoheptane (3-1h). Prepared using general azide method B and
isolated as a clear oil.

1

H NMR (CDCl3, 600 MHz) δ 3.43-3.40 (m,

1H), 1.52-1.27 (m, 8H), 1.25 (d, 3H, J = 6 Hz), 0.89 (t, 3H, J = 6 Hz).

13

C NMR (CDCl3,

151 MHz) δ 58.2, 36.3, 31.7, 25.9, 22.7, 19.6, 14.1. IR (film) νmax 2110 cm-1. MS (ESI)
m/z calculated 114.128 (C7H16N, [M-N2+H]+), m/z observed 114.129 (C7H16N, [MN2+H]+).

6-azidohexanoic acid (3-1k).

Prepared using general azide

method B and isolated as a clear oil in 98.1% yield.

1

H NMR

(CDCl3, 600 MHz) δ 3.29 (t, 2H, J = 7.2), 2.38 (t, 2H, J = 7.2 Hz), 1.70-1.60 (m, 4H),
1.47-1.42 (m, 2H).

13

C NMR (CDCl3, 151 MHz) δ 179.50, 51.32, 33.94, 28.65, 26.28,

24.29. IR (film) νmax 2098.55 cm-1. MS (ESI) m/z calculated 130.087 (C6H12NO2, [MN2+H]+), m/z observed 130.087 (C6H12NO2 [M-N2+H]+).
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General

Alkyne

Method.

Aryl

iodide

(10

mmol),

dichlorobis-

(triphenylphosphine)palladium(II) (0.25 mmol), and CuI (0.15 mmol) were combined in a
round bottom flask and flushed with N2. Anhydrous THF was added (12.5 mL) followed
by a dropwise addition of triethylamine (15 mmol) and trimethylsilylacetylene (15 mmol)
in anhydrous THF (12.5 mL). Reaction was stirred at room temperature and monitored
by TLC. Upon completion, solvent was removed in vacuo and purified by silica gel
chromatography to yield the corresponding trimethylsilyl protected alkyne.

To the

protected alkyne (10 mmol) in MeOH (20 mL) was added solid K 2CO3 (1.5 mmol) and
the resulting suspension stirred at room temperature, with reaction progress monitored
by TLC. Upon completion, the reaction was concentrated in vacuo, and the residue
brought up in DCM and water. The aqueous layer was extracted with DCM (x3). The
combined organic layers were washed with water (x1), sat’d NaHCO 3, and brine. The
solution was dried over sodium sulfate, concentrated in vacuo and purified by silica
column chromatography to yield corresponding terminal alkyne.

1-ethynyl-2,4-dimethylbenzene (3-2e). Prepared using general alkyne
method

from

1-iodo

2,4-dimethylbenzene.

Purified

by

silica

chromatography using gradient elution of hexanes and ethyl acetate to
yield a red oil in 61% yield. 1H NMR (CDCl3, 600 MHz) δ 7.35 (d, 1H, J = 7.8 Hz), 7.02
(s, 1H), 6.95 (d, 1H, J = 7.8 Hz), 3.22 (s, 1H), 2.42 (s, 3H), 2.32 (s, 3H).

13

C NMR

(CDCl3, 151 MHz) δ 140.7, 139.0, 132.6, 130.4, 126.5, 119.0, 82.9, 80.3, 21.6, 20.6.
HRMS (ESI) m/z calculated 131.08608 (C10H11, [M+H]+), m/z observed 131.08606.
(C10H11, [M+H]+).

1-ethynyl-4-methoxybenzene (3-2f). Prepared using general alkyne
method from 4-iodoanisole. Purified by silica chromatography using
gradient elution of hexanes and ethyl acetate to yield a yellow oil in
65% yield. 1H NMR (CDCl3, 500 MHz) δ 7.43 (d, 2H, J = 7 Hz), 6.85 (d, 2H, J = 7 Hz),
3.82 (s, 3H), 2.99 (s, 1H).

13

C NMR (CDCl3, 125 MHz) δ 160.1, 133.7, 114.3, 114.1,

100

83.8, 75.9, 55.4.

HRMS (ESI) m/z calculated 133.06534 (C9H9O, [M+H]+), m/z

observed 133.06486. (C9H9O, [M+H]+).

methyl 4-ethynylbenzoate (3-2g). Prepared using general alkyne
method from methyl-4-iodobenzoate.

Purified by silica column

chromatography using gradient elution of hexanes and ethyl acetate
to yield an off-white solid in 91% yield. 1H NMR (CDCl3, 600 MHz) δ 8.00 (d, 2H, J = 8.4
Hz), 7.55 (d, 2H, J = 8.4 Hz), 3.92 (s, 3H), 3.23, (s, 1H).

13

166.6, 132.2, 130.3, 129.6, 126.9, 82.9, 80.2, 52.4.

HRMS (ESI) m/z calculated

C NMR (CDCl3, 151 MHz) δ

+

161.06025 (C10H9O2, [M+H] ), m/z observed 161.05971. (C10H9O2, [M+H]+).

methyl 2-ethynylbenzoate (3-2h). Prepared using general alkyne method
from methyl-2-iodobenzoate.

Purified by silica column chromatography

using gradient elution of hexanes and ethyl acetate to yield an orange oil in
1

88% yield. H NMR (CDCl3, 600 MHz) δ 7.94 (dd, 1H, J = 7.8, 1.2 Hz), 7.63 (dd, 1H, J =
7.8, 1.2 Hz), 7.48 (td, 1H, J = 7.8, 1.2 Hz), 7.41 (td, 1H, J = 7.8, 1.2 Hz), 3.94 (s, 3H),
3.40 (s, 1H).

13

C NMR (CDCl3, 151 MHz) δ 166.6, 135.1, 132.6, 131.9, 130.4, 128.6,

122.8, 82.4, 82.2, 52.3. HRMS (ESI) m/z calculated 161.06025 (C10H9O2, [M+H]+), m/z
observed 161.06039. (C10H9O2, [M+H]+).

General Triazole Method A: Azide (1 mmol), alkyne (1 mmol), and triethylamine (1
mmol) were dissolved in acetonitrile (5 mL). (1) (10 μmol) and tetrakis(acetonitrileN)copper(I) tetrafluoroborate (10 μmol) were added to the reaction solution and stirred
at room temperature for 18 hours.

Concentration in vacuo and purification yielded

desired 1,2,3-triazole product.

General Triazole Method B: Azide (1 mmol), alkyne (1 mmol), and triethylamine (1
mmol) were dissolved in dichloromethane (5 mL).

(1) (10 μmol) and copper(II)

tetrafluoroborate hexahydrate (10 μmol) were added to the reaction solution and stirred
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at room temperature for 18 hours.

Concentration in vacuo and purification yielded

desired 1,2,3-triazole product.

General Triazole Method C: Azide (1 mmol), alkyne (1 mmol), and triethylamine (1
(1) (10 μmol) and copper(II)

mmol) were dissolved in dichloroethane (5 mL).

tetrafluoroborate hexahydrate (10 μmol) were added to the reaction solution and stirred
at room temperature for 1 hour. Reaction mixture was poured directly onto silica and
purification yielded desired 1,2,3-triazole product.

1-benzyl-4-phenyl-1H-1,2,3-triazole (3-3a).
general

triazole

method

C.

Purified

Prepared using

by

silica

column

chromatography using gradient elution of hexanes and ethyl acetate as a white solid in
97% yield.

1

H NMR (CDCl3, 600 MHz) δ 7.80 (d, 2H, J = 8.4 Hz), 7.66 (s, 1H), 7.41-

7.37 (m, 5H), 7.32-7.31 (m, 3H), 5.58 (s, 2H).

13

C NMR (CDCl3, 151 MHz) δ 148.4,

134.8, 130.7, 129.3, 128.9, 128.3, 128.2, 125.8, 119.6, 54.4.

HRMS (ESI) m/z

calculated 236.11877 (C15H14N3, [M+H]+), m/z observed 236.11898 (C15H14N3, [M+H]+).

1,4-diphenyl-1H-1,2,3-triazole (3-3b). Prepared using general
triazole method A. Precipitated from 5% nitric acid as a brown
solid in 95% yield.

1

H NMR (CDCl3, 600 MHz) δ 8.20 (s, 1H),

7.93 (d, 2H, J = 6.6 Hz), 7.81 (d, 2H, J = 7.8 Hz), 7.55 (t, 2H, J = 7.8 Hz), 7.48-7.46 (m,
3H), 7.38 (t, 1H, J = 7.8 Hz).

13

C NMR (CDCl3, 151 MHz) δ 148.6, 137.2, 130.4, 129.9,

129.1, 128.9, 128.6, 126.0, 120.7, 117.7 .

HRMS (ESI) m/z calculated 222.10312

(C14H12N3, [M+H]+), m/z observed 222.10280 (C14H12N3, [M+H]+).

1-(4-methoxyphenyl)-4-phenyl-1H-1,2,3-triazole
Prepared using general triazole method A.

(3-3c).

Precipitated

from 5% nitric acid as a brown solid in 83% yield.

1

H NMR

(CDCl3, 600 MHz) δ 8.11 (s, 1H), 7.91 (d, 2H, J = 7.2 Hz), 7.69 (d, 2H, J = 7.8 Hz), 7.46
102

(t, 2H, J = 7.2 Hz), 7.37 (t, 1H, J = 7.2 Hz), 7.05 (d, 2H, J = 7.8 Hz) 3.88 (s, 3H).

13

C

NMR (CDCl3, 151 MHz) δ 160.0, 148.4, 130.7, 130.5, 129.0, 128.5, 126.0, 122.3, 118.0,
115.0, 55.8. HRMS (ESI) m/z calculated 252.11369 (C15H14N3O, [M+H]+), m/z observed
252.11371 (C15H14N3O, [M+H]+).

methyl 4-(4-phenyl)-1H-1,2,3-triazol-1-yl)benzoate (33d).

Prepared using general triazole method A.

Precipitated from 5% nitric acid as a yellow solid in 91%
yield.

1

H NMR (d6-DMSO, 600 MHz) δ 9.46 (s, 1H), 8.21

(d, 2H, J = 9 Hz), 8.15 (d, 2H, J = 8.4 Hz), 7.97 (d, 2H, J = 7.8 Hz), 7.52 (t, 2H, J = 7.8
13

C NMR (d6-DMSO, 151 MHz) δ 165.4,

Hz), 7.41 (t, 1H, J = 7.8 Hz), 3.91 (s, 1H).

147.6, 139.8, 131.1, 130.0, 129.4, 129.1, 128.4, 125.4, 119.8, 119.7, 52.4. HRMS (ESI)
m/z calculated 280.10860 (C16H14N3O2, [M+H]+), m/z observed 280.10883 (C16H14N3O2,
[M+H]+).

1-(2,4-dimethylphenyl)-4-phenyl-1H-1,2,3-triazole

(3-3e).

Prepared using general triazole method A. Purified by silica
column chromatography using gradient elution of hexanes and
ethyl acetate as a white solid in 90% yield.

1

H NMR (CDCl3, 600 MHz) δ 7.92 (d, 3H, J

= 9 Hz), 7.46 (t, 2H, J = 7.8 Hz), 7.36 (t, 1H, J = 7.2 Hz) 7.27 (d, 1H, J = 7.8 Hz), 7.20
(s, 1H), 7.15 (d, 1H, J = 7.8 Hz), 2.41 (s, 3H), 2.23 (s, 3H).

13

C NMR (CDCl3, 151 MHz)

δ 147.6, 140.1, 134.3, 133.6, 132.2, 130.6, 129.0, 128.4, 127.6, 125.92, 125.91, 121.3,
21.3, 18.0. HRMS (ESI) m/z calculated 250.13442 (C16H16N3, [M+H]+), m/z observed
250.13462 (C16H16N3, [M+H]+).

1-(2,6-dimethylphenyl)-4-phenyl-1H-1,2,3-triazole
Prepared using general triazole method A.

(3-3f).

Purified by silica

column chromatography using a gradient elution of hexanes and
ethyl acetate as a white solid in 83% yield.

1

H NMR (CDCl3, 600 MHz) δ 7.94 (d, 2H, J
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= 8.4 Hz), 7.87 (s, 1H), 7.47 (t, 2H, J = 7.2 Hz), 7.37 (t, 1H, J = 7.8 Hz), 7.34 (t, 1H, J =
7.2 Hz), 7.21 (d, 2H, J = 7.8 Hz), 2.07 (s, 6H).

13

C NMR (CDCl3, 151 MHz) δ 147.8,

136.1, 135.6, 130.6, 130.2, 129.1, 128.6, 128.5, 125.9, 121.4, 17.6. HRMS (ESI) m/z
calculated 250.13442 (C16H16N3, [M+H]+), m/z observed 250.13497 (C16H16N3, [M+H]+).

1-heptyl-4-phenyl-1H-1,2,3-triazole (3-3g).
using general triazole method A.

Prepared

Purified by silica

column chromatography using gradient elution of hexanes and ethyl acetate as a white
solid in 88% yield.

1

H NMR (CDCl3, 600 MHz) δ 7.84 (d, 2H, J = 7.8 Hz), 7.74 (s, 1H),

7.42 (t, 2H, J = 7.8 Hz), 7.33 (t, 1H, J = 7.8 Hz), 4.39 (t, 2H, J = 7.2 Hz), 1.97-1.92 (m,
2H,), 1.35-1.27 (m, 8H), 0.88 (t, 3H, J = 7.2 Hz).

13

C NMR (CDCl3, 151 MHz) δ 147.9,

130.9, 128.9, 128.2, 125.8, 119.5, 50.6, 31.7, 30.5, 28.8, 26.6, 22.7, 14.2. HRMS (ESI)
m/z calculated 244.18137 (C15H22N3, [M+H]+), m/z observed 244.18152

(C15H22N3,

[M+H]+).

1-(heptan-2-yl)-4-phenyl-1H-1,2,3-triazole
Prepared using general triazole method A.

(3-3h).
Purified by

silica column chromatography using gradient elution of
hexanes and ethyl acetate as a white solid in 80% yield.

1

H NMR (CDCl3, 600 MHz) δ

7.85 (d, 2H, J = 7.8 Hz), 7.74 (s, 1H), 7.42 (t, 2H, J = 7.8 Hz), 7.32 (t, 1H, J = 7.2 Hz),
4.74-4.68 (m, 1H), 1.97-1.92 (m, 1H), 1.86-1.82 (m, 1H), 1.60 (d, 3H, J = 6.6 Hz), 1.281.18 (m, 6H), 0.86 (t, 3H, J = 6.6 Hz).

13

C NMR (CDCl3, 151 MHz) δ 147.7, 131.0,

128.9, 128.1, 125.8, 117.4, 57.7, 37.4, 31.5, 25.8, 22.6, 21.6, 14.1. HRMS (ESI) m/z
calculated 244.18137 (C15H22N3, [M+H]+), m/z observed 244.18197 (C15H22N3, [M+H]+).

2-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)pyridine

(3-3i).

Prepared using general triazole method C. Purified by silica
column chromatograph using gradient elution of hexanes and ethyl acetate and isolated
as white solid in 88% yield. 1H NMR (CDCl3, 500 MHz) δ 8.62 (d, 1H, J = 5.0 Hz), 7.94
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(s, 1H), 7.83 (d, 2H, J = 7.5 Hz), 7.70 (t, 1H, J = 7.5 Hz), 7.41 (t, 2H, J= 8.0 Hz), 7.32 (t,
1H, J= 7.0 Hz) 7.23 – 7.29 (m, 2H), 5.71 (s, 2H).

13

C NMR (CDCl3, 125 MHz) δ 154.7,

149.9, 148.4, 137.6, 130.7, 129,0, 128.3, 125.9, 123.6, 122.6, 120.3, 55.9. HRMS (ESI)
m/z calculated 237.11402 (C14H13N4, [M+H]+), m/z observed 237.11389

(C14H13N4,

[M+H]+).

1-(adamantan-1-yl)-4-phenyl-1H-1,2,3-triazole (3-3j). Prepared
using general triazole method A.

Purified by silica column

chromatography using gradient elution of hexanes and ethyl
acetate as a white solid in 5% yield.

1

H NMR (CDCl3, 600 MHz) δ 7.85-7.82 (m, 3H),

7.41 (t, 2H, J = 6.0 Hz), 7.31 (t, 1H, J = 6.0 Hz), 2.30 (s, 9 H), 1.82 (s, 6 H).

13

C NMR

(CDCl3, 151 MHz) δ 146.9, 131.3, 128.9, 128.0, 125.8, 116.1, 59.7, 43.2, 36.1, 29.6.
HRMS (ESI) m/z calculated 280.18137 (C10H20N3O, [M+H]+), m/z observed 280.18240
(C10H20N3O, [M+H]+).

(1-benzyl-1H-1,2,3-triazol-4-yl)methanol (3-3l) Prepared using
general

triazole

method

A.

Purified

by silica

column

chromatography using gradient elution of ethyl acetate and methanol to yield a white
solid in 76% yield. 1H NMR (CDCl3, 600 MHz) δ 7.44 (s, 1H), 7.37 (m, 3H), 7.27 (d, 2H,
J = 9 Hz), 5.51 (s, 2H), 4.76 (s, 2H), 2.49 (s, 1H).

13

C NMR (CDCl3, 151 MHz) δ 148.2,

134.6, 128.3, 129.0, 128.3, 121.7, 56.7, 54.4. HRMS (ESI) m/z calculated 190.09804
(C10H12N3O, [M+H]+), m/z observed 190.09876. (C10H12N3O, [M+H]+).

2-(1-benzyl-1H-1,2,3-triazol-4-yl)propan-2-ol (3-3m) Prepared
using general triazole method A.

Purified by silica column

chromatography using gradient elution of hexanes and ethyl
acetate to yield a white solid in 80.0% yield. 1H NMR (CDCl3, 600 MHz) δ 7.39-7.36 (m,
3H), 7.34 (s, 1H), 7.28 (d, 2H, J = 7.2 Hz), 5.50 (s, 2H), 2.41 (s, 1H), 1.61 (s, 6H).
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13

C

NMR (CDCl3, 151 MHz) δ 156.1, 134.7, 129.3, 128.9, 128.3, 119.0, 68.7, 54.3, 30.6.
HRMS (ESI) m/z calculated 218.12934 (C12H16N3O, [M+H]+), m/z observed 218.13039.
(C12H16N3O, [M+H]+).

1-(1-benzyl-1H-1,2,3-triazol-4-yl)cyclohexanol

(3-3n)

Prepared using general triazole method A. Purified by silica
column chromatography using gradient elution of hexanes and
ethyl acetate to yield a white solid in 79% yield. 1H NMR (CDCl3, 600 MHz) δ 7.37 (d,
3H, J = 9 Hz), 7.34 (s, 1H), 7.27 (d, 2H, J = 9 Hz), 5.50 (s, 2H), 2.24 (s, 1H), 1.94 (t, 2H,
J = 10.8 Hz), 1.85 (d, 2H, J = 13.2 Hz), 1.69-1.75 (m, 2H), 1.59-1.65 (m, 1H), 1.53-1.55
(m, 2H), 1.31-1.37 (m, 1H).

13

C NMR (CDCl3, 151 MHz) δ 156.2, 134.8, 129.3, 128.9,

128.3, 119.5, 69.8, 54.3, 38.3, 25.5, 22.1.

HRMS (ESI) m/z calculated 258.16064

(C15H20N3O, [M+H]+), m/z observed 258.16137. (C15H20N3O, [M+H]+).

1-benzyl-4-(2,4-dimethylphenyl)-1H-1,2,3-triazole

(3-3o)

Prepared using general triazole method A. Purified by silica
column chromatography using gradient elution with hexanes
and ethyl acetate to yield a white solid in 68.4% yield.

1

H NMR (CDCl3, 600 MHz) δ

7.63 (d, 1H, J = 7.8 Hz), 7.52 (s, 1H), 7.36-7.40 (m, 3H), 7.31 (d, 2H, J = 7.8 Hz), 7.1
(m, 2H), 5.60 (s, 2H), 2.39 (s, 3H), 2.34 (s, 3H).

13

C NMR (CDCl3, 151 MHz) δ 147.8,

135.4, 135.0, 131.7, 129.3, 128.9, 128.8, 128.1, 127.2, 126.9, 121.5, 54.3, 21.4, 21.3.
HRMS (ESI) m/z calculated 264.15007 (C17H18N3, [M+H]+), m/z observed 264.15016.
(C17H18N3, [M+H]+).

1-benzyl-4-(4-methoxyphenyl)-1H-1,2,3-triazole (3-3p)
Prepared using general triazole method B. Purified by
silica column chromatography using gradient elution of hexanes and ethyl acetate to
yield a white solid in 87% yield. 1H NMR (CDCl3, 600 MHz) δ 7.72 (d, 2H, J = 8.4 Hz),
7.57 (s, 1H), 7.35-7.41 (m, 3H), 7.30-7.32 (m, 2H), 6.93 (d, 2H, J = 9 Hz), 5.57 (s, 2H),
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3.83 (s, 3H).

13

C NMR (CDCl3, 151 MHz) δ 159.7, 148.3, 134.9, 129.3, 128.9, 128.2,

127.2, 123,4, 118.8, 114.3, 55.5, 54.4.

HRMS (ESI) m/z calculated 266.12934

(C16H16N3O, [M+H]+), m/z observed 266.13042. (C16H16N3O, [M+H]+).

methyl 4-(1-benzyl-1H-1,2,3-triazol-4-yl) benzoate (33q) Prepared using general triazole method B. Purified
by silica column chromatography using gradient elution of hexanes and ethyl acetate to
yield a white solid in 86% yield. 1H NMR (CDCl3, 600 MHz) δ 8.07 (d, 2H, J = 8.4 Hz),
7.88 (d, 2H, J = 8.4 Hz), 7.74 (s, 1H), 7.36-7.42 (m, 3H), 7.32-7.33 (m, 2H), 5.59 (s, 2H),
3.92 (s, 3H).

13

C NMR (CDCl3, 151 MHz) δ 166.9, 147.3, 135.0, 134.6, 130.3, 129.7,

129.4, 129.1, 128.3, 125.6, 120.5, 54.5, 52.3. HRMS (ESI) m/z calculated 294.12425
(C17H16N3O2, [M+H]+), m/z observed 294.12490. (C17H16N3O2, [M+H]+).

methyl

2-(1-benzyl-1H-1,2,3-triazol-4-yl)benzoate

(3-3r)

Prepared using general triazole method B. Purified by silica
column chromatography using gradient elution of hexanes and
ethyl acetate to yield an off-white solid in 89% yield. 1H NMR (CDCl3, 600 MHz) δ 7.81
(d, 1H, J = 7.8 Hz), 7.77 (d, 1H, J = 7.8 Hz), 7.72 (s, 1H), 7.54 (td, 1H, J = 7.8, 1.2 Hz),
7.35-7.41 (m, 4H), 7.31-7.32 (m, 2H), 5.59 (s, 2H), 3.72 (s, 3H).

13

C NMR (CDCl3, 151

MHz) δ 168.9, 146.3, 135.0, 131.6, 130.5, 130.4, 130.3, 129.3, 128.9, 128.2, 122.7,
54.3, 52.3. HRMS (ESI) m/z calculated 294.12425 (C17H16N3O2, [M+H]+), m/z observed
294.12508. (C17H16N3O2, [M+H]+).

2-(1-benzyl-1H-1,2,3-triazol-4-yl)pyridine (3-3s). Prepared
using general triazole method C. Purified by silica column
chromatography using gradient elution of hexanes and ethyl acetate to yield a white
solid in 92% yield. 1H NMR (CDCl3, 500 MHz) δ 8.45 (d, 1H, J = 4.0 Hz), 8.18 (d, 1H, J
= 8.0 Hz), 8,04 (s, 1H), 7.77 (tt, 1H, J = 8.0, 2.0 Hz), 7.30-7.40 (m, 5H), 7.21 (t, 1H, J =
6.5 Hz), 5.58 (s, 2H).

13

C NMR (CDCl3, 125 MHz) δ 150.4, 149.5, 148.9, 137.0, 134.5,
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129.3, 123.0, 122.0, 120.4, 54.6. HRMS (ESI) m/z calculated 237.11402. (C14H13N4,
[M+H]+), m/z observed 237.11410. (C14H13N4, [M+H]+).
1-benzyl-4-octyl-1H-1,2,3-triazole (3-3t). Prepared
using general triazole method C. Purified by silica
column chromatography using gradient elution of hexanes and ethyl acetate to yield a
white solid in 23% yield. 1H NMR (CDCl3, 500 MHz) δ 7.34 – 7.39 (m, 2H), 7.24 – 7.26
(m, 3H), 7.17 (s, 1H), 5.49 (s, 2H), 2.68 (t, 2H, J = 8.0 Hz), 1.63 (q, 2H, 7.5 Hz), 1.2 –
1.4 (m, 10H), 0.869 (t, 3H, J = 7.0 Hz).

13

C NMR (CDCl3, 125 MHz) δ149.2, 135.2,

129.2, 128.7, 128.1, 120.6, 105.2, 54.1, 32.0, 29.6, 29.4, 29.3, 25.9, 22.8, 14.2. HRMS
(ESI) m/z calculated 272.21267 (C17H26N3, [M+H]+), m/z observed 272.21304
(C17H26N3, [M+H]+).
4-(1-benzyl-1H-1,2,3-triazol-4-yl)benzonitrile

(3-3u).

Prepared using general triazole method C. Purified by
silica column chromatography using gradient elution of hexanes and ethyl acetate to
yield a white solid in 95% yield.

1

H NMR (CDCl3, 500 MHz) δ 7.91 (d, 2H, J = 9.0 Hz),

7.74 (s, 1H), 7.69 (d, 2H, J = 8.5 Hz), 7.37 – 7.43 (m, 3H), 7.31 – 7.34 (m, 2H), 5.60 (s,
2H).

13

C NMR (CDCl3, 125 MHz) δ 146.5, 135.1, 134.4, 132.8, 129.4, 129.2, 128.3,

126.2, 120.7, 118.9, 111.7, 54.6. HRMS (ESI) m/z calculated 261.11402 (C16H13N4,
[M+H]+), m/z observed 261.11498. (C16H13N4, [M+H]+).

3,3'-dibenzyl-5,5'-diphenyl-3H,3'H-4,4'-bi(1,2,3-triazole)

(3-

4). Isolated as by-product when using general triazole method
A.

Purified by silica column chromatography using gradient

elution of hexanes and ethyl acetate to yield a white solid in 3%
1

yield. H NMR (CDCl3, 600 MHz) δ 7.42–7.46 (m, 4H), 7.22–7.25 (m, 2H), 7.18–7.22
(m, 4H), 7.11–7.16 (m, 2H), 7.08 (t, 4H, J = 7.2 Hz), 6.80 (d, 4H, J = 7.2 Hz), 4.69 (d,
2H, J = 15 Hz), 4.62 (d, 2H, J = 15 Hz).

13

C NMR (CDCl3, 151 MHz) δ 148.0, 133.1,

129.4, 129.1, 129.0, 128.92, 128.86, 128.3, 126.0, 120.0, 52.8. HRMS (ESI) m/z
calculated 469.21407 (C30H25N6, [M+H]+), m/z observed 469.21239. (C30H25N6, [M+H]+).
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5-bromopicolinohydrazonamide (3-26). To a stirring suspension
of 3-25 (1.0 g, 5.5 mmol) in 5 mL of EtOH was added hydrazine
hydrate (0.584 mL, 7.7 mmol). The suspension was stirred at room
temperature for 72 h and progress of the reaction was monitored by TLC. The pale
1

yellow precipitate was then filtered and washed with Et 2O in 79% yield.

H NMR

(CDCl3, 600 MHz) δ 8.57 (s, 1H), 7.91 (dd, 1H, J = 8.4, 2.4 Hz), 7.81 (dt, 1H, J = 9.0,
2.4 Hz), 5.16 (bs, 1H), 4.60 (bs, 1H).
147.9, 139.2, 121.14, 121.08.

13

C NMR (CDCl3, 151 MHz) δ 149.6, 149.0,

HRMS (ESI) m/z calculated 214.99323 (C 6H8BrN4,

+

[M+H] ), m/z observed 214.99251 (C6H8BrN4, [M+H]+).

3-(5-bromopyridin-2-yl)-5,6-diphenyl-1,2,4-triazine

(3-27).

3-26 (800 mg, 3.72 mmol) and benzil (782 mg, 3.72) were
added to 15 mL of EtOH. The slurry was heated overnight at
80°C with complete dissolution. Progress of the reaction was
monitored by TLC. The reaction mixture was cooled to room temperature and the
resulting precipitate was filtered and washed with EtOH and Et 2O resulting in a 91%
yield. 1H NMR (CDCl3, 600 MHz) δ 8.97 (s, 1H), 8.62 (dd, 1H, J = 9.0,1.8 Hz), 8.07 (dt,
1H, J = 8.4, 3.0 Hz), 7.67 (d, 2H, J = 6.6 Hz), 7.64 (d, 2H, J = 7.2 Hz), 7.47-7.44 (m,
2H), 7.41-7.36 (m, 4H).

13

C NMR (CDCl3, 151 MHz) δ 160.4, 156.8, 156.6, 151.8,

151.5, 139.9, 135.6, 135.3, 131.0, 130.1, 130.0, 129.7, 128.81, 128.79, 125.4, 123.6.
MS (ESI) m/z calculated 389.04018 (C20H14BrN4, [M+H]+), m/z observed 389.02638
(C20H14BrN4, [M+H]+).

3-(5-ethynylpyridin-2-yl)-5,6-diphenyl-1,2,4-triazine (4-16).
4-15

(1.0

g,

2.57

dichlorobis(triphenylphosphine)palladium(II) (90

mmol),
mg,

0.13

mmol), copper iodide (24 mg, 0.13 mmol), and anhydrous
THF (13 mL) were combined and placed under nitrogen.
Triethylamine (780 mg, 7.71 mmol) and ethynyltrimethylsilane (757 mg, 7.71 mmol)
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were added and the reaction was heated overnight at 80°C. Reaction progress was
monitored by TLC. After concentration in vacuo, the crude intermediate was purified by
silica gel chromatography with gradient elution using EtOAc and hexanes.

The

intermediate was then dissolved in 8 mL of EtOH, 4 mL of MeOH, and 4 mL DCM.
Potassium carbonate (0.1 eq) was added the reaction was allowed to stir overnight at
room temperature with reaction progress monitored by TLC. Upon completion, the
reaction was concentrated in vacuo and purified by silica gel chromatography with
gradient elution using EtOAc and hexanes to yield a yellow solid in 62% yield.

1

H NMR

(CDCl3, 600 MHz) δ 9.00 (s, 1H), 8.70 (d, 1H, J = 8.4 Hz), 8.01 (dd, 1H, J = 8.4, 1.8 Hz),
7.67 (d, 2H, J = 7.2 Hz), 7.63 (d, 2H, J = 7.2 Hz), 7.47-7.44 (m, 2H), 7.41-7.36 (m, 4H),
3.38 (s, 1H).

13

C NMR (CDCl3, 151 MHz) δ 160.4, 156.7, 156.6, 153.5, 152.2, 140.3,

135.7, 135.3, 131.0, 130.1, 130.0, 129.8, 128.80, 128.78, 123.5, 121.2, 82.8, 80.5. MS
(ESI) m/z calculated 335.12967 (C22H15N4, [M+H]+), m/z observed 335.12451
(C22H15N4, [M+H]+).

2-(4-bromophenyl)-2-oxoacetaldehyde (3-30).

Selenium dioxide

(1.67 g, 15 mmol) was suspended in dioxane (7.5 mL) and water (0.36
mL)

and

heated

at

55°C

until

mostly

dissolved.

1-(4-

bromophenyl)ethanone (3 g, 15.0 mmol) was then added and the reaction was refluxed
for 3 h. After cooling to room temperature, the reaction was filtered and the filtrate was
concentrated in vacuo. The crude product was used in further reactions. MS (ESI) m/z
calculated 212.95512 (C8H6BrO2, [M+H]+), m/z observed 212.986 (C8H6BrO2, [M+H]+).

5-(4-bromophenyl)-3-(pyridin-2-yl)-1,2,4-triazine (3-31).

3-

30 (782 mg, 3.7 mmol) and picolinohydrazonamide (500 mg,
3.7 mmol) were added to 14 mL of EtOH.
heated overnight at 80°C with complete dissolution.

The slurry was

Progress of the reaction was

monitored by TLC. The reaction mixture was cooled to room temperature and the
resulting precipitate was filtered and washed with EtOH resulting in a 46% yield.
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1

H

NMR (CDCl3, 600 MHz) δ 9.70 (s, 1H), 8.94 (d, 1H, J = 4.2 Hz), 8.68 (d, 1H, J = 7.8 Hz),
8.20 (d, 2H, J = 7.8 Hz), 7.96 (t, 1H, J = 7.8 Hz), 7.75 (d, 2H, J = 6.6 Hz), 7.51 (t, 1H, J
= 6.0 Hz).

13

C NMR (CDCl3, 151 MHz) δ 132.6, 132.48, 132.45, 132.1, 131.7, 131.5,

131.2, 130.2, 88.9, 87.5. MS (ESI) m/z calculated 313.00888 (C14H10BrN4, [M+H]+), m/z
observed 313.00791 (C14H10BrN4, [M+H]+).

5-(4-ethynylphenyl)-3-(pyridin-2-yl)-1,2,4-triazine

(3-32).

3-31

mmol),

(594

mg,

1.9

dichlorobis(triphenylphosphine)palladium(II)

(67

mg,

0.1

mmol), copper iodide (18 mg, 0.1 mmol), and anhydrous THF
(7.5 mL) were combined and placed under nitrogen. Triethylamine (577 mg, 5.7 mmol)
and ethynyltrimethylsilane (560 mg, 5.7 mmol) were added and the reaction refluxed
overnight. Reaction progress was monitored by TLC. After concentration in vacuo, the
crude intermediate was purified by silica gel chromatography with gradient elution using
EtOAc and hexanes. The intermediate was then dissolved in a 0.5 M alcohol solution (2
EtOH : 1 MeOH) and 0.1 eq of potassium carbonate was added. The reaction was
allowed to stir at room temperature and reaction progress was monitored by TLC. Upon
completion, the reaction was concentrated in vacuo and purified by silica gel
chromatography with gradient elution using EtOAc and hexanes to yield a pale brown
solid in 44% yield.

1

H NMR (CDCl3, 600 MHz) δ 9.72 (s, 1H), 8.95 (d, 1H, J = 4.8 Hz),

8.69 (d, 1H, J = 7.8 Hz), 8.30 (d, 2H, J = 8.4 Hz), 7.96 (dt, 1H, J = 7.8, 1.8 Hz), 7.71 (d,
2H, J = 8.4 Hz), 7.52–7.50 (m, 1H), 3.3 (s, 1H).

13

C NMR (CDCl3, 151 MHz) δ 163.0,

155.1, 153.1, 150.7, 145.3, 137.3, 133.7, 133.2, 127.9, 126.8, 125.9, 124.4, 82.9, 80.8.
HRMS (ESI) m/z calculated 259.09837 (C16H11N4, [M+H]+), m/z observed 259.09788
(C16H11N4, [M+H]+).

General 1,2,4-Triazine-Accelerated Sonogashira Reaction.

Iodobenzene (0.10

mmol), phenylacetylene (0.10 mmol), and triethylamine (0.10 mmol) were added to the
triazine ligand (variable) and palladium source (variable) at 0.4 M, with respect to
111

substrates, in solvent.

Reactions were heated 5.5 hours at 60°C, cooled to room

temperature, and analyzed by HPLC using a C18 column with an isocratic mobile phase
of 80% acetonitrile. Percent yields were determined using an external calibration curve.

Polystyrene-Supported Azide Method. Merrifield resin (14 mmol), sodium azide (42
mmol), tetrabutylammonium iodide (14 mmol) were added to 60 mL of NMP and 10 mL
of water. Reaction was heated at 80°C overnight. After cooling to room temperature,
the resin was filtered, washed with NMP, water, DCM, MeOH, and Et2O, and air dried.

Heterogeneous CuAAC Method A.

A solution of phenylacetylene (1.07 mmol),

triethylamine (1.07 mmol), 2-17 (9.72 μmol), and tetrakis(acetonitrile-N)copper(I)
tetrafluoroborate (9.72 μmol) dissolved in 1 mL of ACN and 4 mL of DCE was added to
the supported azide (0.972 mmol). Reaction was heated at 60 °C for 4 h. After cooling
to room temperature, the support was filtered and washed with DCE, water, MeOH, and
Et2O and air dried.

Heterogeneous CuAAC Method B.
triazine

(2.38

mmol),

triethylamine

The corresponding alkyne-substituted 1,2,4(2.38

mmol),

2-17

(22.0

μmol),

and

tetrakis(acetonitrile-N)copper(I) tetrafluoroborate (22.0 μmol) were dissolved in 4.4 mL
of ACN and 8.8 mL of DCE and added to the supported azide (2.16 mmol). Reaction
was heated at 60°C for 18 h. After cooling to room temperature, an aliquot of the
reaction solution was appropriately diluted and analyzed by HPLC to determine loading
of the 1,2,4-triazine. The support was then filtered, washed with DCE, water, MeOH,
and Et2O and air dried.

Heterogeneous CuAAC Method C.

A solution of 2-ethynyl pyridine (1.07 mmol),

triethylamine (1.07 mmol), 2-17 (9.72 μmol), copper(II)tetrafluoroborate (9.72 μmol)
dissolved in 1 mL of ACN and 4 mL of DCE was added to the supported azide (0.972
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mmol). Reaction was heated at 60°C for 4 h. After cooling to room temperature, the
support was filtered and washed with DCE, water, MeOH, and Et2O and air dried.

Polystyrene-Supported Complexation Method.

A 10 mM stock solution of the

corresponding copper source in 1:1 ACN:DCE was prepared. Copper (0.0594 mmol)
was added to the resin (0.054 mmol) and heated at 60°C for 2 h. An equivalent volume
of copper stock solution was concentrated and analyzed by ICP-OES as a control. After
cooling to room temperature, the resin was filtered, washed with ACN, DCM, MeOH,
and Et2O and air dried. The filtrate was concentrated in vacuo, analyzed by ICP-OES,
and compared to the ICP-OES value of the aforementioned control solution.

Silica-Supported Complexation Method.

A 10 mM stock solution of the

corresponding copper source in ACN was prepared. Copper (0.0226 mmol) was added
to the silica (0.0205 mmol) and heated at 60°C for 2 h. An equivalent volume of copper
stock solution was concentrated and analyzed by ICP-OES as a control. After cooling
to room temperature, the silica was filtered, washed with ACN, DCM, MeOH, and Et 2O
and air dried.

The filtrate was concentrated in vacuo, analyzed by ICP-OES, and

compared to the ICP-OES value of the aforementioned control solution.

ICP-OES Methodology.

The filtrate recovered from complexation reactions was

redissolved in 2% nitric acid and 1% MeOH to a final concentration of 75 ppm copper
(assuming all copper from the reaction was still present). Samples from the initial 10
mM copper stock solutions were treated in the same manner. All samples were heated
at 60°C for 10 min and left undisturbed at room temperature overnight to ensure all
copper was dissolved.

Quantification of copper was determined using an external

calibration curve ranging from 75 ppm – 1 ppm at a wavelength of 324.75 nm.
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General Heterogeneous 1,2,4-Triazine-Accelerated CuAAC Reaction. Benzyl azide
(0.25 mmol), phenylacetylene (0.25 mmol), and triethylamine (0.25 mmol) were added
to the heterogeneous catalyst (1 mol% copper) at 0.2 M, with respect to substrates, in
acetonitrile. Reactions were heated at 60°C for 4 h, cooled to room temperature, and
filtered to remove catalyst. The filtrate was concentrated in vacuo to yield 1,2,3-triazole
as a white solid.

Recyclability of Heterogeneous Catalysts. After CuAAC reaction was complete and
filtered, the catalyst was rinsed with dichloromethane, methanol, and ether. Catalyst
was air dried and reused without additional treatment.

Copper Retention of Heterogeneous Catalysts. A solution of 2% HNO3 (4 mL) and
MeOH (0.04 mL) were added to isolated 1,2,3-triazole products. After heating at 60°C
for approximately 10 min, the suspension was left standing at room temperature
overnight. After filtration, the filtrate was analyzed by ICP-OES in order to calculate the
percent of copper retained by the catalyst. Copper was quantified using an external
calibration curve ranging from 75 ppm – 1 ppm at a wavelength of 324.75 nm.
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Chapter 4.
Design and Synthesis of Metalloenzyme
Inhibitors
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4.1.

Background and Significance of Histone Deacetylase (HDAC)

Cancer has been a difficult target for researchers, owing to its ability to avoid
therapeutic strategies, propagate through the body, and circumvent normal cell cycle
regulatory processes.98 Through years of research much information has been gained
about causes and effects of cancer, but a cure for all cancer subtypes is still out of
reach.
Mutations to healthy cells in which the genetic information is permanently changed is
one target of cancer therapy. Another is the regulation of non-mutated DNA through
epigenetic modifications. Epigenetics look at inheritable changes in gene expression
without altering the coding sequence.99 Epigenetics encompasses a wide range of
regulating mechanisms, including DNA methylation, post-translational modification of
histone proteins,99 chromatin remodeling,100 transcription factors,101 and noncoding
RNA.102 Post-translational modification of histone and non-histone proteins has drawn
much attention over the past 15 years, specifically with regards to histone deacetylase
enzymes. Why are histone proteins important and how do chemical modifications effect
regulation of DNA?
Histones are chromatin-associated proteins where chromatin is the tightly packaged
genetic material made of repeating nucleosome units. This condensed package
regulates transcription, DNA replication and repair, mitosis, and apoptosis.99 Within
each nucleosome unit is DNA that has been wound around a histone octamer, where
histones are small basic proteins, containing an abundance of lysine and arginine
residues (Figure 4.1). The location of the lysine tails is of upmost importance in
regulating transcription. The lysine side chains extend toward the outer edges of the
nucleosome, leaving them available for an array of post-translational modifications,
such as acetylation, methylation, or phosphorylation, to name a few. Histones can be
either acetylated or deacetylated, in processes controlled by the action of HAT (Histone
Acetyl Transferase) or HDAC (Histone Deacetylase) enzymes. As the name suggests,
one is responsible for transferring the acetyl group to the lysine of the histone protein
and the other removes the acetyl group. The two states control the accessibility of DNA
and therefore, transcription.
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In the deacetylated form (Figure 4.1), the lysine residues will be positively charged
amines at physiological pH. This will lead to an electrostatic interaction with the
negatively charged phosphates of the DNA backbone. This causes the chromatin to
condense, leaving it inaccessible to transcription factors. In the acetylated form, the
lysine residues are now neutral weakening the interaction between DNA and histone.
The chromatin adopts a relaxed state, allowing space for transcriptional factors, and
thereby activating transcription. Although the name implies the deacetylase activity only
occurs at histone proteins, there are at least 50 non-histone substrates which have
been linked to the HDAC enzyme.103 The equilibrium between these acetylation and
deacetylation mechanisms is required for the delicate balance of a host of nuclear
processes. The improper regulation has been implicated in a variety of cancer
subtypes,104 as well as neurodegenerative diseases,105 and immune disorders.106

Figure 4.1 Equilibrium between transcriptional repression and transcriptional activation.
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Overexpression of HDACs has been found in a variety of cancers. This can lead to
silencing of guardian proteins and mediate tumor cell proliferation.107 Studies on
inhibition of HDACs have shown a promising ability to affect processes that have gone
awry in neoplastic cells, including an ability to induce cell cycle arrest, or induce
apoptosis by expression of tumor suppressor proteins.107,108
For this reason, much research has been devoted to development of histone
deacetylase inhibitors, with end goals as promising pharmaceuticals, especially in the
fields of anti-cancer agents, neuroprotective agents, or anti-inflammatory agents. The
first interest in histone deacetylase inhibitors (HDACi) was sparked about 35 years ago
during

research

to

elucidate

why

DMSO

caused

terminal

differentiation

in

erythroleukemia cells.109,110 Since that time a number of researchers have developed
interest in design, synthesis, and studies of histone deacetylase inhibitors.
In order to target HDACs effectively, it is important to know about their structure and
physiological relevance. Fortunately, some structural and functional knowledge has
been determined. Eighteen known HDAC isoforms exist and they are divided between
four structural categories depending on their sequence similarities and cellular
locations. Class I, II, and IV are all zinc dependent while Class III is mediated by
nicotinamide adenine dinucleotide (NAD+) and often referred to as sirtuins. Sirtuins will
not be focused on for this work. Class I includes HDAC isoforms HDAC-1,-2, -3, and -8,
and are found within the nucleus of many cell types. Class II is further broken down into
IIa (HDAC-4,-5,-7,and-9) and IIb (HDAC-6,-10). Class IIa are able to shuttle between
nuclear and cytoplasmic locations while IIb are primarily located in the cytoplasm. Class
IIb is unique due to the presence of two active enzyme sites. Class IV consists of
HDAC-11 and exhibits properties of both Class I and II HDACs. Very little is known
about this isoform.
The specific functions of each HDAC are not completely understood, but mammalian
studies using knockout and transgenic mice, along with siRNA techniques have
highlighted some key roles for the various isoforms. The information about the various
HDAC isoforms is highlighted in Table 4.1.
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Table 4.1 Features of the various isoforms of HDAC Class I, II and IV. Modified from

Fattori, et al.,111 Marks, et al.,112 and Oyelere, et al.98

Primary

Amino

Location

Acid

Physiological role

Crystal
Structure

Residues
proliferation, development, gene

HDAC1

nucleus

483

HDAC2

nucleus

488

cardiac development, proliferation

1

HDAC3

nucleus

428

regulation of mitosis

0

HDAC8

nucleus

377

muscle contraction

21

HDAC4

HDAC5

HDAC7

HDAC9

nucleus /
cytoplasm
nucleus /
cytoplasm
nucleus /
cytoplasm
nucleus /
cytoplasm

1084

1122

855

1011

regulation

bone development, neuronal cell
death mediator
cardiac development
regulation of apoptosis in developing
T-cells
cardiac development
controls status of tubulin,

0

8

0

3

1

HDAC6

cytoplasm

1215

HDAC10

cytoplasm

669

NA

0

HDAC11

nucleus

347

NA

0

microtubules, and HSP90
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0

Some structural information regarding the zinc-dependent HDACs has become
available in the past ten years. The first structural insights were gained from the crystal
structure of a histone deacetylase-like protein (HDLP) complexed with inhibitors and
isolated from a bacteria species with approximately 35% similarity to human HDAC-1.113
The first human HDAC structure to be co-crystallized with inhibitors was HDAC-8. From
the table above, it can be seen that an abundance of HDAC-8 crystal structures have
been determined while some HDACs such as HDAC-1, HDAC-6, have shown limited
success in obtaining crystal structures, although structures of bacterial homologues
exist. The reason for this disproportionality is that most HDACs occur as high molecular
weight multiprotein complexes, rather than individual monomeric proteins making it
difficult to obtain a crystal structure of the HDAC protein.111
From the crystal structure of HDAC-8 and HDLP, some general features of HDAC active
sites have been inferred. The active site contains a hydrophobic tunnel of 11-14 Å, with
the exact length varying between isoforms. Contained within this tunnel are residues
which are conserved across the class I HDACs (Phe152, Phe208, His180, Gly151, and
Tyr306). The catalytic site lies at the bottom of the tunnel containing a Zn 2+ ion
coordinated to Asp178, His180 and Asp267.114 Tyrosine, histidine, and aspartic acid
residues within the catalytic site interact with one another, substrate, or inhibitors. The
proposed interaction between the zinc ion, amino acids, and either the substrate or a
known inhibitor is shown in Figure 4.2.
The structural insight gained has been used recently to develop the new inhibitors for
HDAC activity. This was not always the case in designing inhibitors. Prior to the
availability of crystal structure evidence, several inhibitors had been designed or
isolated from natural products. The design of early inhibitors, coupled with the structural
information

known,

has

allowed

researchers

relationships between a variety of structural scaffolds.
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to

investigate

structure-activity

Figure 4.2 Representation of binding with A) substrate (proposed) and with B)
hydroxamate inhibitor. Amino acids are shown in green, substrate, or hydroxamate inhibitor
in blue, and interactions in red.114

4.2.

Histone Deacetylase Inhibitors (HDACi)

There is a common theme in a large majority of HDAC inhibitors to begin with a
common scaffold, consisting of a zinc-chelating functional group, linker region to occupy
the hydrophobic tunnel, and a surface recognition unit, or cap group (Figure 4.3). This
scaffold mimics the natural substrate, an acetylated lysine residue. The zinc binding
group can further divide inhibitors into hydroxamic acid and non-hydroxamic acid
inhibitors. Some non-hydroxamic acid inhibitors include small carboxylic acids,
benzamides, ketones, cyclic peptides, and depsipeptides. A collection of inhibitors is
shown in Figure 4.4. A significant amount of the literature and research has focused on
hydroxamate inhibitors, but an increasing amount of work has surfaced in an attempt to
determine other zinc binding groups of comparable potency and increased selectivity.
A comprehensive list of molecules designed and synthesized for HDAC inhibition is
outside the scope of this work, and has been the focus of other reviews, 99,108,111 but a
brief highlighting of some of the common or clinically relevant molecules will be
discussed here.
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Figure 4.3 The general regions for consideration in design of HDAC inhibitors

Figure 4.4 Selected HDAC inhibitors
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Some of the most recognizable inhibitors are SAHA (suberoylanilide hydroxamic acid)
and TSA (trichostatin A). SAHA is one of many HDAC inhibitors that have entered
clinical trials. SAHA is unique in that is one of two HDAC inhibitors approved by the FDA
for treatment of cutaneous T-cell lymphoma (CTCL) with the other being FK-228.115
SAHA is the standard by which most HDAC inhibitors are compared and has been
mimicked and modified in efforts to discover potent and selective inhibitors. Typical
modifications involve changing the linker region, in distance by adding methylene
groups, in rigidity by adding unsaturation, aromatic groups, or cinnamoyl linkers, or in
hydrophobicity, by modifying linker substituents. Reviews comparing the activity of the
various modified structures have been written.111,116 The cap group is also amenable to
modifications. This area seems to be accepting of the most diversity. It is not restricted
by size of the tunnel, as the linker region is, allowing extensive substitution. By these
modifications, the activity of the molecule can be tuned. Although some more potent
molecules have been discovered, a downfall to this is the decrease in isoform
selectivity, or off-target toxicity. TSA, a natural product, is a strong nanomolar inhibitor
that suffers from the drawback of being too potent for multiple isoforms.
In general, most of the inhibitors thus far have been pan-inhibitors unable to distinguish
between the multiple isoforms. SAHA and TSA fall into this category. Because of the
conserved sequence homology between HDAC isoforms, design and synthesis of
isoform selective inhibitors has been difficult. Some inhibitors have emerged to have a
slight selectivity for one class over the others. Class specificity is the first target of
selectivity, and then isoform specificity. FK228 (Figure 4.4), the other FDA approved
HDACi, is a prodrug depsipeptide that releases an alkyl thiol in vivo by reduction of the
disulfide bond117 and has shown selectivity for Class I HDACs. MS-275 and other
related benzamides have also shown promise as Class I selective HDAC inhibitors. The
selectivity has been a trade-off for potency as the IC50 now resides in the micromolar
region instead of nanomolar region of hydroxamic acids. With the decreased potency,
there has also been a decrease in the off-target side effects such as cardiac toxicity.98
Tubacin, although not a good drug candidate, (Figure 4.4) was found to be an inhibitor
of HDAC6 and also led to a linking of HDAC-6 to tubulin deacetylase activity. This
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paved the way for Tubastatin A to be discovered with a nanomolar inhibition and 1000fold selectivity for HDAC6.
In addition to hydroxamic acids, carboxylic acids such as butyric acid and valproic acids
were observed to inhibit cancer cell growth and induce apoptosis, but in general
carboxylic acids were not particularly potent (requiring millimolar concentrations), not
selective, and had low bioavailability.99 The downfalls to HDAC inhibitors thus far are
their ineffectiveness against solid tumors. Majority of patients did not respond to
treatment and side effects were high. Some patients did experience stabilization of their
disease, so there is opportunity for inhibitors to be used in combination with other
chemotherapeutic drugs for treatment of solid tumors.
Some of the keys to overcoming the barriers that have prevented more HDAC inhibitors
from progression through clinical trials, are targeted therapy and selective delivery.98
This is of course easier to suggest than it is to carry out. If HDACs could be targeted by
an inhibitor for a single isoform, the effectiveness should increase and off-target toxicity
should decrease. Designing tools to selectively deliver these molecules to the location
of interest is another pathway that should be explored.

4.3.

Strategies for Synthesis

The use of triazoles for biological applications has greatly emerged with the discovery of
copper-catalyzed azide-alkyne cycloaddition. The field of HDAC inhibitors is no
exception. As a mimic of SAHA, three independent research groups incorporated a
triazole in order to increase the affinity in the inhibitor cap region with the HDAC enzyme
active site. The major goal was to create isoform selectivity, since a major downfall of
most HDAC inhibitors is a lack of specificity between various HDAC isoforms.
Researchers at University of Illinois, Chicago25 reconfigured the cap group of SAHA by
incorporating a triazole attached to the phenyl group of SAHA. They examined both 1,4
and 1,5-disubstituted triazoles (Figure 4.3, 4-1) in their efforts to find selective and
potent HDAC inhibitors. Two additional research groups decided to substitute a 1,2,3triazole as an isostere of the amide bond (4-2) in order to increase affinity in the cap
region of HDAC enzymes.118,119 Both references report similar findings that replacement
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of the amide with a triazole led to an increase in the HDAC inhibition. Further
modifications to the cap group revealed even more potent inhibitors. These compounds
still contained a hydroxamic acid as the zinc binding group. While hydroxamic acids are
among the most common zinc binding group used in HDAC inhibitors, they can suffer
from short clearance in vivo and often lack isoform specificity. There are many other
zinc metalloenzymes so lack of specificity could lead to adverse side effects. This has
led researchers to investigate non-hydroxamic zinc binding groups, although finding a
similar strong affinity group is not an easy task.
To this end, researchers manipulated an oxazole scaffold, which was shown to have
HDAC and antitumor activity,120 to incorporate a 1,2,3-triazole (4-3).121 This molecule
doesn’t have a strict zinc binding functionality. While not screened directly against
HDAC activity, it did show antiproliferative activity against several cancer cell lines. The
final inspiration for this work incorporated the triazole into the linker and moved it in
closer proximity to the hydroxamic acid. While the triazole adjacent to the hydroxamic
acid was not particularly active, moving the triazole within the linker displayed similar
activity as SAHA.122
From the previous work and as a further modification of this scaffold, we decided to
incorporate a 1,2,3-triazole into the zinc binding domain. By examining electrostatic
potential maps of hydroxamic acids in relation to the endogenous lysine substrate and
to 1,2,3-triazoles (Figure 4.6), it was hypothesized that the latter could serve as an
efficient, stable replacement of the previously known zinc binding group. The nitrogen of
the triazole could serve as a hydrogen bond acceptor similar to that of the hydroxamic
acid carbonyl. The alcohol appended to the triazole could serve as a hydrogen bond
donor or acceptor similar to that of the hydroxamic acid oxygen. Due to the structural
similarities and increased stability of 1,2,3-triazoles, their incorporation into a histone
deacetylase inhibitor seemed a favorable approach.
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Figure 4.5 Molecules synthesized for HDAC inhibition involving 1,2,3-triazoles.

Figure 4.6 Electrostatic potential map comparing 1,2,3-triazoles to hydroxamic acids.
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4.3.1. Solid Phase Approach
The original synthetic scheme utilized solid phase organic synthesis. The envisioned
plan was to construct the HDAC inhibitor beginning with the zinc binding group and
concluding with the cap group. Three different resins (Figure 4.7) were to be employed:
Wang resin, Weinreb amide resin, and Fmoc-Hydroxylamine 2-chlorotrityl resin with
each resulting in a different functional group upon cleavage (alcohol or acids,
aldehydes, and hydroxamic acids). Various alkynes were chosen to anchor to the solid
support. Known protocols were chosen to attach propargyl alcohol, homopropargyl
alcohol, and propionic acid to Wang resin.123 This resulted in terminal alkynes on a solid
support. Two consecutive CuAAC reactions were then carried out first with a diazide
and then with an aryl alkyne. This scheme could potentially be rapidly modified with
various diazides to adjust the linker length between cap group and zinc binding group.
In addition the aryl alkyne could be easily changed to rapidly assemble a small library of
compounds. Upon cleavage from the solid support, this would result in terminal alcohols
or acids appended to a 1,2,3-triazole. This scheme is illustrated in Scheme 4.1.

Figure 4.7 Different solid phase resins for HDAC inhibitor synthesis.
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Scheme 4.1 Solid phase synthetic scheme for HDAC inhibitors.

In addition, synthesis of a hydroxamic acid substituted triazole was also planned using
2-chlorotrityl resins and propionic acid. The CuAAC steps would proceed as described
above to furnish the desired compound. Finally, an aldehyde substituted triazole was
proposed by using Weinreb amide resin loaded with propionic acid. As a control, a
traditional hydroxamic acid lacking a 1,2,3-triazole was also envisioned via a solid
phase route.
Although some of the solid phase syntheses appeared promising, as confirmed by TLC,
HPLC, and HRMS, difficulties arose in obtaining a sufficient amount of pure material.
Products cleaved from the solid support contained trace byproducts that would need to
be removed either through recrystallization or column chromatography. This did not
result in enough product material for full characterization and enzyme testing. It was
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perceived to be a more expensive route to scale up the solid phase approach, and
therefore, a complementary solution phase approach was designed.

4.3.2. Solution Phase Approach
The solution phase approach would utilize many of the same precursors used for the
solid phase approach, but it would eliminate the loading of propargyl alcohols onto a
solid support. This method could be readily scaled up and purification performed after
each step if desired. Although this resulted in a longer synthesis, the solution phase
route allowed for the synthesis of pure material in a quantity that could be fully
characterized and tested. Two routes were planned in order to obtain the final product.
The initial solution phase scheme was to synthesize the desired HDAC inhibitor in a
one-pot reaction involving two alkynes and one diazide linker (Scheme 4.2). This
approach successfully led to the formation of the desired product (4-6) but also resulted
in two additional byproducts, the unreacted triazole azide (4-5) and the symmetric
bistriazole (4-7). This decreased the yield of the desired product to 38%. Separation of
the three products was achieved by column chromatography and identity of the three
products formed was confirmed by NMR and HRMS.

Scheme 4.2 One pot procedure for synthesis of HDAC inhibitors.

129

A two-step sequence was also investigated simultaneously (Scheme 4.3). Excess
diazide was reacted with phenylacetylene to obtain the desired azido triazole. This was
then reacted with propargyl alcohol to produce the desired product. This route involved
two steps with chromatography after each one. This allowed for better control and less
side product formation so this route was taken to synthesize a small library of
compound in which the linker diazide length and alkynol were varied.

Scheme 4.3 Two-step synthesis for HDAC inhibitors containing 1,2,3-triazoles.

Through this route we were able to synthesize a series of 8 compounds containing
1,2,3-triazoles in both the cap group region as well as in the zinc binding group domain.
The initial step of converting dibromides to diazides was high yielding (> 86%). The
synthesis of monoazide triazoles resulted in lower yields ranging from 27% of 4-12 to
68% of 4-14. The decreased yields resulted from formation of the bistriazole (4-7) where
phenylacetylene reacted with both of the azides on a single alkyl linker. For the
bistriazoles, 4-16 to 4-23, better isolated yields resulted, since only one azide was
available to react. Initially, column chromatography was used to separate the product
triazoles from any residual copper or other slight byproducts. Upon scale-up, this led to
some difficulties in that the bistriazoles were not very soluble in organic solvents such
as DCM or MeOH, leading to broad elution from silica gel chromatography. Since the
triazoles were not soluble, but the copper salts were, we could isolate the triazole
product by filtration in both higher yield and purity than was observed from column
chromatography. By filtration we recovered 82% yield of 4-16. Yields of compounds
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isolated by chromatography ranged from 48% (4-17) to ~80% (4-18, 4-19, 4-20, 4-23).
Yields over 3 steps ranged from 18% for compound 4-20 to 51% for compound 4-18.
This solution phase scheme allowed access to the alcohol substituted triazoles, but did
not allow for synthesis of the aldehyde or acid substituents for the triazole zinc binding
group. Due to the primary alcohol functional group appended to the triazole, it was
hypothesized that this could be oxidized to the corresponding acid or aldehyde,
depending on the reagents employed. A series of test reactions were conducted with a
simplified triazole (3-3l) before using the more complicated bistriazoles (4-16 to 4-23).
Two methods were utilized: Jones Reagent to oxidize the alcohol to the carboxylic acid
or Swern oxidation to afford the aldehyde. Both methods resulted in consumption of the
starting material in the model systems. When applied to the more complicated
bistriazoles, neither of these methods proved to be effective leading to recovery of only
starting materials. Additional oxidants, such as TEMPO and oxone, were also tried, but
these failed. The low solubility of these bistriazoles in organic solvents is a possible
reason that the oxidations failed to work on this system. Because of the struggles with
this chemistry, this route was abandoned and the focus moved to other potential zinc
binding domains.
Since the 1,2,3-triazoles had been successfully synthesized, we decided to incorporate
a 1,2,4-triazole to test their ability to function as a zinc binding group. Both are five
membered rings with three nitrogen atoms, but we felt that the difference in geometry
might make a difference in the zinc binding ability. Furthermore, work by lab mates had
previously explored synthesis of 1,2,4-triazoles, and several intact 1,2,4-triazoles were
commercially available. This synthesis could rely on some of the starting materials used
for the 1,2,3-triazole synthetic scheme so it was a logical progression.
In this scheme (Scheme 4.4), dibromides were used for a linker as before, but were
converted to monoazides instead of diazides in the initial step. The monoazides were
not purified prior to use, so a lower overall yield was observed in these reactions. A
CuAAC reaction resulted in an aryl triazole with a terminal bromide at the end of an alkyl
linker (compounds 4-28 to 4-31). These compounds were isolated in ~30% yield, with
the low yield attributed to using the crude azidobromoalkane. The bromide was then
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displaced by a suitable nucleophile. In this case, commercial triazoles were chosen as
the nucleophiles. Previous work in our group had illustrated this reaction was indeed
regioselective, reacting preferentially at the N1, and using the intact triazole was easier
than synthesizing the 5-membered heterocycle.
This led to the quick synthesis of 4 additional molecules containing both 1,2,3- and
1,2,4-triazoles using commercially available 1,2,4-triazole. The displacement of the
bromide with 1,2,4-triazole resulted in the product in 76 – 84% yield, with the 4-carbon
linker resulting in only 44% yield. We also tried using 3-amino-1,2,4-triazole as the
nucleophile, but this led to a 50/50 mixture of products by NMR. The two products
observed were regioisomers as two nucleophilic sites existed in the starting material.

Scheme 4.4 Synthetic scheme for synthesis of 1,2,4-triazole containing HDAC inhibitors.

As a final compound in this series, we chose to synthesize a previously published
HDAC inhibitor molecule containing the triazole in the cap region with the standard
hydroxamic acid as the zinc binding group to serve as a synthesized positive control
(Scheme 4.5). The precursor for this molecule had been synthesized during the catalytic
studies from Chapter 3. The acid functional group was converted into the methyl ester in
85% yield, and conversion to the hydroxamic acid under MW irradiation resulted in the
product in 60% yield.
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Scheme 4.5 Synthesis of previously published HDAC Inhibitor.

It was also of interest to explore other 1,2,4-triazoles positioned in the zinc binding
domain. For the next series of molecules, we decided to leave the amide bond of SAHA
intact, and instead just manipulate the zinc binding domain (Scheme 4.6). First, the
amide bond was synthesized in 82% yield by reacting aniline with 5-bromovaleric acid
that had been converted to the more active acyl chloride with DMF and oxalyl chloride.
The resultant bromoanilide could then be subjected to a solution of the desired triazole
with K2CO3 in DMF. The triazole chosen as the nucleophile was 3-methyl-1,2,4-triazole
carboxylate. This reaction proceeded to produce the 1,2,4-triazole with a methyl ester
appended to the three position. Two regioisomers were possible, but only one of the two
was isolated in 39% yield. The position of the substituent was confirmed by 2D NMR, by
examining the HMBC correlations. The lower yield for this step can be attributed to
difficulty in removing all the DMF from the product. In the final step, methyl esters are
easily converted to the hydroxamic acid using hydroxylamine hydrochloride and K2CO3
in MeOH under microwave conditions. This reaction proceeded smoothly and product
was easily isolated with an aqueous workup in 58% yield. Prior experience with 1,2,4triazoles had shown that the functional groups attached are not nearly as reactive when
compared to other aromatic systems. We hoped to use this to our advantage to create a
hydroxamic acid-like compound that could match the potency, but with decreased
toxicity as compared to standard hydroxamic acids.
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Scheme 4.6 Synthesis of 1,2,4-triazole hydroxamic acid compound.

Since the 1,2,4-triazole compound above was synthesized using a bromoanilide, it was
decided that a similar process should be used to make a 1,2,3-triazole compound
containing an amide in the cap region. This would be complementary to the 1,2,4triazole compound, so the activities could be directly correlated. The amide bond was
made between aniline and 6-bromohexanoic acid using DMF and oxalyl chloride in 85%
yield. The bromide was displaced with sodium azide and an azide-alkyne cycloaddition
performed using propargyl alcohol to afford the desired triazole compound in 40% yield
over the two steps (Scheme 4.7).
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Scheme 4.7 Synthesis of 1,2,3-triazole anilide.

4.4.

Screening of Synthesized Small Molecules for HDAC inhibition

Upon synthesis, the molecules were subjected to a commercial high throughput assay
to determine their relative activities for three different HDAC isoforms, HDAC-1, -6, and
-8 using human recombinant HDAC enzymes. A comparison of HDAC-1 and HDAC-6
will allow us to determine if any selectivity is observed between different classes of
enzymes while two isoforms from Class I (HDAC-1 and -8) were screened to see if any
selectivity between isoforms existed.
The commercial assay is designed with a fluorogenic substrate based on p53 residues
379-382 that includes an acetylated lysine side chain. When incubated with HDAC, the
acetyl group is removed, leaving a free amine to react with the proprietary developer
which generates a fluorophore. Fluorescence of samples containing inhibitor is
compared to samples with no inhibitor to determine percent inhibition. If HDAC enzyme
is active, a large fluorescence signal is observed. If reduced fluorescence is observed
compared to the no inhibitor control, then inhibition of the HDAC enzyme is occurring.

4.4.1. General procedure for performing enzyme inhibition assays:
Enzyme kits were purchased from EnzoLife Sciences. Upon receipt of enzyme kit,
components were defrosted and aliquotted into microcentrifuge tubes and refrozen with
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liquid nitrogen to avoid multiple freeze/thaw cycles. All components were stored at 80°C until used.
HDAC Assay Buffer II was defrosted and allowed to warm to room temperature. Test
inhibitors were diluted to 10 mM with DMSO. Test inhibitors were further diluted down
with HDAC Assay Buffer II to a concentration of 100 μM, which is 5X the concentrations
used in the assay. A known inhibitor, Trichostatin A, was diluted with DMSO to an initial
concentration of 2 μM with DMSO. Further dilutions were performed with HDAC Assay
Buffer II to a final concentration of 31.25 nM. Finally, DMSO was diluted to 1% with
HDAC Assay Buffer II to match the concentration of DMSO found in the inhibitor
samples. 10 μL of each test inhibitor was added to low retention microcentrifuge tubes.
For the no-inhibitor control, 10 μL of DMSO was instead added. Microcentrifuge tubes
were sealed and added to incubator at 33°C. Fluor de Lys-SIRT1 Deacetylase
Substrate was diluted with HDAC Assay Buffer II to give a substrate concentration of 20
μM and placed in incubator at 33°C for 10 minutes. HDAC Enzyme was thawed and
chilled enzyme was diluted into warm HDAC Assay Buffer II. 15 μL of HDAC Enzyme
was then added to all samples, except the no enzyme control, mixed, and incubated at
33°C. After 10 minutes, 25μL of the diluted substrate was added to all samples, mixed
thoroughly, and incubated for 40 minutes at 33°C. While samples were incubating, Fluor
de Lys-Developer II Concentrate was thawed and diluted 5-fold with HDAC Assay
Buffer I. Trichostatin A was then diluted 100-fold in the 1x developer just prepared.
Diluted developer was stored on ice until ready for use. After the HDAC, inhibitor,
substrate mixture was allowed to react for the desired time, 50 μL of developer was
added to all samples. Samples were then incubated at room temperature for 45
minutes. Samples were then transferred to a white ½ volume microplate and
fluorescence measured using a Biotek Synergy platereader with excitation filters of
360/40 and emission filters of 440/30. Samples were read with a top 50% mirror or
dichroic 410 mirror.
Data analysis: Fluorescence reading from no enzyme control well (background) was
subtracted from all sample readings. The sample fluorescence values were compared
to the no inhibitor control
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4.5.

Analysis of Enzyme Inhibition Results

The inhibition of each HDAC enzyme was evaluated with each of the 14 synthetic
compounds. To our dismay and disappointment, none of the 1,2,3-triazole zinc binding
groups showed any inhibition with regards to any of the enzymes studied (Figure 4.8).
The samples containing test compounds were not statistically different from the sample
with no inhibitor present. The positive control with TSA, showed approximately 50%
inhibition in all three enzymes. The binding potential of the triazole with zinc may not be
strong enough to bind the inhibitor in the pocket. In comparison to the hydroxamic acid,
the hydrogen bond with the NH would be missing in the 1,2,3-triazole inhibitors we
designed. This hydrogen bonding interaction could be replaced with a H-bond between
the C(5)-H of the triazole and the imidazole of the histidine residue (Figure 4.9). An
additional hypothesis is that the 1,2,3-triazole may be too bulky to appropriately fit into
the catalytic pocket. Furthermore, the 1,2,3-triazole might also be too polar for the
hydrophobic channel leading to the catalytic zinc binding domain. Triazoles are known
to be much more polar than their amide bond counterparts 12 which may prevent access
to the catalytic pocket.
To test these hypotheses, the compounds could be mixed with a zinc (II) salt to see if a
complex forms. The zinc triazole complex may require increased temperature, which
would not be biologically relevant. To test the other theory, modeling could be utilized to
predict the lowest energy conformation of the molecule. Some preliminary modeling
studies showed that especially with the longer linker, the molecule would adopt an
almost U-shaped conformation. Since these were preliminary studies, we weren’t
confident in the parameters used to optimize the geometry. We initially thought this was
due more to inexperience with modeling software than the actual geometry. A closer
look at the modeling studies could be of value.
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Figure 4.8 Analysis of 1,2,3-triazoles as zinc binding groups for HDAC inhibition.

138

Figure 4.9 Comparison of interaction with A) hydroxamic acid and B) proposed inhibitor.

The terminal 1,2,4-triazoles as a zinc binding group did not fare any better in the
enzyme assay (Figure 4.10). There was no distinguishable activity for the four 1,2,4triazoles synthesized. Even the hydroxamic acid substituted 1,2,4-triazole did not show
any inhibitory activity of any of the three HDAC isoforms tested. In hindsight, this
followed similar results observed by Shen et. al.122 Their research described attachment
of a hydroxamic acid to a 1,2,3-triazole, but their compounds were not significantly
active for HDAC inhibition, with the largest percentage of inhibited HDAC activity being
20% with 500 nM of test compound. Of the synthesized inhibitors, the only one that
showed any activity against HDAC was the control compound that was synthesized to
match a previously reported compound.118 As with the 1,2,3-triazoles, the increased
polarity of the zinc binding group or the size could be preventing the synthesized
compounds from interacting with the enzyme active site. Further modeling or evaluation
against other metalloenzymes could be a worthwhile pursuit.
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Figure 4.10 Analysis of 1,2,4-triazoles as zinc binding groups for HDAC inhibition.
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4.6.

Conclusions

A small library of compounds was designed and synthesized as inhibitors of various
HDAC isoforms. The goal of the research was to investigate the potential of 1,2,3- or
1,2,4-triazoles as zinc binding groups. A solid phase route was originally carried out, but
led to additional byproducts that were difficult to separate on such a small scale. A
similar solution phase synthesis was designed and successfully carried out. This led to
the synthesis of a series of molecules containing 1,2,3-triazoles in both the cap group
and zinc binding domain. Additional molecules containing a 1,2,4-triazole in the zinc
binding domain and a 1,2,3-triazole in the cap group were also synthesized. In an effort
to match the zinc binding ability of hydroxamic acids, a compound containing a 1,2,4triazole substituted with a hydroxamic acid was also designed and synthesized. A
control compound that had been previously reported with activity against HDAC was
also synthesized to serve as a positive control.
Despite evidence that would suggest triazoles as effective zinc binding groups, the
designed molecules did not show activity for the enzymes tested. The molecules were
screened against two enzymes from Class I (HDAC-1 and HDAC-8) to look for isoform
specificity and one enzyme from Class II-b (HDAC-6) to examine class specificity. The
only molecule to show activity was an already published inhibitor that was synthesized
as a control. Future work could include more modeling studies in the design process or
the screening of these molecules against other metalloenzymes, specifically ones that
had wider enzyme active sites or that involved more polar amino acid residues.

4.7.

Experimental

Materials and General Methods. Reagents and solvents were purchased from various
commercial sources and used without further purification unless otherwise stated.
Anhydrous solvents were purified using a Grubbs solvent system. Analytical thin-layer
chromatography (TLC) was performed using aluminum backed silica gel TLC plates
with UV indicator from Sorbent Technologies.

Flash column chromatography was

performed using 40 – 63 μm (230 x 400 mesh) silica gel from Sorbent Technologies.
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Microwave reactions were performed in sealed vials using a Biotage Initiator
Microwave. 1H and

13

C NMR were recorded at 600 MHz and 151 MHz, respectively, on

a Varian Inova spectrometer or at 500 MHz and 125 MHz, respectively, on a Varian
VNMRS spectrometer.

All chemical shifts were reported in δ units relative to

tetramehtylsilane or the corresponding deuterated solvent. High resolution mass spectra
(HRMS) were obtained on a JEOL AccuTOF DART spectrometer. Infrared spectra
were recorded on a Varian 4100 FT-IR using KBr pellets or KBR salt plates. Absorption
spectra were collected on a Thermo Scientific Evolution 600. High pressure liquid
chromatography (HPLC) was performed using a Beckman Coulter System equipped
with a UV-Vis detector, autosampler, Varian C18 column, and a mobile phase
composed of acetonitrile and trifluoracetic acid.

General Diazide Procedure: Dibromide (4 mmol) was dissolved in dimethylformamide
and water (9:1 mL). Sodium azide (9 mmol) was added as a solid and the solution
stirred overnight at room temperature. Progress of the reaction was monitored by GCMS. Upon completion, the reaction was quenched with 30 mL of water (exothermic) and
stirred until reaching room temperature. The solution was then extracted with diethyl
ether (3x). The combined organics were washed with water (2x), copper sulftate (1x)
and brine (1x). The solution was dried over sodium sulfate, filtered, and concentrated in
vacuo to yield the desired diazide.

1,3-diazidopropane (4-8).

Prepared using the General Diazide

Procedure from 1,3-dibromopropane. Isolated as a pale yellow oil in 86% yield.
NMR (CDCl3, 600 MHz) δ 3.42 (t, 4H, J = 6.6 Hz), 1.84 (q, 2H, J = 6.6 Hz).

1

H

13

C NMR

(CDCl3, 151 MHz) δ 48.6, 28.5. MS (ESI) m/z calculated 70.05 (C3H6N2, [M-N2-N2]+),
m/z observed 70.10. (C6H6N2, [M-N2-N2]+).

1,4-diazidobutane (4-9).

Prepared using the General Diazide

Procedure from 1,4-dibromobutane. Isolated as a pale yellow oil in 98% yield.
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1

H NMR

(CDCl3, 600 MHz) δ 3.33 (t, 4H, J = 6.0 Hz), 1.69 (q, 4H, J = 3.0 Hz).
151 MHz) δ 51.1, 26.3.

13

C NMR (CDCl3,

MS (ESI) m/z calculated 84.07 (C4H8N2, [M-N2-N2]+), m/z

observed 84.10. (C4H8N2, [M-N2-N2]+).

1,5-diazidopentane (4-10).

Prepared using the General Diazide

Procedure from 1,5-dibromopentane. Isolated as a pale yellow oil in 90% yield.

1

H

NMR (CDCl3, 600 MHz) δ 3.29 (t, 4H, J = 6.6 Hz), 1.63 (q, 4H, J = 6.6 Hz), 1.44 – 1.50
(m, 2H).

13

C NMR (CDCl3, 151 MHz) δ 51.4, 28.6, 24.1. MS (ESI) m/z calculated 98.08

(C5H10N2, [M-N2-N2]+), m/z observed 98.10. (C5H10N2, [M-N2-N2]+).

1,6-diazidohexane (4-11). Prepared using the General Diazide
Procedure from 1,6-dibromohexane. Isolated as a pale yellow oil in 98% yield. 1H NMR
(CDCl3, 600 MHz) δ 3.28 (t, 4H, J = 6.6 Hz), 1.59 – 1.65 (m, 4H), 1.39 – 1.44 (m, 4H).
13

C NMR (CDCl3, 151 MHz) δ 51.5, 28.9, 26.5.

MS (ESI) m/z calculated 112.10

+

(C6H12N2, [M-N2-N2] ), m/z observed 112.10. (C6H12N4, [M-N2-N2]+).

General Procedure for Azido 1,2,3-triazoles: Diazide (2.5 mmol) was dissolved in
acetonitrile (10 mL). Phenylacetylene (1 mmol) and triethylamine (1 mmol) were added.
A solution of triazine 2-17 (0.01 mmol) in acetonitrile was added, followed by a solution
of tetrakis(acetonitrle-N)copper(I) tetrafluoroborate (0.01 mmol) in acetonitrile. The
resulting solution was stirred at room temperature overnight. Reaction progress was
followed by TLC. Upon completion, the mixture was concentrated in vacuo and purified
via silica gel chromatography eluting with a gradient of hexanes and ethyl acetate to
yield the desired azidoalkyl phenyl-1,2,3-triazole.

1-(3-azidopropyl)-4-phenyl-1H-1,2,3-triazole

(4-12).

Prepared using General Procedure for Azido 1,2,3-triazoles
from 1,3-diazidopropane (4-8) and isolated as pale yellow
solid in 27% yield.

1

H NMR (d6-DMSO, 600 MHz) δ 8.61 (s, 1H), 7.84 (d, 2H, J = 8.4
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Hz), 7.45 (t, 2H, J = 7.2 Hz), 7.33 (t, 1H, J = 7.2 Hz), 4.47 (t, 2H, J = 6.6 Hz), 3.42 (t, 2H,
J = 6.6 Hz), 2.13 (q, 2H, J = 6.6 Hz).

13

C NMR (d6-DMSO, 151 MHz) δ 146.4, 130.8,

128.9, 127.9, 125.2, 121.5, 47.9, 47.0, 29.0. HRMS (ESI) m/z calculated 229.12017
(C11H13N6, [M+H]+), m/z observed 229.11965. (C11H13N6, [M+H]+).

1-(4-azidobutyl)-4-phenyl-1H-1,2,3-triazole

(4-13).

Prepared using General Procedure for Azido 1,2,3-triazoles
from 1,4-diazidobutane (4-9) and isolated as an off-white
solid in 60% yield

1

H NMR (d6-DMSO, 600 MHz) δ 8.59 (s, 1H), 7.84 (d, 2H, J = 7.2

Hz), 7.45 (t, 2H, J = 7.2 Hz), 7.33 (t, 1H, J = 7.2 Hz), 4.44 (t, 2H, J = 7.2 Hz), 3.39 (t, 2H,
J = 6.6 Hz), 1.93 (q, 2H, J = 7.2 Hz), 1.54 (q, 2H, J = 6.6 Hz).

13

C NMR (d6-DMSO, 151

MHz) δ 146.3, 130.8, 128.9, 127.8, 125.1, 121.3, 50.0, 49.0, 26.9, 25.4. HRMS (ESI)
m/z calculated 243.13582 (C12H15N6, [M+H]+), m/z observed 243.13586. (C12H15N6,
[M+H]+).

1-(5-azidopentyl)-4-phenyl-1H-1,2,3-triazole

(4-14).

Prepared using General Procedure for Azido 1,2,3triazoles from 1,5-diazidopentane (4-10) and isolated as
an off-white solid in 68% yield.

1

H NMR (d6-DMSO, 600 MHz) δ 8.58 (s, 1H), 7.84 (d,

2H, J = 7.8 Hz), 7.44 (t, 2H, J = 7.8 Hz), 7.33 (t, 1H, J = 7.2 Hz), 4.40 (t, 2H, J = 7.2 Hz),
3.32 (t, 2H), 1.89 (q, 2H, J = 7.2 Hz), 1.57 (q, 2H, J = 7.2 Hz), 1.32 (q, 2H, J = 7.2 Hz).
13

C NMR (d6-DMSO, 151 MHz) δ 146.3, 130.9, 128.9, 127.8, 125.1, 121.3, 50.4, 49.3,

29.1, 27.6, 23.1.

HRMS (ESI) m/z calculated 257.15147 (C13H17N6, [M+H]+), m/z

observed 257.15147. (C13H17N6, [M+H]+).

1-(6-azidohexyl)-4-phenyl-1H-1,2,3-triazole

(4-15).

Prepared using General Prodedure for Azido 1,2,3triazoles from 1,6-diazidohexane (4-11) and isolated as
an off-white solid in 47% yield.

1

H NMR (d6-DMSO, 600 MHz) δ 8.58 (s, 1H), 7.84 (d,
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2H, J = 8.4 Hz), 7.44 (t, 2H, J = 7.8 Hz), 7.33 (t, 1H, J = 7.8 Hz), 4.39 (t, 2H, J = 6.6 Hz),
3.31 (t, 2H, J = 6.6 Hz), 1.87 (q, 2H, J = 7.2 Hz), 1.52 (q, 2H, J = 7.2 Hz), 1.36 (q, 2H, J
= 7.2 Hz), 1.29 (q, 2H, J = 7.2 Hz).

13

C NMR (d6-DMSO, 151 MHz) δ 146.3, 130.9,

128.9, 127.8, 125.1, 121.2, 50.5, 49.4, 29.4, 28.0, 25.5, 25.4.

HRMS (ESI) m/z

calculated 271.16712 (C14H19N6, [M+H]+), m/z observed 271.16567. (C14H19N6, [M+H]+).

General Procedure for Bistriazoles: Azidoalkyl-phenyl 1,2,3-triazole (1.0 mmol) was
dissolved in acetonitrile (2.5 mL). Propargyl or homopropargyl alcohol (1 mmol) and
triethylamine (1 mmol) were added. A solution of triazine 2-17 (0.01 mmol) in
acetonitrile (750 μL) was added, followed by a solution of tetrakis(acetonitrleN)copper(I) tetrafluoroborate (0.01 mmol) in acetonitrile (750 μL). The resulting solution
was stirred 60°C overnight. Reaction progress was followed by TLC. Upon completion,
the mixture was concentrated in vacuo and purified via silica gel chromatography eluting
with a gradient of ethyl acetate and methanol to yield the desired bistriazoles.

(1-(3-(4-phenyl-1H-1,2,3-triazol-1-yl)propyl)-1H1,2,3-triazol-4-yl)methanol (4-16). Prepared using
General Procedure for Bistriazoles from 4-12 and
propargyl alcohol with following modification: isolated
by filtration to yield a white solid in 82% yield. 1H NMR (d6-DMSO, 600 MHz) δ 8.59 (s,
1H), 8.02 (s, 1H), 7.84 (d, 2H, J = 7.8 Hz), 7.45 (t, 2H, J = 7.8 Hz), 7.34 (t, 1H, J = 7.8
Hz), 5.17 (t, 1H, J = 6.0 Hz), 4.51 (d, 2H, J = 6.0 Hz), 4.42 (q, 4H, J = 7.2 Hz), 2.46 (q,
2H, J = 7.2 Hz).

13

C NMR (d6-DMSO, 151 MHz) δ 148.1, 146.4, 130.7, 128.9, 127.9,

125.1, 122.9, 121.5, 55.1, 46.9, 46.5, 30.2. HRMS (ESI) m/z calculated 285.14638
(C14H17N6O, [M+H]+), m/z observed 285.14514. (C14H17N6O, [M+H]+).

2-(1-(3-(4-phenyl-1H-1,2,3-triazol-1-yl)propyl)-1H1,2,3-triazol-4-yl)ethanol (4-17). Prepared using
General Procedure for Bistriazoles from 4-12 and
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homopropargyl alcohol and isolated as a white solid in 76% yield.

1

H NMR (d6-DMSO,

500 MHz) δ 8.58 (s, 1H), 7.90 (s, 1H), 7.83 (d, 2H, J = 7.0 Hz), 7.45 (t, 2H, J = 7.5 Hz),
7.33 (tt, 1H, J = 7.8 Hz, J = 1.5 Hz), 4.67 (t, 1H, J = 5.5 Hz), 4.44 (t, 2H, J = 7.0 Hz),
4.39 (t, 2H, J = 7.0 Hz), 3.62 (q, 2H, J = 7.0 Hz), 2.76 (t, 2H, J = 7.0 Hz), 2.45 (q, 2H, J
= 7.0 Hz).

13

C NMR (d6-DMSO, 125 MHz) δ 146.4, 144.4, 130.7, 128.9, 127.8, 125.1,

122.6, 121.5, 60.3, 46.9, 46.5, 30.1, 29.2.

HRMS (ESI) m/z calculated 299.16203

(C15H19N6O, [M+H]+), m/z observed 299.16128. (C15H19N6O, [M+H]+).

(1-(4-(4-phenyl-1H-1,2,3-triazol-1-yl)butyl)-1H1,2,3-triazol-4-yl)methanol

(4-18).

Prepared

using General Procedure for Bistriazoles from 4-13
and propargyl alcohol and isolated as a white solid in 48% yield.

1

H NMR (d6-DMSO,

600 MHz) δ 8.56 (s, 1H), 7.96 (s, 1H), 7.83 (d, 2H, J = 7.2 Hz), 7.44 (t, 2H, J = 7.2 Hz),
7.33 (t, 1H, J = 7.2 Hz), 5.15 (t, 1H, J = 6.0 Hz), 4.50 (d, 2H, J = 6.0 Hz), 4.43 (t, 2H, J =
6.6 Hz), 4.38 (t, 2H, J = 6.6 Hz) 1.81 – 1.84 (m, 4H).

13

C NMR (d6-DMSO, 151 MHz) δ

148.0, 146.3, 130.8, 128.9, 127.8, 125.1, 122.7, 121.4, 55.1, 48.9, 48.6, 26.9, 26.8.
HRMS (ESI) m/z calculated 299.16203 (C15H19N6O, [M+H]+), m/z observed 299.16125.
(C15H19N6O, [M+H]+).

2-(1-(4-(4-phenyl-1H-1,2,3-triazol-1-yl)butyl)1H-1,2,3-triazol-4-yl)ethanol (4-19). Prepared
using General Procedure for Bistriazoles from 413 and homopropargyl alcohol and isolated as a white solid in 64% yield.

1

H NMR (d6-

DMSO, 600 MHz) δ 8.56 (s, 1H), 7.85 (s, 1H), 7.83 (d, 2H, J = 6.6 Hz), 7.44 (t, 2H, J =
7.8 Hz), 7.33 (t, 1H, J = 7.8 Hz), 4.67 (t, 1H, J = 5.4 Hz), 4.43 (t, 2H, J = 6.6 Hz), 4.35 (t,
2H, J = 6.6 Hz), 3.61 (q, 2H, J = 6.6 Hz), 2.75 (t, 2H, J = 6.6 Hz), 1.77 – 1.87 (m, 4H).
13

C NMR (d6-DMSO, 151 MHz) δ 146.3, 144.3, 130.8, 128.9, 127.8, 125.1, 122.6,

121.3, 60.4, 48.9, 48.4, 29.2, 26.8, 26.7.

HRMS (ESI) m/z calculated 313.17768

(C16H21N6O, [M+H]+), m/z observed 313.17625. (C16H21N6O, [M+H]+).
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(1-(5-(4-phenyl-1H-1,2,3-triazol-1-yl)pentyl)-1H1,2,3-triazol-4-yl)methanol (4-20).

Prepared

using General Procedure for Bistriazoles from 414 and propargyl alcohol and isolated as a white
solid in 84% yield.

1

H NMR (d6-DMSO, 500 MHz) δ 8.56 (s, 1H), 7.95 (s, 1H), 7.83 (d,

2H, J = 7.0 Hz), 7.45 (t, 2H, J = 7.5 Hz), 7.33 (tt, 1H, J = 7.5 Hz, J = 1.5 Hz), 5.14 (t, 1H,
J = 6.0 Hz), 4.49 (d, 2H, J = 6.0 Hz), 4.39 (t, 2H, J = 7.0 Hz), 4.33 (t, 2H, J = 7.0 Hz),
1.82 – 1.94 (m, 4H), 1.21 – 1.28 (m, 2H).

13

C NMR (d6-DMSO, 125 MHz) δ 147.9,

146.2, 130.8, 128.9, 127.8, 125.1, 122.5, 121.2, 55.0, 49.3, 48.9, 29.1, 29.0, 22.8.
HRMS (ESI) m/z calculated 313.17768 (C16H21N6O, [M+H]+), m/z observed 313.17693.
(C16H21N6O, [M+H]+).

2-(1-(5-(4-phenyl-1H-1,2,3-triazol-1yl)pentyl)-1H-1,2,3-triazol-4-yl)ethanol
21).

(4-

Prepared using General Procedure for

Bistriazoles from 4-14 and homopropargyl alcohol and isolated as a white solid in 64%
yield. 1H NMR (d6-DMSO, 600 MHz) δ 8.55 (s, 1H), 7.82 – 7.85 (m, 3H), 7.45 (t, 2H, J =
7.8 Hz), 7.33 (tt, 1H, J = 7.8 Hz, J = 1.2 Hz), 4.66 (t, 1H, J = 5.4 Hz), 4.38 (t, 2H, J = 7.2
Hz), 4.29 (t, 2H, J = 7.2 Hz), 3.60 (q, 2H, J = 6.6 Hz), 2.73 (t, 2H, J = 6.6 Hz), 1.89 (q,
2H, J = 7.2 Hz), 1.84 (q, 2H, J = 7.2 Hz), 1.21 – 1.27 (m, 2H).

13

C NMR (d6-DMSO, 151

MHz) δ 146.2, 144.3, 130.8, 128.9, 127.8, 125.1, 122.2, 121.2, 60.4, 49.2, 48.8, 29.2,
29.1, 29.0, 22.8.

HRMS (ESI) m/z calculated 327.19333 (C17H23N6O, [M+H]+), m/z

observed 327.19218. (C17H23N6O, [M+H]+).

(1-(6-(4-phenyl-1H-1,2,3-triazol-1-yl)hexyl)1H-1,2,3-triazol-4-yl)methanol
Prepared

using

General

(4-22).
Procedure

for

Bistriazoles from 4-15 and propargyl alcohol and isolated as a white solid in 87% yield.
1

H NMR (d6-DMSO, 500 MHz) δ 8.57 (s, 1H), 7.95 (s,1H), 7.83 (d, 2H, J = 7.0 Hz), 7.44

(t, 2H, J = 7.5 Hz), 7.32 (tt, 1H, J = 7.5 Hz, J = 1.5 Hz), 5.13 (t, 1H, J = 5.5 Hz), 4.37 (t,
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2H, J = 7.5 Hz), 4.31 (t, 2H, J = 7.0 Hz), 1.85 (q, 2H, J = 7.0 Hz), 1.80 (q, 2H, J = 7.0
Hz), 1.25 – 1.31 (m, 4H).

13

C NMR (d6-DMSO, 125 MHz) δ 147.9, 146.2, 130.8, 128.9,

127.7, 125.1, 122.5, 121.2, 55.1, 49.4, 49.0, 29.5, 29.4, 25.25, 25.23. HRMS (ESI) m/z
calculated 327.19333 (C17H23N6O, [M+H]+), m/z observed 327.19240. (C17H23N6O,
[M+H]+).

2-(1-(6-(4-phenyl-1H-1,2,3-triazol-1yl)hexyl)-1H-1,2,3-triazol-4-yl)ethanol

(4-

23). Prepared using General Procedure for
Bistriazoles from 4-15 and homopropargyl alcohol and isolated as a white solid in 81%
yield. 1H NMR (d6-DMSO, 600 MHz) δ 8.57 (s, 1H), 7.82 – 7.85 (m, 3H), 7.44 (t, 2H, J =
7.8 Hz), 7.32 (t, 1H, J = 7.8 Hz), 4.67 (t, 1H, J = 5.4 Hz), 4.37 (t, 2H, J = 7.2 Hz), 4.27 (t,
2H, J = 6.6 Hz), 3.61 (q, 2H, J = 6.6 Hz), 2.74 (t, 2H, J = 6.6 Hz), 1.85 (q, 2H, J = 7.2
Hz), 1.85 (q, 2H, J = 7.2 Hz), 1.78 (q, 2H, J = 7.2 Hz), 1.26 – 1.31 (m, 4H).

13

C NMR

(d6-DMSO, 151 MHz) δ 146.3, 144.3, 130.9, 128.9, 127.8, 125.1, 122.2, 121.2, 60.4,
49.4, 49.0, 29.5, 29.4, 29.2, 25.29, 25.26.

HRMS (ESI) m/z calculated 341.20898

(C18H25N6O, [M+H]+), m/z observed 341.21026. (C18H25N6O, [M+H]+).

General procedure for azido bromo-alkanes: Dibromide (1.2 mmol) was dissolved in
dimethylformamide and water (9:1 mL). Sodium azide (1 mmol) was added as a solid
and the solution stirred overnight at room temperature. Progress of the reaction was
monitored by GC-MS. This reaction resulted in a mixture of unreacted dibromide, the
desired azidobromoalkane, and diazidoalkane. The reaction was quenched with 20 mL
of water (exothermic) and stirred until reaching room temperature. The solution was
then extracted with diethyl ether (3x). The combined organics were washed with water
(2x), copper sulftate (1x) and brine (1x). The solution was dried over sodium sulfate,
filtered, and concentrated in vacuo to yield the crude azidobromoalkane as a pale
yellow oil. This solution was used in the next step without further purification.
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General procedure for bromo 1,2,3-triazoles: Using the crude azidobromoalkane, it
was assumed (based on GC-MS results) that ~30% of the mixture was desired
azidobromoalkane. Excess azidobromoalkane (1 mmol) was measured out (mmol were
calculated by multiplying mass by 0.3 and using molecular weight of desired
azidobromoalkane) and dissolved in acetonitrile (8 mL). ). Phenylacetylene (3.3 mmol)
and triethylamine (3.3 mmol) were added. A solution of triazine 2-17 (0.033 mmol) in
acetonitrile (4 mL) was added, followed by a solution of tetrakis(acetonitrle-N)copper(I)
tetrafluoroborate (0.033 mmol) in acetonitrile (4 mL). The resulting solution was stirred
at room temperature overnight. Reaction progress was followed by TLC. Upon
completion, the mixture was concentrated in vacuo and purified via silica gel
chromatography eluting with a gradient of hexanes and ethyl acetate to yield the desired
bromoalkyl phenyl-1,2,3-triazole.

1-(3-bromopropyl)-4-phenyl-1H-1,2,3-triazole

(4-28).

Prepared using General Procedure for bromo-1,2,3-triazoles
from 1-azido-3-bromopropane 4-24 and isolated as a white
solid in 28% yield.

1

H NMR (CDCl3, 600 MHz) δ 7.84 (d, 2H, J = 7.8 Hz), 7.82 (s, 1H),

7.43 (t, 2H, J = 7.8 Hz), 7.34 (t, 1H, J = 7.8 Hz), 4.61 (t, 2H, J = 6.6 Hz), 3.40 (t, 2H, J =
6.0 Hz), 2.52 (q, 2H, J = 6.6 Hz).

13

C NMR (CDCl3, 151 MHz) δ 147.9, 130.6, 129.0,

128.4, 125.9, 120.4, 48.3, 32.7, 29.7.

HRMS (ESI) m/z calculated 266.02929

+

(C11H13BrN3, [M+H] ), m/z observed 266.02908. (C11H12BrN3, [M+H]+).

1-(4-bromobutyl)-4-phenyl-1H-1,2,3-triazole

(4-29).

Prepared using General Procedure for bromo-1,2,3-triazoles
from 1-azido-4-bromobutane 4-25 and isolated as a white
solid in 34% yield.

1

H NMR (CDCl3, 600 MHz) δ 7.83 (d, 2H, J = 7.2 Hz), 7.77 (s, 1H),

7.43 (t, 2H, J = 7.8 Hz), 7.34 (t, 1H, J = 7.8 Hz), 4.45 (t, 2H, J = 6.6 Hz), 3.44 (t, 2H, J =
6.6 Hz), 2.14 (q, 2H, J = 7.2 Hz), 1.92 (q, 2H, J = 7.2 Hz).

13

C NMR (CDCl3, 151 MHz)

δ 148.1, 130.7, 129.0, 128.3, 125.8, 119.5, 49.5, 32.6, 29.4, 28.9. HRMS (ESI) m/z

149

calculated 280.04494 (C12H15BrN3, [M+H]+), m/z observed 280.04348. (C12H15BrN3,
[M+H]+).

1-(5-bromopentyl)-4-phenyl-1H-1,2,3-triazole

(4-30).

Prepared using General Procedure for bromo-1,2,3triazoles from 1-azido-5-bromopentane 4-26 and isolated
as a white solid in 29% yield.

1

H NMR (CDCl3, 600 MHz) δ 7.83 (d, 2H, J = 7.8 Hz),

7.75 (s, 1H), 7.43 (t, 2H, J = 7.8 Hz), 7.33 (t, 1H, J = 7.8 Hz), 4.42 (t, 2H, J = 7.2 Hz),
3.40 (t, 2H, J = 6.6 Hz), 2.00 (q, 2H, J = 7.2 Hz), 1.92 (q, 2H, J = 7.2 Hz), 1.50 – 1.56
(m, 2H).

13

C NMR (CDCl3, 151 MHz) δ 148.0, 130.8, 129.0, 128.3, 125.8, 119.6, 50.2,

33.3, 32.1, 29.7, 25.2. HRMS (ESI) m/z calculated 294.06059 (C13H17BrN3, [M+H]+),
m/z observed 294.05971. (C13H17BrN3, [M+H]+).

1-(6-bromohexyl)-4-phenyl-1H-1,2,3-triazole

(4-31).

Prepared using General Procedure for bromo-1,2,3triazoles from 1-azido-6-bromohexane 4-27 and isolated
as a white solid in 32% yield.

1

H NMR (CDCl3, 600 MHz) δ 7.83 (d, 2H, J = 7.8 Hz),

7.75 (s, 1H), 7.43 (t, 2H, J = 7.8 Hz), 7.33 (t, 1H, J = 7.2 Hz), 4.41 (t, 2H, J = 7.2 Hz),
3.40 (t, 2H, J = 6.6 Hz), 1.98 (q, 2H, J = 7.8 Hz), 1.86 (q, 2H, J = 7.2 Hz), 1.52 (q, 2H, J
= 7.2 Hz), 1.39 (q, 2H, J = 7.8 Hz).

13

C NMR (CDCl3, 151 MHz) δ 148.0, 130.8, 129.0,

128.3, 125.8, 119.5, 50.3, 33.7, 32.5, 30.3, 27.6, 25.8. HRMS (ESI) m/z calculated
308.07624 (C14H19BrN3, [M+H]+), m/z observed 308.07481. (C14H19BrN3, [M+H]+).

General procedure for 1,2,4-triazolyl-12,3-triazoles: Bromoalkyl phenyl-1,2,3-triazole
(1 mmol) was dissolved in DMF (4 mL). 1H-1,2,4-triazole (1 mmol) was added along
with solid K2CO3 (2 mmol). This heterogeneous mixture was stirred at room temperature
overnight. Reaction progress was followed by TLC. Reaction mixture was diluted with
water and extracted with ethyl acetate (3x). Combined organics were washed with water
(1x) and saturated sodium chloride (1x). The organic layer was dried over sodium
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sulfate, filtered, and concentrated in vacuo to yield the desired 1,2,4-triazolyl-1,2,3triazole.

1-(3-(1H-1,2,4-triazol-1-yl)propyl)-4-phenyl-1H-1,2,3triazole (4-32). Prepared using the general procedure for
1,2,4-triazolyl-1,2,3-triazoles from
1,2,4-triazole. Isolated as a white solid in 76% yield.

bromide 4-28 and 1H-

1

H NMR (CDCl3, 600 MHz) δ 8.17

(s, 1H), 8.00 (s, 1H), 7.83 (m, 3H), 7.44 (t, 2H, J = 7.8 Hz), 7.35 (t, 1H, J = 7.8 Hz), 4.43
(t, 2H, J = 6.6 Hz), 4.25 (t, 2H, J = 6.6 Hz), 2.55 (q, 2H, J = 6.6 Hz).

13

C NMR (CDCl3,

151 MHz) δ 152.6, 148.2, 144.4, 130.4, 129.1, 128.5, 125.9, 120.3, 46.8, 45.9, 30.4.
HRMS (ESI) m/z calculated 255.13582 (C13H15N6, [M+H]+), m/z observed 255.13509.
(C13H15N6, [M+H]+).

1-(4-(1H-1,2,4-triazol-1-yl)butyl)-4-phenyl-1H-1,2,3triazole (4-33). Prepared using the general procedure
for 1,2,4-triazolyl-1,2,3-triazoles from bromide 4-29 and
1H-1,2,4-triazole. Isolated as a white solid in 44% yield.

1

H NMR (CDCl3, 600 MHz) δ

8.05 (s, 1H), 7.95 (s, 1H), 7.82 (d, 2H, J = 7.8 Hz), 7.72 (s, 1H), 7.43 (t, 2H, J = 7.8 Hz),
7.34 (t, 1H, J = 7.8 Hz), 4.44 (t, 2H, J = 6.0 Hz), 4.22 (t, 2H, J = 6.0 Hz), 1.97 – 1.99 (m,
4H).

13

C NMR (CDCl3, 151 MHz) δ 152.4, 148.2, 143.2, 130.6, 129.0, 128.4, 125.8,

119.6, 49.6, 48.8, 27.4, 27.0.

HRMS (ESI) m/z calculated 269.15147 (C14H17N6,

[M+H]+), m/z observed 269.15093. (C14H17N6, [M+H]+).

1-(5-(1H-1,2,4-triazol-1-yl)pentyl)-4-phenyl-1H-1,2,3triazole (4-34). Prepared using the general procedure
for 1,2,4-triazolyl-1,2,3-triazoles from

bromide 4-30

1

and 1H-1,2,4-triazole. Isolated as a white solid in 76% yield. H NMR (CDCl3, 600 MHz)
δ 8.03 (s, 1H), 7.93 (s, 1H), 7.82 (d, 2H, J = 7.2 Hz), 7.72 (s, 1H), 7.43 (t, 2H, J = 7.2
Hz), 7.34 (t, 1H, J = 7.2 Hz), 4.39 (t, 2H, J = 6.6 Hz), 4.16 (t, 2H, J = 6.6 Hz), 1.93 –
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2.02 (m, 4H), 1.33 – 1.40 (m, 2H).

13

C NMR (CDCl3, 151 MHz) δ 152.2, 148.0, 143.2,

130.7, 129.0, 128.3, 125.8, 119.6, 50.1, 49.4, 29.9, 29.3, 23.6.

HRMS (ESI) m/z

calculated 283.16712 (C15H19N6, [M+H]+), m/z observed 283.16605. (C15H19N6, [M+H]+).

1-(6-(1H-1,2,4-triazol-1-yl)hexyl)-4-phenyl-1H1,2,3-triazole (4-35). ). Prepared using the general
procedure

for

1,2,4-triazolyl-1,2,3-triazoles

bromide 4-31 and 1H-1,2,4-triazole. Isolated as a white solid in 84% yield.

from

1

H NMR

(CDCl3, 600 MHz) δ 8.03 (s, 1H), 7.93 (s, 1H), 7.83 (d, 2H, J = 7.2 Hz), 7.73 (s, 1H),
7.42 (t, 2H, J = 7.8 Hz), 7.33 (t, 1H, J = 7.8 Hz), 4.39 (t, 2H, J = 6.6 Hz), 4.15 (t, 2H, J =
7.2 Hz), 1.95 (q, 2H, J = 7.2 Hz), 1.89 (q, 2H, J = 6.6 Hz), 1.32 – 1.42 (m, 4H).

13

C

NMR (CDCl3, 151 MHz) δ 152.1, 148.0, 143.0, 130.7, 129.0, 128.3, 125.8, 119.5, 50.2,
49.5, 30.2, 29.7, 26.02, 25.99.

HRMS (ESI) m/z calculated 297.18277 (C16H21N6,

[M+H]+), m/z observed 297.18213. (C16H21N6, [M+H]+).

methyl

6-(4-phenyl-1H-1,2,3-triazol-1-

yl)hexanoate (4-36). 1,2,3-Triazoyl carboxylic acid
3-3k (1 mmol) was dissolved in methanol (2.5 mL) with a catalytic amount of H2SO4
(100 μL). The mixture was refluxed overnight and reaction progress monitored by TLC.
Solution was concentrated in vacuo, and residue redissolved in DCM and water. The
aqueous layer was made neutral by dropwise addition of 6 M NaOH and extracted with
DCM (3x). The combined organics were washed with 2 M NaOH (1x), H 2O (1x), and
saturated NaCl (1x). The organic layer was dried over sodium sulfate, filtered, and
concentrated in vacuo to yield an off-white solid in 85% yield.

N-hydroxy-6-(4-phenyl-1H-1,2,3-triazol-1yl)hexanamide (4-37). Triazolyl methyl ester 4-36
(1 mmol) was added to a microwave vial. To this
was added methanol (5 mL), hydroxylamine hydrochloride (3 mmol) and crushed NaOH
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(6 mmol). The heterogeneous mixture was microwaved at 120°C for 30 minutes.
Starting material consumption was confirmed by TLC and methanol was removed in
vacuo. Water and DCM were added to the residue and the aqueous layer acidified to
pH of 4-5 with glacial acetic acid. The water layer was then extracted with DCM (3x).
Combined organics were washed with ammonium chloride and saturated NaCl. The
organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to yield
an off-white solid in 60% yield.

5-bromo-N-phenylpentanamide (4-40).

5-bromopentanoic

acid (1 mmol) was dissolved in DCM (2.85 mL) and cooled to
0°C in ice bath. A solution of oxalyl chloride in DCM (2M, 1.1
mmol) was added dropwise along with a catalytic amount of DMF (0.1 mmol). The ice
bath was removed and the solution stirred at room temperature for 1 hour. TLC
confirmed consumption of starting material. Volatiles were removed under a stream of
N2. The resulting residue was dissolved in DCM (4.25 mL) and cooled to 0°C in an ice
bath. Dropwise add a solution of DIEA (2.1 mmol) and aniline (1.2 mmol) dissolved in
DCM (0.5 mL). Remove ice bath and stir overnight at room temperature. Reaction
progress was monitored by TLC. Upon completion, water was added and extracted with
DCM (3x). The combined organics were washed with 1 M HCl, saturated sodium
bicarbonate, and saturated NaCl. The organic layer was then dried over sodium sulfate,
filtered, and concentrated in vacuo to yield a pale pink solid in 84% yield.

6-bromo-N-phenylhexanamide (4-41).

5-bromopentanoic

acid (1 mmol) was dissolved in DCM (2.85 mL) and cooled
to 0°C in ice bath. A solution of oxalyl chloride in DCM (2M,
1.1 mmol) was added dropwise along with a catalytic amount of DMF (0.1 mmol). The
ice bath was removed and the solution stirred at room temperature for 1 hour. TLC
confirmed consumption of starting material. Volatiles were removed under a stream of
N2. The resulting residue was dissolved in DCM (4.25 mL) and cooled to 0°C in an ice
bath. Dropwise add a solution of DIEA (2.1 mmol) and aniline (1.2 mmol) dissolved in
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DCM (0.5 mL). Remove ice bath and stir overnight at room temperature. Reaction
progress was monitored by TLC. Upon completion, water was added and extracted with
DCM (3x). The combined organics were washed with 1 M HCl, saturated sodium
bicarbonate, and saturated NaCl. The organic layer was then dried over sodium sulfate,
filtered, and concentrated in vacuo to yield an off-white solid in 82% yield.

methyl 1-(5-oxo-5-(phenylamino)pentyl)-1H-1,2,4triazole-3-carboxylate

(4-42).

5-bromo-N-

phenylpentanamide 4-40 (1 mmol) was dissolved in
DMF (4 mL). Methyl 1-H-1,2,4-triazole-3-carboxylate
and K2CO3 were added as solids. The heterogeneous mixture was stirred overnight at
room temperature. Reaction progress was monitored by TLC. Upon completion, a small
amount of water was added and extracted with ethyl acetate (3x). The organic layer was
dried over sodium sulfate, filtered, and concentrated in vacuo. Crude material still
contained DMF. Purify via silica gel chromatography eluting with gradient of hexanes
and ethyl acetate to yield a white solid in 39% yield. Experiments on 600 NMR – HMBC
in particular showed correlation between CH of triazole and CH2 of alkyl linker. 1H NMR
(CDCl3, 500 MHz) δ 8.18 (s, 1H), 7.49 (d, 2H, J = 7.5 Hz), 7.35 (br, 1H), 7.31 (t, 2H, J =
7.5 Hz), 7.10 (t, 1H, J = 7.5 Hz), 4.28 (t, 2H, J = 7.0 Hz), 3.91 (s, 3H), 2.40 (q, 2H, J =
7.0 Hz), 2.04 (q, 2H, J = 7.0 Hz).

13

C NMR (CDCl3, 125 MHz) δ 170.3, 160.3, 155.1,

144.7, 137.8, 129.2, 124.6, 120.0, 52.9, 50.4, 36.6, 29.3, 22.2.

HRMS (ESI) m/z

calculated 303.1457 (C15H19N4O3, [M+H]+), m/z observed 304.14590. (C15H19N4O3,
[M+H]+).
N-hydroxy-1-(5-oxo-5-(phenylamino)pentyl)-1H1,2,4-triazole-3-carboxamide (4-44). Methyl ester 442 (1 mmol) was suspended in methanol (5 mL) in a
microwave vial. Hydroxylamine hydrochloride (3
mmol) and crushed NaOH (6 mmol) were added as solids and the resulting
heteroenous mixture was microwaved for 1 hour at 120°C. Starting material
consumption was confirmed by TLC and methanol was removed in vacuo. Water and
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ethyl acetate were added to the residue and the aqueous layer acidified to pH of 4-5
with glacial acetic acid. The water layer was then extracted with ethyl acetate (3x).
Combined organics were dried over sodium sulfate, filtered, and concentrated in vacuo
to yield a white solid in 58% yield.

1

H NMR (d6-DMSO, 600 MHz) δ 11.22 (s, 1H), 9.88

(s, 1H), 9.10 (s, 1H), 8.62 (s, 1H), 7.57 (d, 2H, J = 7.8 Hz), 7.27 (t, 2H, J = 7.2 Hz), 7.01
(t, 1H, J = 7.8 Hz), 4.24 (t, 2H, J = 6.6 Hz Hz), 2.34 (t, 2H, J = 7.2 Hz), 1.84 (q, 2H, J =
6.6 Hz), 1.54 (q, 2H, J = 7.2 Hz).

13

C NMR (d6-DMSO, 151 MHz) δ 170.8, 156.8, 155.7,

144.9, 139.2, 128.6, 123.0, 119.0, 49.0, 35.6, 28.8, 22.0. HRMS (ESI) m/z calculated
303.1331 (C14H17N5O3, [M+H]+), m/z observed 303.13299. (C14H17N5O3, [M+H]+).

6-azido-N-phenylhexanamide (4-43). Bromoamide 4-41 (1
mmol) was dissolved in dimethylformamide and water (2.25
mL : 0.25 mL). Sodium azide (1.25 mmol) was added as a
solid and the solution stirred overnight at room temperature. Progress of the reaction
was monitored by TLC. Upon completion, the reaction was quenched with 30 mL of
water (exothermic) and stirred until reaching room temperature. The solution was then
extracted with DCM (3x). The combined organics were washed with water (3x), copper
sulftate (1x) and brine (1x). The solution was dried over sodium sulfate, filtered, and
concentrated in vacuo to yield the desired azide as a yellow-orange oil in 75% yield.

6-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)-Nphenylhexanamide (4-46).

Azide 4-41 (1 mmol)

was dissolved in acetonitrile (3.0 mL). Propargyl
alcohol (1.05 mmol) and triethylamine (1 mmol) were added. A solution of triazine 2-17
(0.01 mmol) in acetonitrile (1000 μL) was added, followed by a solution of
tetrakis(acetonitrle-N)copper(I) tetrafluoroborate (0.01 mmol) in acetonitrile (1000 μL).
The resulting solution was stirred 60°C overnight. Reaction progress was followed by
TLC. Upon completion, the mixture was concentrated in vacuo and purified via silica gel
chromatography eluting with a gradient of ethyl acetate and methanol to yield the
desired 1,2,3-triazole as an off-white solid in 53% yield.
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Chapter 5.
Conclusions and Future Work
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5.1.

Concluding Remarks

In this dissertation, efforts to design new ligands for copper-catalyzed azide–alkyne
cycloadditions were discussed. A series of 1,2,4-triazine ligands was successfully
synthesized by varying the substituents at the 3-position and 5- and 6-positions. The
triazine core scaffold was replaced with other nitrogen containing heterocycles. These
compounds were then screened for CuAAC activity. Work is still needed to make this a
true “click” reaction as our isolation technique still involved chromatographic separation.
The use of water as a solvent was not explored in our optimization conditions, and
should be given more focus in the future.
1,2,4-Triazine ligands were also attached to solid supports to create heterogeneous
catalysts for CuAAC. Both polystyrene and silica catalysts were effective catalysts with
simple isolation of triazole products. The use of water proved to be beneficial for both
heterogeneous systems. This should also be explored more in the future. Decreased
temperatures might be achievable by altering the solvent or other parameters.
Recyclability studies and copper retention were not examined with respect to reactions
carried out in water. These results would give additional information on the future
viability of these supports.
Finally, 1,2,4-triazine ligands were used to synthesize a library of compounds containing
1,2,3- or 1,2,4-triazoles as mimics of hydroxamic acid zinc-binding groups. Although,
the synthesis was successful, the HDAC inhibition data was not promising. Modeling
studies could help to design a better scaffold of inhibitors for future work. Additional
metalloenzymes could also be screened for activity.
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